Non-canonical roles of Oligoadenylate Synthetase 1 during viral and bacterial infections by Perez, Joseph
   
 
Title Page  
Non-canonical roles of Oligoadenylate Synthetase 1 during viral and bacterial infections 
 
 
 
 
 
 
by 
 
Joseph Perez 
 
Bachelor of Sciences, University of Puerto Rico at Cayey, 2015 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
 
School of Medicine in partial fulfillment 
  
of the requirements for the degree of 
 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2020
 ii 
Committee Membership Page  
UNIVERSITY OF PITTSBURGH 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Joseph Perez 
 
 
It was defended on 
 
August 3, 2020 
 
and approved by 
 
Neal A. DeLuca, Ph.D. 
Professor, Microbiology & Molecular Genetics  
 
Jeffrey Brodsky, Ph.D. 
Professor, Biological Sciences 
 
Greg M. Delgoffe, PhD 
Associate Professor, Immunology 
 
John V. Williams, M.D. 
Member 
Molecular Virology & Microbiology 
 
Dissertation Director:  
Saumendra N. Sarkar, Ph.D. 
Associate Professor, Molecular Virology & Microbiology 
 
 
 
  
 iii 
Title Page  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © by Joseph Perez 
 
2020 
 
 
 
 
 iv 
Abstract 
Non-canonical roles of Oligoadenylate Synthetase 1 during viral and bacterial infections 
 
Joseph Perez, PhD 
 
University of Pittsburgh, 2020 
 
 
Interferons inhibit growth of several intracellular pathogens, including virus and bacteria, 
through the expression of interferon stimulated genes (ISGs). We have found that a specific 
isoform of one such ISG, Oligoadenylate Synthetase 1 (OAS1) enhances translation of a select set 
of mRNAs, thereby increases the steady state and induced levels of specific proteins with antiviral 
and antibacterial properties. This OAS1 isoform (OAS1 P46) in humans is generated due to an 
alternative splice acceptor site at the C-terminus of OAS1 gene. The SNP rs10774671 at this site 
has been associated with disease severity to West Nile Virus (WNV) and Mycobacterium 
tuberculosis. We show that human OAS1-KO cells have lower basal levels of cGAS protein and 
can be rescued by OAS1 P46 expression, independent of its enzyme activity. Inducible expression 
of OAS1 P46 in cGAS-KO cells does not suppress WNV replication, suggesting that the antiviral 
activity of OAS1 is mediated through cGAS. We also have established functional equivalence 
between OAS1 P46 and a mouse ortholog, Oas1b (no enzyme activity), which similarly affects 
WNV susceptibility. Through RNA-protein crosslinking experiments we have identified target 
mRNAs that bind to OAS1 and Oas1b. We have demonstrated increased sensitivity of WNV in 
OAS1/Oas1b RNA binding mutants. To define the antibacterial activity of OAS1, we screened 
OAS1-deficient THP1 cells for bacterial growth using the intracellular bacteria Listeria 
monocytogenes and Francisella novicida as model bacterial pathogens. Inducible expression of 
OAS1 P46 WT and enzymatically inactive mutant rescued this antibacterial activity of OAS1 in 
OAS1-KO cells. Further investigation of OAS1-KO cells indicated defective type II IFN signaling 
due to the reduced expression of IRF1. Like cGAS, OAS1 bound to IRF1 mRNA and enhanced 
 v 
protein synthesis of IRF1. Inducible expression of OAS1 P46 in IRF1-KO cells did not inhibit 
bacterial growth suggesting that antibacterial activity of OAS1 is mediated through IRF1. Lastly, 
we found that Oas1b knock-in (Oas1b-KI) mice showed improved survival with L. monocytogenes 
or F. novicida as compared to WT mice. These findings suggest a new mechanism of OAS1 in 
which it binds to target mRNAs, enhances the translation of these RNAs and limits virus and 
bacterial infections. 
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1.0 Introduction 
On a daily basis the human body is exposed to a vast number of microbial pathogens, many 
of which are capable of causing disease. Fortunately, higher organisms have developed a 
sophisticated defense system comprised of cellular and chemical networks that together orchestrate 
protection against invading microorganisms. The existence of microbial protection has been 
recorded since ancient times, examples of this include noticeable protection against pathogen re-
exposure during plagues, followed by practices over 3 centuries ago of exposure to pathogen 
agents in order to develop an acquired immunity (1, 2). In order for the immune system to fight 
off infections it must recognize and respond to microbial agents, target invaders for destruction 
and minimize spread by inducing cellular death. There is a large diversity of microorganisms and 
it is logical to conclude that they infect their host through a variety of distinct mechanism and vary 
greatly in composition. This thought led Charles Janeway Jr. to propose the existence of various 
receptors expressed on immune cells, which detect distinct pathogens and are known today as 
PRRs (3). These PRRs are located on cellular and endosomal membranes or in the cytosol and 
upon recognition of PAMPs induce downstream signaling pathways that lead to the expression of 
proinflammatory cytokines required to control infection (4, 5). As alluded previously, different 
microorganisms are detected by different receptors, mostly dependent on infection routes of the 
pathogen, and illicit distinct signaling responses. Innate immune responses to bacterial infection 
mostly rely on the recognition of bacterial ligands by TLRs and NLRs leading to the induction of 
pro-inflammatory cytokines and antibacterial gene expression (6). Additionally, bacterial nucleic 
acids can lead to the activation of cGAS-STING pathways and promote IFN signaling (7). During 
viral infection, intracellular TLRs and cytosolic nucleic acid sensors detect viral genetic material 
 2 
and initiate cellular innate immune responses. Signaling by these receptors results in the activation 
of transcription factors, such as NF-B and IRF-3, required for the production of type I interferons 
(8). Interferons, through JAK-STAT signaling, promote the expression of hundreds of IFN 
stimulated genes with profound antiviral effects (9).  
Among these ISGs exist the Oligoadenylate Synthetase (OAS) family proteins, a group of 
type I IFN inducible proteins that bind viral dsRNA, and through their Nucleotidyltransferase 
(NTase) domain, and synthesize 2’-5’ oligoadenylates (2-5(A)). These 2-5(A) molecules cause 
activation of a latent RNase, RNase L through dimerization (10). In addition to multiple antiviral 
effects (11), OAS proteins have been associated to defense against intracellular bacteria such as 
Mycobacterium tuberculosis (12). There are 4 human OAS-family proteins, 3 of them which are 
enzymatically active (OAS1, OAS2 and OAS3), and one (OASL) which is enzymatically inactive 
but confers antiviral protection by enhancing RIG-I signaling (13). Additionally, mice have a 
variety of OAS homologs, some that are also enzymatically inactive (11, 14). The biological 
significance of these enzymatically inactive OAS proteins lays in their ability to confer antiviral 
protection, as seen in OASL and protection against WNV infection by the human OAS1 mouse 
homolog Oas1b (15, 16). Recent studies have shown that OAS3 is necessary and sufficient for the 
activation of RNase L, yet overexpression of OAS1 or OAS2 can reduce virus susceptibility (17), 
suggesting that non-canonical functions exist for both enzymatically active and inactive members 
of the OAS family proteins. The non-canonical role of OAS1 during viral and bacterial infection 
has yet to be defined and these unique mechanisms of OAS1 will be explained in this dissertation.   
 3 
1.1 Innate Immune Signaling  
Innate Immunity is an evolutionarily conserved system characterized by a number of non-
specific responses to foreign invasion in order to protect the host from infections. It ranges from 
the most basic physiological barriers of defense, such as: mucosal membranes, acidic 
environments and chemical mediators, to more complex immune systems reliant on cellular and 
molecular responses. Cellular responses are mediated through specialized myeloid and lymphoid 
sensors and effector  cells, which become active during tissue damage, infection or stress (18). 
During infection, macrophages, neutrophils and dendritic cells can engulf and destroy pathogens 
by phagocytosis followed by processing and presentation of antigens by macrophages and 
dendritic cells to lymphoid cells, serving as a bridge between innate and adaptive immunity. 
However, the clearance of infection is not limited to phagocytosis, there are number of innate 
defense mechanisms that are stimulated upon recognition of PAMPs. These include production of 
pro-inflammatory cytokines (e.g. TNF, IL-1, IL6), chemokine secretion (e.g. CXCL proteins) 
and chemotaxis of other immune cells, pathogen clearance by the Complement system and lysis 
by antimicrobial peptides (e.g. Lysosomes) among other mechanisms (19–22).  
Specific PAMPs are recognized by a distinct variety of PRRs to elicit signaling cascades, 
and of these receptors first described were TLRs. Parallels between cytokine mediated NF-B 
activation and signaling of Toll proteins in Drosophila and the discovery of TLR4 as the receptor 
for LPS (23, 24) suggested that other TLRs could be responsible for recognition of PAMPs of 
microbial and viral origin (5). After years of extensive research, understanding of the TLR family 
has become clear and TLRs have been well characterized in mammalian hosts. Humans express 
10 TLR proteins (TLRs 1-10), while mice express 11 TLR proteins (TLRs 1-9 and TLRs 11-12) 
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and what is common between mammalian species is the distribution of TLRs in the cell.  Human 
TLRs expressed on the cell surface include TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 and 
mostly bind to PAMPs of bacterial origin (e.g. lipopolysaccharides, lipoproteins and proteins). 
Intracellular TLRs, found in endosomes, include TLR3, TLR7, TLR8 and TLR9 and bind to DNA 
or RNA derived from virus, bacteria or self-nucleic acids from damaged cells (regularly not found 
in cytosol) (25).  
TLRs are type I integral membrane receptors consisting of a N-terminal ligand recognition 
domain, transmembrane helix and a C-terminal signaling domain located in the cytosol (26). The 
N-terminal domain consists of leucine-rich repeats (LRR), a motif found on several proteins of 
animals, plants and microorganisms.  Once TLRs have bound to their ligand (summarized in Fig. 
1), the C-terminal domains of receptors come close together allowing the signaling domains, 
known as Toll IL-1 receptor domains (TIR), to interact and form dimers. Dimeric receptors recruit 
TIR domain-containing adaptor proteins such as MyD88 and TRIF, which activate transcription 
factors and promote gene expression. MyD88 mediates downstream signaling pathways of all TLR 
proteins, with the exception of TLR3, and consists of a TIR domain and death domain. MyD88 
interacts with TLRs through TIR and the death domain interacts with the death domain of IL-1 
receptor-associated kinase-4 (IRAK-4) forming a complex that recruits IRAK-1 and IRAK-2, 
resulting phosphorylation of  IRAK proteins (27). TNF receptor-associated factor 6 (TRAF6) is 
recruited and activated by IRAK-1 forming a complex that dissociates from the receptor and 
associates to TGF--activated kinase 1 (TAK1) and TAK1-binding proteins (TABs)(28). The 
TRAF6, TAK1 and TAB complex moves to the cytosol and is polyubiquitinated with K63-
ubiquitin chains by E2 ubiquitin ligases Ubc13/Uev1A inducing TRAF6 activation, which then 
promotes IB Kinase (IKK) complex phosphorylation and activation of NF-B (29, 30). The IKK 
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complex is composed of two catalytic subunits (IKK and IKK) and one regulator subunit NF-
B essential modulator (NEMO)/IKK NF-B subunits share a Rel homology domain, required 
for DNA binding and dimerization, and NF-B is tightly regulated by IB (inhibitor of NF-B),   
which masks nuclear localization signals found in NF-B family proteins (31, 32).  Activation of 
IKK complex leads to the phosphorylation of IB, which then becomes poly-ubiquitinated by E3 
ubiquitin ligases and degraded in the proteasome, therefore releasing NF-B and allowing NF-B 
heterodimer translocation into the nucleus (33). Once in the nucleus, NF-B promotes 
transcription of genes involved in inflammatory responses (e.g. TNF, IL-1, INOS, ICAM), 
proliferation (e.g. Cyclins, MYC, CDK) and survival among others (34, 35). TRAF6 also promotes 
down-stream activation of the transcription factor activator protein 1 (AP-1). AP-1 is a heterodimer 
assembled by basic region leucine zipper (bZIP) domains in Fos and Jun (proto-oncogene) family 
protein subunits (36). AP-1 is activated by mitogen-activated protein kinases (MAPK), specifically 
MAPKs p38, the extracellular signal-related kinase (ERK) and Jun N-terminal kinase (JNK), all 
serine/threonine kinases that influence the phosphorylation and activation of multiple transcription 
factors (37).  
Similar to NF-B signaling, TAK1 is responsible for activating mitogen-activated protein 
kinases (MAPKs) signaling cascades leading to the activation and translocation of AP-1 to the 
nucleus (38). Once in the nucleus, AP-1 promotes expression of genes regulating proliferation, 
differentiation and apoptosis (39, 40). Similar to cell surface TLRs, intracellular TLR 7, 8 and 9 
also lead to the activation of TRAF6 and MAPK pathways promoting NF-B and AP-1, 
translocation to the nucleus and enhance transcription of target genes. In addition to MyD88, the 
adaptor protein TIR-domain-containing adapter-inducing IFN (TRIF) also regulates signaling of 
TLRs, specifically TLR3 and TLR4 (41, 42). TRIF recruits TNF receptor-associated factor 3 
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(TRAF3), which becomes active after K63-polyubiquitination by the E3 ubiquitin-protein ligase 
HECTD3 and activated TRAF3 promotes activation of TANK-binding kinase 1 (TBK1) and 
IKK (–). TBK1 and IKK kinase phosphorylate IRF3, which forms homodimers, 
translocates to the nucleus and promotes type I IFN expression (46). In addition to TLRs, there are 
several other PRRs that work to detect cytosolic genetic material of viral, microbial or self-origin, 
including NLRs, cGAS, and RIG-I like receptors (RLRs).  
 
Figure 1. TLR Signaling in human cells.  
Schematic of TLR signaling of cell surface and intracellular receptors in human cells. Once TLRs bind PAMPs 
associated to extracellular or intracellular pathogens, they recruit adaptor proteins and induce signaling cascades 
leading to the activation of transcription factors, which promote gene expression of pro-inflammatory cytokines and 
type I IFNs.   
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1.1.1  Recognition of cytosolic DNA and RNA  
In addition to TLRs which detect PAMPs in endosomes, there are several cytoplasmic 
sensors of nucleic acids that elicit innate immune responses to pathogen invasion or host cellular 
damage. Among these are NLRs, a family of proteins that form part of intracellular multiprotein 
complexes called inflammasomes. These inflammasome structures mediate inflammatory and cell 
death pathways. The NLR family is divided into a variety of subfamilies, differing in their N-
terminus, and there are several non-NLR proteins (AIM2, Pyrin and IFI16), which can also form 
inflammasomes (reviewed in (47)). Inflammasome structures consist of a sensor protein (NLR, 
AIM2, Pyrin), ASC adaptor protein, and pro-caspase1 (or pro-caspase11 in non-canonical 
inflammasomes) effector protein (48). Upon activation, pro-caspase1 is cleaved into caspase1 and 
active caspase1 processes the conversion of pro-IL-1 and pro-IL-18 into IL-1 and IL-18 
respectively, followed by their secretion. Additionally, caspase1 also triggers pyroptosis through 
GasderminD limiting the spread of infectious agents to other cells (49). In addition to NLRs, cGAS 
and RLRs are well characterized sensors of cytosolic DNA and RNA respectively, which promote 
inflammatory gene and IFN expression (Fig. 2). In response to DNA of viral, bacterial or self-
origin, cGAS synthesizes 2’-3’-cyclic guanosine monophosphate-adenosine monophosphate 
(cGAMP) a second messenger responsible for activating Stimulator of IFN genes (STING). 
STING resides in the endoplasmic reticulum (ER) and upon activation promotes NF-B and 
TBK1-mediated activation of IRF3. In response to viral dsRNA, RLRs interacts with and activates 
Mitochondrial antiviral-signaling protein (MAVS), followed by oligomerization of MAVS on the 
mitochondrial surface. MAVS then activates TRAF3 (similar to TLR3 signaling) and TRAF6 
leading to activation of IRF3 and NF-B respectively.   
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Figure 2. Sensing of cytosolic DNA and RNA in human cells. 
Schematic of innate immune response to cytosolic DNA (left) and RNA (right) in human cells. Cytosolic DNA of 
viral, bacterial or host origin is sensed in the cytosol by cGAS, which converts ATP and GTP to 2’-3’-cGAMP. 
cGAMP then activates STING signaling pathway. Cytosolic RNA of viral origin is sensed by RLRs, which activate 
MAVS signaling pathway. Both pathways lead to the activation of transcription factors that promote transcription of 
pro-inflammatory cytokines and type I IFNs.   
1.1.1.1 RNA Sensors 
 
RLRs are intracellular PRRs crucial for detecting cytosolic RNA of invading RNA viruses. 
These receptors are a family of DExD/H box RNA helicases and include: RIG-I, melanoma 
differentiation association gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) 
protein (50). The structure of these RLRs are quite similar, they share a central DExD/H box RNA 
helicase core required for RNA binding, a C-terminal harboring a repressor domain involved in 
autoregulation, and in the case of RIG-I and MDA5 a N-terminal CARD signaling domain (51). 
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Although LGP2 lacks N-terminal CARD domains, it binds tightly to dsRNA and works as a 
negative or positive regulator of RIG-I and MDA5 signaling (52, 53).  
RIG-I was the first RLR to be characterized in the induction of IFN in response to RNA 
virus infection or p(I):p(C) transfection. RIG-I mediated IFN expression was shown to be 
alternative to TLR3 signaling and the CARD domain of RIG-I was shown to be a crucial interface 
between dsRNA sensing and downstream signaling (54). Prior to the engagement of dsRNA, RIG-
I remains in a folded inactivated state in which CARD domains are associated to the helicase 
domain of RIG-I and are not available for signaling (55). RIG-I, through its helicase and C-
terminal domain, monitors the 5’ end of RNA and is activated upon recognition of free non-capped 
diphosphate or triphosphate groups on RNA (56, 57). Additionally, methylation of the 2’-hydroxyl 
group of the 5’-terminal nucleotide of endogenous RNA and is crucial for distinguishing self RNA 
and repressing RIG-I activation, and the absence of methylation at this group aids in recognition 
of foreign RNA by RIG-I (58, 59). Upon association of dsRNA with the helicase domain of RIG-
I, RIG-I undergoes a conformational change that exposes the CARD domains of RIG-I, which then 
become K63 poly-ubiquitinated by the E3 ligase tripartite motif-containing 25 (TRIM25)(60). 
Once poly-ubiquitinated, RIG-I oligomerizes through its CARD domains, which promotes 
interactions with MAVS adaptor protein (61, 62). Contrary to RIG-I, MDA5 remains in an open 
state and upon interaction with longer dsRNAs forms filamentous oligomers increasing the affinity 
to the RNA ligand (63, 64). Similar to RIG-I, the CARD domains on oligomerized MDA5 proteins 
are K63 poly-ubiquitinated and active oligomers interact with the CARD domains of MAVS, 
however the mechanism of MDA5 K63 poly-ubiquitinated remains unclear (65).  
MAVS was identified as a meditator of RLR dependent activation of IFN by IRF3 and 
NF-B signaling pathways (66). It was also shown that MAVS contained N-terminal CARD 
 10 
domains and a C-terminal transmembrane domain, which targets MAVS to mitochondrial 
membranes, both crucial for the signaling activity of MAVS (67). Additionally, MAVS contains 
several TRAF-interacting motifs (TIMs), two in the proline-rich region and one near the C-
terminal transmembrane domain, and crystal structures of MAVS interacting with TRAF proteins 
have been characterized (68–70). Once MAVS interacts with RIG-I or MDA5, MAVS proteins 
cluster together on the mitochondrial surface becoming activate, which then promotes the 
recruitment of TRAF proteins (Fig. 2) and assembly of a multiprotein complex required for 
signaling and IFN induction (71, 72). Once recruited, TRAF3 protein complex leads to the 
induction of type I IFNs mediated by TBK1, IKK, and TRAF6, which promotes NF-B signaling 
leading to the transcription of inflammatory genes.  
1.1.1.2 DNA Sensors  
 
As previously discussed, TLRs found in endosomal compartments are capable of 
recognizing single-stranded or unmethylated CpG DNA and through MyD88 signaling pathways 
elicit inflammatory gene and IFN expression. However studies in MyD88 and TRIF KO cells 
evidently showed that TLR independent pathways of IFN expression existed in response to 
cytosolic DNA and must be related to cytosolic protein sensors to DNA (73) . Extensive research 
to identify which proteins could be responsible for sensing DNA in the cytosol identified the 
adaptor protein STING as a crucial mediator of antiviral activity in response to cytosolic DNA. 
STING was shown to activate both NF-B and IRF3 signaling pathways, however it was clear that 
it did not directly interact with DNA, and STING alone was not sufficient for induction of IFNs 
(74, 75). The discovery of bacterial cyclic di-nucleotides as a mediator of STING activation 
 11 
confirmed the existence of proteins up-stream of STING that regulated DNA sensing pathways to 
induce type I IFN signaling (76–78).  
cGAS structure is quite similar to that of OAS1 It contains a NTase core and a unique zinc-
binding site conserved throughout cGAS orthologues (79, 80). cGAS interacts with dsDNA 
through two binding sites and can bind shorter or longer DNA molecules based on specific amino 
acid (a.a.) residues at these binding sites. The cGAS enzymatic activity is also regulated by the 
dsDNA length, which has been seen to be different in human and mouse cGAS (81, 82). After 
engaging with DNA, cGAS becomes active and catalyzes the conversion of GTP and ATP into the 
second messenger cGAMP, which then binds to STING in the ER and promotes the formation of 
STING oligomers (83). STING consists of a cytosolic domain, required for ligand binding and 
interaction of TBK1 and IRF3 through its C-terminal tail, and transmembrane domains that anchor 
STING to the ER. When STING binds cGAMP, there is a 180º rotation of the ligand-binding 
domain allowing STING oligomers to tightly pack side to side, followed by trafficking through 
ER-Golgi intermediate compartments to the Golgi apparatus (82). Once translocated to the Golgi, 
STING physically interacts with TBK1, through a conserved PLPLRT/SD motif in the C-terminal 
tail of STING, and becomes phosphorylated by TBK1 resulting in recruitment of IRF3 to the C-
terminal tail of STING and subsequent phosphorylation and activation by TBK1 (84, 85). 
Additionally, STING has been show to activate the IKK complex, through TRAF6 and TAK1 
signaling, resulting in activation of NF-B (86, 87). Once activate, IRF3 and NF-B translocate 
to the nucleus and promote transcription of IFNs and pro-inflammatory cytokines respectively 
(Fig. 2).  
 12 
1.1.2  Interferon Signaling  
The discovery of IFNs dates back to the 1950s. Studies of chick chorioallantois membranes 
in nutrient fluid highlighted the released a novel factor in response to heat killed influenza. Since 
this factor had the capability of “interfering” with the replication of live virus, it was termed 
Interferon (88). Approximately 20 years after its discovery, IFN, IFN and IFN were 
successfully purified, analyzed and characterized (89–91). As of today, several human IFNs have 
been identified and characterized, listed in Fig. 3, and are grouped as Type I, II and III IFNs based 
on sequence homology and receptor binding (92, 93). Type II IFNs are specific to immune cells 
while Type I IFNs are expressed by most nucleated cells. Type I and III IFNs are induced 
downstream of RNA and DNA sensing signaling pathways. Type II IFNs are predominantly 
secreted by activated T cells and NK cells in response to mitogen or cytokine (IL-12, IL-15, IL-18 
and type I IFN) stimulation (94). All IFN receptors consist of two subunits, which come together 
upon ligand interaction and relay signaling through JAK-STAT pathways (Fig. 3). The subunits 
of IFN receptors consist of N-terminal ligand domains, a transmembrane domain and cytosolic 
domain. The subunits of type I IFN receptors are characterized by alpha and beta chains 
respectively and are termed Interferon alpha/beta receptor alpha or beta chain (IFNAR1 and 
IFNAR2). The receptors of type III IFNs are composed of Interleukin 28 receptor alpha (IL28RA 
or more recently known as IFNR1) and Interleukin 10 receptor beta (IL10RB), which also 
functions in IL-10 signal transduction (95). Type II IFN receptors consist of two subunits made of 
alpha and beta chains (IFNGR1 and IFNGR2 respectively), however these receptors work in a 
four-chain complex in which IFNGR1 homodimers first interact with ligand facilitating IFNGR2 
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dimer association. Structures of IFNs and their receptors are listed and reviewed by Pestka et al. 
2004 (96).  
All IFNs share similar signaling and induction of ISGs through JAK-STAT signaling 
pathways. However, distinct Janus kinases that associate to the different classes of IFN receptors 
can lead to the formation of hetero or homo dimers of STAT proteins leading to the activation of 
select promoters (Fig. 3). IFN binding promotes interaction between receptor subunits, which 
brings receptor-associated Janus kinases JAK1 and TYK2 in close proximity to allow cross 
phosphorylation of the receptors (at tyrosine residues) leading to the recruitment of STAT1 and 
STAT2 proteins followed by their phosphorylation at specific tyrosine residues and  dimerization 
(97, 98). STAT1 and STAT2 heterodimer then recruits IRF9 and together form the ISGF3 
transcription factor complex. ISGF3 translocates to the nucleus and binds to IFN-stimulated 
response elements (ISREs) in the promoter regions of ISGs. STAT1 homodimers activated 
downstream of IFNGR activation are sufficient to induce the transcription of several ISGs by 
binding to the interferon gamma activated sequence (GAS) in the promoters of said ISGs. Together 
IFNs play crucial immunoregulatory roles including modulation of cells involved in innate and 
adaptive immunity, inflammation, regulation of tumor growth, antimicrobials defense and antiviral 
activity. During viral infections, IFNs lead to the expression of several ISGs, for example OAS, 
PKR, IFITs and MX1 after type I stimulation and IRF1, CXCL10, GBPs and MHC related proteins 
after type II stimulation. The goal of these proteins is to disrupt viral replication, by targeting viral 
nucleic acids for degradation or inactivation of viral proteins, enhancing MHC function of antigen 
presenting cells (APCs) and the induction of chemokines needed for the recruitment of immune 
cells responsible for clearing virus infected cells (reviewed in (99–101)).  
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In response to bacterial infections, type I IFNs can be protective or detrimental to the host 
and this outcome is reliant on bacterial replication and virulence factors (reviewed in (7, 102). 
Similarly IFN plays a crucial role during microbial infections and was validated by observations 
of increased pathogenicity to intracellular bacterial in mice with deficiencies in several proteins of 
the IFN signaling pathway (103). Some examples of IFN mediated antimicrobial immunity 
include expression of GBPs known to disrupt bacterial membranes or bacteria containing vacuoles, 
regulation of cytotoxic T cells and stimulation of autophagy (104–106). Type III IFNs share 
similarities to Type I IFNs in their signaling pathway, however immunoregulatory functions seem 
to be confined to epithelial and mucosal structures during viral and bacterial infections (107, 108). 
Overall IFN are responsible for conferring antiviral or antimicrobial resistance through the 
regulation of immune cells and expression of ISGs.   
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Figure 3. Type I, II and III IFN signaling 
Schematic of IFN signaling pathway following IFN engagement to respective receptors. Once IFN receptors become 
active they recruit JAK and STAT signaling proteins leading to the phosphorylation and dimerization of STAT 
proteins, followed by interactions with IRF9 during type I IFN signaling, and translocation to the nucleus. STAT homo 
or hetero dimers in complex with IRF9 bind to target promoters and induce expression of IFN stimulated genes.  
1.1.3  Interferon Regulatory Factors  
IRFs are a family of transcription factors that play crucial immunoregulatory roles in cell 
development and differentiation (109–112), oncogenesis (113, 114) and infection (115). Many IRF 
proteins are constitutively expressed and function in regulating IFN signaling pathways in 
response to viral or microbial infections (for example IRF3, IRF7 and IRF9). Several are IFN 
inducible and function in tumor suppression, lymphocyte development and intracellular infections. 
The expression and function of human IRF1-9 are summarized in Table 1. The structure of human 
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IRFs are quite similar, they share N-terminal DNA binding domains, nuclear localization 
sequences, signal-responding domains, C-terminal interferon association domains (which allow 
interactions with other IRFs) (Fig. 4). Additionally, for multiple IRFs there are activation or 
repressor domains at their C-terminus (116, 117). IRF proteins exist in the cytosol as monomers, 
but when phosphorylated in the signal responding domains by serine/threonine kinases undergo 
conformational changes to form dimeric structures and translocate to the nucleus to promote 
transcription. IRFs involved in type I IFN induction bind to the positive regulatory domains 
(PRDs) I and III of the IFN promoter and PRD-LE of the IFN promoter, through their DNA 
binding domains, and induce transcription of these genes (118). Different from other IRFs, IRF9 
works together with STAT1/STAT2 heterodimers during IFN signaling. It forms a complex 
referred to as ISGF3, which translocates to the nucleus and binds to ISRE in the promoter of several 
ISGs. Together IRFs are key regulators of inflammation, cellular development and differentiation, 
infection and in some cases progression of cancer.   
 
Figure 4. Structure of IRF family proteins 
IRF proteins are composed of a N-terminal DNA binding domain (blue) contain tryptophan (W) repeats and a C-
terminal regulatory domain (green). Type I (yellow) and type II (orange) interferon association domains are found 
within the regulatory domain. Several IRFs contain nuclear localization domains (purple) and some harbor repressor 
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domains (red). The activity of IRF1, 3, 5 and 7 is dependent on phosphorylation. Figure was adapted from Lohoff and 
Mak 2005 (119). 
 
Table 1. Summary of Interferon Regulatory Factors 
IRF Expression Function Reference 
IRF1 Inducible expression, highest 
with IFN, in most cell types 
Induction of antiviral and antimicrobial ISGs, 
type I IFN induction, regulation of immune cell 
function and differentiation, inflammasome 
activation and tumor suppression 
(104, 120), 
(118), (121–
123), (124, 125), 
(113, 126) 
IRF2 Constitutive and Inducible 
expression in various cell 
types 
Antagonism of IRF1 driven transcription, 
regulation of immune cell development and pro- 
or anti- oncogenic roles in Cancer  
(127), (128, 
129), (113, 130) 
IRF3 Constitutive expression in 
most cell types 
TLR dependent and independent induction of 
type I IFNs,  
(131, 132) 
IRF4 Constitutive expression in B 
cells, Macrophages and DC, 
inducible expression in T 
cells 
Negative regulation of pro-inflammatory 
cytokines by TLR signaling, regulates 
differentiation and development of various 
plasma and lymphocyte cells, promotes tumor 
growth in several cancers   
(133), (134), 
(113, 135) 
IRF5 Inducible expression in 
several myeloid cells and B 
cells 
Induction of pro-inflammatory cytokines and 
type I IFNs, roles in DNA damage mediated 
apoptosis, tumor suppressor  
(136, 137), (132, 
138), (113, 138) 
IRF6 Constitutive expression in 
epidermal cells  
Regulates epidermal cell development and 
differentiation, tumor suppressor  
(139–141), (113, 
142) 
IRF7 Constitutive expression in 
macrophages and 
plasmacytoid dendritic cells 
(pDCs), and inducible in 
other cell types 
TLR dependent and independent induction of 
type I IFNs, tumor suppressor  
(132, 143), (113, 
144)  
IRF8 Constitutive expression in B 
cells and DCs, inducible in 
Macrophages and T cells 
Type I IFN induction, regulates myeloid and 
lymphocyte differentiation, regulation of 
apoptosis and tumor suppressor  
(145), (146, 
147), (113, 148) 
IRF9 Constitutive and inducible 
expression in most cell types 
Promotes transcription of type I ISGs (as part of 
the ISGF3 complex), regulates induction of p53 
tumor suppressor protein 
(149, 150), (113, 
151, 152) 
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1.1.4  Interferon Stimulated Genes  
ISGs are simply defined as genes that are transcriptionally induced downstream of IFN 
signaling. Once IFNs are induced, following infection or recognition of self-nucleic acids, they 
bind to their receptors and through JAK-STAT signaling promote activation of transcription 
factors, which translocate to the nucleus and regulate ISG expression. As early as the 1980s it was 
found that treatment of cells with IFN lead to gene expression of several proteins that were not 
found in un-treated cells and inhibition of active translation by actinomycin D in IFN treated cells 
resulted in decreased levels of these IFN inducible proteins (153, 154). These data represent some 
of the earliest findings of ISGs and proposed that the antiviral state of IFN signaling may be 
mediated by the existence of these IFN inducible proteins. As of today, hundreds of genes have 
been identified as IFN inducible by microarray and transcriptome analysis in diverse mammalian 
species (155, 156). Although the role of ISGs was first described in the context of antiviral activity, 
ISGs have proven to be quite diverse and have been shown to regulate apoptosis, induce cytokine 
secretion, promote chemotaxis and cell adhesion, and provide antimicrobial immunity (155, 157–
159).  
In response to virus infection, viral nucleic acids lead  to the induction of IFN and 
subsequently the expression of multiple ISGs, which directly affect virus replication (160, 161). 
There are several conventional ISGs known to suppress viral replication by degrading virus genetic 
material and inhibiting viral protein synthesis. The antiviral activity of OAS proteins involves 
binding to dsRNA, synthesize 2’-5’ oligoadenylate links and activate the endoribonuclease RNase 
L. RNase L exists as inactive monomers and upon binding 2’-5’ oligoadenylates forms active 
dimeric structures that targets and cleave viral RNA, therefore inhibiting viral protein synthesis 
(162, 163). Protein Kinase R (PKR) is an ISG that inhibits the spread of virus by suppressing 
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protein synthesis. PKR is a serine/threonine kinase that becomes active when bound to dsRNA and 
phosphorylates the eukaryotic initiation factor 2 (eIF2) alpha subunit, which leads to global 
translational arrest and consequently inhibition of viral protein synthesis (164). Similar to OAS1 
and PKR, the Double -stranded RNA-specific adenosine deaminase ADAR exhibits its antiviral 
activity by binding to virus dsRNA. ADAR edits dsRNA by catalyzing the conversion of adenosine 
to inosine, which destabilizes the RNA and suppresses RNA virus replication (165). IFITs are a 
family of IFN inducible cytosolic proteins with direct or indirect antiviral mechanisms reviewed 
in (164, 166). IFIT1 and 2 can inhibit protein translation by binding to eukaryotic initiation factor 
3, therefore inhibiting formation of the translational initiation complex. Additionally, both IFIT1 
and 2 can directly bind to and sequester viral RNA therefore limiting viral replication. IFIT1 
specifically binds to RNAs lacking 2’-O-methylation at their 5’ cap or RNAs bearing a 5’ 
triphosphate group and IFIT2 can bind to AU rich RNAs. IFIT3 is known to form a large protein 
complex with IFIT1 and 2 and this interaction is needed for IFIT1 antiviral activity by sequestering 
RNA. Additionally, IFIT3 itself can promote antiviral activity by enhancing MAVS signaling by 
functioning as an adaptor between MAVS and TBK1 (167). Human MX proteins 1 and 2 are 
dynamin-like GTPases with broad antiviral activity depending on the species of virus. MX1 
interferes with influenza ribonucleoproteins therefore affecting viral transcription and mRNA 
translation and MX2 has been shown to inhibit nuclear import of HIV DNA and therefore 
integration of DNA into the host genome (168–170). Viperin is an example of an ISG capable of 
restricting a variety of DNA and RNA viruses by interacting with both viral and host proteins (171, 
172).  Similar to RNase L, Zinc-finger antiviral protein (ZAP) restrict RNA virus replication by 
targeting RNA for degradation. ZAP binds to CG-rich sequences on viral RNA through its N-
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terminal domains. This interaction interferes with the assembly of the translation initiation 
complex and ZAP recruits RNA processing proteins, which degrade viral RNA (173).  
ISG15 is di-ubiquitin like protein that is significantly induced during viral infection, 
however the mechanisms of its antiviral activity remain unclear. Mice deficient in ISG15 are 
susceptible to influenza and herpes virus, confirming the ISG15 indeed confers antiviral immunity 
(174). Evidence suggests that ISG15 may disrupt viral and host protein interactions required for 
replication and can prevent release of viral particles through post-translational modification 
(ISGylation) of both viral and host proteins (160, 175). Some studies have reported that ISG15 
promotes secretion of IFN and IL10 secretion, suggesting potential immunomodulatory roles of 
ISG15 (176). Immunomodulation in the host is also carried out by many other ISGs, several which 
enhance the transcription of other ISGs, for example IRFs. IRF1 is an IFN stimulated ISG, which 
also acts as a modulator of type I IFNs, tumor suppressor genes and of cytokines and chemokines 
required for immune cell development (120). Additionally, ISGs can lead to the secretion of 
several immunomodulatory cytokines including IL-12, IFN and TNF. Early studies have shown 
that IFN is capable of inducing IL-12 in antigen presenting cells leading to subsequent induction 
and secretion of IFN IFN then regulates the activation and differentiation of T cells and 
potentiates the effects of IL-12 on APCs (177–181).  
ISGs also play crucial roles in cell chemotaxis and development, for example chemokines 
that recruit myeloid and lymphocytes to the sites of infection and MHC proteins, which help bridge 
innate and adaptive immunity. CXCL9, 10 and 11 are all examples of IFN inducible chemokines 
secreted mostly by monocytes, endothelial cells and fibroblasts. These chemokines bind to their 
receptor, CXCR3, on the surface of other monocytes, T cells,  natural killer (NK) cells and DCs 
promoting cellular chemotaxis and proliferation (182, 183). Both type I and type II IFNs are 
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important modulators of MHC class I and II expression, which is required for antigen presentation 
and activation of adaptive immune cells in response to pathogen infection or cancer progression 
to mediate regulatory and cytotoxic roles (184–187).  
There are several antiviral ISGs that function to inhibit viral entry and uncoating, block 
nuclear import and prevent assembly of virus particles. Nuclear receptor coactivator 7 (NCOA7) 
is an ISG that can inhibit entry of influenza A and hepatitis C virus into the cytosol by regulating 
endosomal physiology preventing viral fusion with endosomal membranes and release of nucleic 
acids into the cytosol (188). The IFN-induced transmembrane (IFITM) family of proteins can also 
inhibit entry of several enveloped viruses (Influenza A, flaviviruses, filoviruses and coronaviruses) 
and have also been shown to traffic virus particles to lysosomes for degradation (155, 166, 189). 
The ISG tripartite motif-containing protein 5 alpha (Trim5) is an E3 ubiquitin ligase that works 
post viral entry but can restrict retroviral replication by targeting viral capsids and inducing 
transcription of inflammatory cytokines mediated by TAK1 signaling (190). A PRYSPRY domain 
in the C-terminus of Trim5 can recognize the HIV-1 capsid forming a hexagonal lattice structure, 
which is targeted for degradation by the proteasome (191, 192). The apolipoprotein B mRNA-
editing enzyme catalytic polypeptide-like protein family (APOBEC) are DNA cytosine 
deaminases that function in the restriction of DNA pathogens and retroviruses. APOBEC3 for 
example inhibits viral gene expression and replication by catalyzing the deamination of cytosine 
to uracil in ssDNA resulting in G to A hypermutations in retroviral cDNA (193).  
Some ISGs are capable of restricting virus by directly binding viral proteins. During HIV assembly 
and trafficking, the transmembrane protein Tetherin anchors virion particles to membranes 
inhibiting their release from infected cells and limits the spread of the virus throughout the host 
(194). 2’-3’ cyclic nucleotide 3’-phosphodiesterase (CNP) is another ISG that targets viral proteins 
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directly, specifically CNP can bind to the major structural protein Gag of HIV inhibiting particle 
assembly (195).  
IFNs also induce or potentiate the effects of several intracellular DNA and RNA sensors. 
IFI16 is one ISG that has been well characterized as a sensor of cytosolic DNA. Additionally, 
IFI16 plays a role in suppressing the transcription of human cytomegalovirus (HMCV) DNA 
polymerase, therefore inhibiting DNA replication (196). IFI16 has also been shown to repress 
herpes simplex virus 1 (HSV-1) gene expression by modulating histone modifications (196, 197). 
In addition to IFI16, many of these intracellular receptors are expressed at lower levels under basal 
conditions to maintain cellular homeostasis and avoid inflammatory damage. However, during 
infection the expression of many PRRs, for example RIG-I, MDA5, IFI16 and cGAS, are enhanced 
by IFN stimulation in order to sensitize cells to pathogen detection and therefore enhance 
antimicrobial or antiviral activity (157, 158, 198). On the other hand there are ISGs, such as 
suppressor of cytokine signaling (SOCS) proteins, which act as inhibitors of TLR and JAK-STAT 
signaling pathways, that desensitize cells in order to maintain immune balance (199). 
As described previously, the antiviral role of ISGs have been extensively studied, however 
their role during bacterial infection remains uncertain. Several ISGs that function in antiviral 
immunity have also been shown to inhibit replication of bacteria, for example ISG15 and Viperin. 
ISG15 promotes IL-6 and IL-8 secretion required for restricting L. monocytogenes infection (200). 
Viperin is another example of an antiviral ISG known to restrict bacterial infections. Viperin 
expression is also upregulated during bacterial infection and can restrict L. monocytogenes and 
Shigella flexneri. For S. flexneri specifically, viperin has been shown to restrict entry into host cells 
(201).  
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Many ISGs that work against bacterial infections function by disrupting bacterial or 
endosomal compartments harboring bacteria. This exposes bacterial ligands to intracellular 
receptors, which promote IFN signaling and inflammasome activation. These pathways regulate 
cytokine secretion needed for the recruitment and activation of cells essential for bacterial killing. 
Additionally, bacterial infection can lead to the transcription of apoptotic ISGs, including Caspase 
and Fas proteins. Caspase-4 is both IFN and IFN inducible and has been shown to promote 
inflammasome activation in response to infection with Gram-negative bacteria (202, 203).  IRF1 
regulates the transcription of several GBPs required for bacterial killing and inflammasome 
activation. Cells infected with the intracellular pathogens Listeria monocytogenes or Fransicella 
novicida lead to the induction of IRF1 followed by GBP expression.  GBPs are responsible for 
disrupting bacterial membranes, which releases bacterial DNA into the cytosol and activate AIM2 
inflammasomes (124, 204). GBPs also provide protection against intracellular parasitic infections, 
for example Toxoplasma gondii, and several viruses. The susceptibility to several pathogens to 
different GBP knock-out mice is reviewed in (104). In addition to inflammasome activation, GBPs 
can re-route phagosomes harboring intracellular pathogens to lysosomal degradation, enhance 
formation of reactive oxygen species and promote autophagy (205–207). 
Overall antimicrobial and antiviral ISGs may vary in function depending on the class of 
pathogen detected in the host and exhibit broad activities in order to clear infection. Therefore, it 
is crucial to study the broad spectrum of ISGs and their functions  to understand the mechanisms 
underlying host-pathogen interactions and develop effective antimicrobial or antiviral therapies. 
This dissertation describes a novel role of the ISG OAS1 in restricting the replication of viral and 
bacterial pathogens by an RNase L independent mechanism.  
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1.2 Oligoadenylate Synthetases  
The OAS family proteins are a group of IFN inducible proteins first described to inhibit 
viral replication by activation of RNase L, a global suppressor of translation. The discovery of 
OAS proteins began with the observation that IFN lead to the activation of proteins, which in 
response to dsRNA inhibited cellular translation, therefore limiting translation of viral genes and 
replication (208). The ability to suppress translation was later attributed to a dsRNA dependent 
protein kinase known as PKR and a low molecular weight (LMW) inhibitor found in cell extracts 
of dsRNA treated cells (209, 210). The LMW inhibitor was identified as 2’-5’ oligoadenylates that 
are linked through 2’-5’ phosphodiester bonds and the enzyme (OAS) responsible for their 
synthesis was purified from mouse cells (211, 212). During the same period of time that OAS 
enzyme was discovered it was apparent that synthesis of 2’-5’ oligoadenylates lead to the 
activation of an endonuclease responsible for the degradation of cellular and viral RNAs.  It wasn’t 
until a few years later that this RNase was successfully cloned and analyzed (213–215). Today we 
know this endonuclease as RNase L, which exists as inactive monomers in the cytosol and comes 
together in a dimeric structure upon binding to 2’-5’ oligoadenylates, thus becoming active and 
leads to RNA cleavage (162, 216, 217). Once OAS enzyme was discovered, it did not take long 
before both mouse and human OAS was purified, revealing the existence of two forms of OAS 
(218–220). Through cDNA expression and sequencing, two forms of OAS (42kd and 46kd) were 
identified and characterized revealing a difference specifically at the C-terminus of these proteins, 
which was elongated in the larger variant (221, 222). In addition to these variants of OAS, the 
existence of two larger forms of OAS (69kd and 100kd) were discovered by monoclonal antibodies 
designed to identify OAS, revealing that several forms of OAS exist and share a homologous 
primary structure (223). Characterization of these larger OAS proteins revealed that they 
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synthesize 2’-5’ oligoadenylates varying in length under different cellular conditions (dsRNA 
concentration and pH for example) and additionally Northern blot hybridization assays revealed 
that probes designated to recognize OAS mRNA did not work on mRNAs from the larger OAS 
variants. This suggested that these larger OAS proteins are translated from mRNAs that were 
transcribed from another set of genes (223–225).  
Currently these OAS variants capable of synthesizing 2’-5’ oligoadenylates are known as 
OAS1, OAS2 and OAS3 and share similar structural and functional domains. They all share a 
NTase domain, required for binding dsRNA and catalyzing 2’-5’ oligoadenylate synthesis from 
ATP, and one, two or three OAS domains on OAS1, OAS2 and OAS3 respectively.  In addition 
to OAS1-3 an enzymatically inactive variant of OAS exists, called OASL, which shares the same 
OAS domain as the other family members but does not contain a NTase domain, instead it has two 
ubiquitin-like domains at its C-terminus that mediate antiviral activity by enhancing RIG-I 
signaling (226, 227). Similar to humans, mouse genomes encode several OAS family proteins, 
some which are enzymatically active and others inactive (14). However, antiviral functions have 
been attributed to enzymatically inactive members of the OAS family, for example OASL antiviral 
activity and flavivirus resistance by the mouse ortholog to human OAS1 (Oas1b) (228, 229). These 
findings indicate that there are several antiviral mechanisms that are yet to be discovered for 
members of the OAS family, which is further implied by the discovery that OAS3 is sufficient and 
necessary for the activation of RNase L (17). However, overexpression of OAS1 and OAS2 still 
confers antiviral resistance, suggesting that RNase L independent mechanisms of antiviral activity 
exists for these proteins.   
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1.2.1  OAS Structure and Function  
The human OAS family is a group of IFN inducible proteins consisting of OAS1, OAS2, 
OAS3 and the enzymatically inactive OASL protein. Through in situ hybridization, OAS1-3 genes 
were mapped to a 130kb region on chromosome 12 (12q24.1) and OASL was mapped in proximity 
to the OAS1-3 gene cluster on chromosome 12q24.2 and are approximately 1Mb apart (225, 230, 
231). In mice the OAS family has been mapped to the murine chromosome 5F. Murine Oas2 and 
Oas3 genes share very similar exon and intron structures to human OAS2 and OAS3 genes, 
however there are 8 Oas1 genes in mice, presumably originating from gene duplication, and are 
all transcriptionally active after IFN treatment (14, 232). For OASL there are two variants in mice, 
Oasl1 which shares 74% identity to human OASL and Oasl2 which shares 49% identity and most 
likely originated from gene duplication of Oasl1 (14). All human and mouse OAS genes share a 
high degree of identity in their first 5 exons, suggesting that the OAS family has originated from 
a common ancestral gene, which has been proposed by Kumar et al. 2000 (233). The positioning 
of both human and mouse OAS family members in their respective genomes is summarized in Fig. 
5, along with their enzymatic activity and potential mechanisms of antiviral functions. 
 
Figure 5. Genomic structure of human and mouse OAS gene family 
Schematic of human (left) and mouse (right) OAS genes and known antiviral functions. Genes encoding enzymatically 
active proteins are labeled in green and genes encoding inactive proteins are labeled in red.  
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All members of the OAS family with the ability to synthesize 2’-5’ oligoadenylates share 
an OAS domain containing NTase domains within them, allowing for binding to RNA substrate 
and processing of ATP into 2’-5’ oligoadenylates through specific catalytic residues (discussed 
below). On the other hand, the catalytically inactive member of the OAS family, OASL, contains 
an OAS-like domain with mutations at key residues that abolish its catalytic function and a unique 
C-terminal domain containing ubiquitin-like sequences. OAS2 and OAS3 contain one and two 
inactive OAS-like domains respectively in addition to the catalytically active domain, the domain 
structure of all human OAS proteins is summarized in Fig. 6.  
 
Figure 6. OAS protein domains 
Schematic of protein domains found in OAS family members. OAS-like domains are colored in blue and gray, OAS 
domains, containing the active NTase domain, are colored in green and gray and ubiquitin-like (UBL) domains are 
identified as orange ovals.  
 
OAS proteins belong to a NTase superfamily and one key feature of this polymerase family 
is the presence of a catalytic triad composed of aspartic or glutamic acids required for coordination 
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between magnesium ions and nucleotides in order to catalyze the nucleotide polymerization (234). 
Structural comparison between DNA polymerase  and OAS2 revealed three aspartate residues 
that formed part of a catalytic triad similar to that of the polymerase, which is conserved among 
OAS family proteins. Mutagenesis of the residues in the catalytic triad to alanine resulted in 
impaired synthetase activity (235). Crystal structure analysis of porcine OAS1 confirmed the 
presence of this catalytic triad formed by three aspartate residues D74, D76  and D147 on different 
beta strands and similar to OAS2 mutations of these residues to alanine abolished catalytic activity 
(236). Additionally, analysis of the crystal structure of porcine OAS1 also revealed a key serine 
residue (S62), which interacts with phosphate on ATP and several arginine and lysine residues 
(R38, K41, K59E, R194, R198 and K203) required for RNA binding. Association with RNA 
promotes conformational changes of OAS proteins required for efficient enzyme activity.  
OASL is devoid of enzyme activity due to a threonine residue present at the third carboxyl 
acid of the catalytic triad instead of aspartate, but shares the same RNA binding residues as OAS1, 
which are required for binding dsRNA and enhancing RIG-I signaling (13, 237). During RNA 
virus infection OASL is induced and binds to RIG-I mimicking polyubiquitin and enhancing RIG-
I sensitivity to the RNA ligand, leading to more IFN production (238). However, during DNA 
virus infection OASL instead downregulates IFN production allowing replication of DNA viruses. 
Ghosh et al. 2018 demonstrated that OASL-deficient cells showed increased levels of IFN and 
lower viral titers for DNA viruses, and that cGAS-mediated IFN induction was needed for 
restricting virus in OASL-deficient cells. OASL was shown to bind directly to cGAS resulting in 
inhibition of cGAMP production, serving as a negative feedback-regulator of cGAS mediated 
immunity, therefore maintaining cellular homeostasis (239). Different to the oligonucleotides 
synthesized by polymerases (3’-5’ phosphodiester links), OAS proteins upon binding dsRNA 
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synthesize 2’-5’ oligoadenylate links that vary in length. OAS1, OAS2 and OAS3 function as 
tetramers, dimers or monomers respectively, which synthesize trimeric or hexameric, tetrameric 
and dimeric 2’-5’ oligoadenylates respectively (235, 236, 240, 241). However it has been reported 
that OAS3 is more sensitive to dsRNA ligand as compared to OAS1 and were shown to synthesize 
longer 2’-5’ oligoadenylates with trimeric structures needed for RNase L activation (242).  
Recent studies by Li et al. 2016, revealed that OAS3 was sufficient for the activation of 
RNase L in response to viral infection. OAS1- and OAS2-deficient cells were still capable of 
activating RNase L and degrading ribosomal RNA (rRNA), however this phenotype was 
completely abolished in OAS3-deficient cells, similar to RNAse L-deficient cells, suggesting that 
RNAse L activation can be mediated by OAS3 alone (17). Although OAS1 and OAS2 are not 
strictly required for activating RNase L, overexpression of these proteins reduced susceptibility to 
viral infections. For example, OAS1 is known to play roles in host defense against WNV, dengue 
virus (DENV), EMCV and has also been shown to provide antimicrobial defense against 
intracellular bacteria such as M. tuberculosis (243–246). The existence of antiviral roles 
independent of RNase L in both catalytically active and inactive members of the human OAS 
family is mirrored in mouse OAS proteins. The exon and intronic structure of mouse Oas2 and 
Oas3 is identical to human OAS2 and OAS3 and the amino acid sequences of these exons share a 
high degree of homology, suggesting that these proteins in mice are functionally equivalent to their 
human counterparts (14). There have been two OASL orthologs identified in mice: Oasl1 which is 
enzymatically inactive and Oasl2 which is active. Oasl2 contains two aspartate residues, which 
allows it to exhibit OAS enzyme activity, however studies in bone marrow derived macrophages 
(BMDMs) from Oasl2-deficient mice revealed reduced RIG-I signaling, resulting in enhanced 
viral replication. (13). In response to DNA virus infection, Oasl2 shares similar functions as human 
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OASL. Oasl2-deficient mice, infected with several DNA viruses, showed higher levels of IFN 
production resulting in reduced viral replication (239). Together these data suggest that Oasl2 
works as the functional equivalent to human OASL. Different to the other murine OAS proteins, 
there are eight Oas1 genes closely related to human OAS1, several which are enzymatically active 
and the rest inactive. Sequence analysis of all murine Oas1 genes revealed a high degree of 
homology between the first five exons of each gene with human OAS1 exons 1-5 and differ in their 
C-terminal amino acid residues (Fig. 7).  
 
 
Figure 7. OAS C-terminal Sequences 
Protein sequence analysis of the C-terminal domain of human OAS1 isoforms and murine Oas1 proteins. Protein 
sequences were aligned using Clustal Omega and compared to the consensus sequence.  Full sequence alignment is 
available in Appendix A.  
 
Among all the murine Oas1 proteins, only Oas1a and Oas1g are capable of synthesizing 
2’-5’ oligoadenylates, however studies show that Oas1b and Oas1d are capable of inhibiting Oas1 
synthetase activity in response to p(I):p(C), suggesting potential negative feedback roles among 
murine Oas1 proteins (247, 248). The inactive Oas1 proteins (b-f, h) are still capable of binding 
dsRNA, but the function of these proteins are still not completely clear (247, 249). Oas1b however 
was mapped to a flavivirus resistance gene and full length Oas1b confers antiviral resistance 
against WNV (248). The susceptibility to flavivirus infection is observed in many common 
laboratory strain mice as compared to several populations of wild Mus musculus domesticus mice 
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(subspecies of house mice), which are resistant to viral infection, and the alleles that determine 
susceptibility and resistance were designated as Flvs and Flvr (250). The gene responsible for the 
flavivirus phenotype was mapped to Oas1b by a positional cloning strategy. Mice susceptible to 
infection encoded a C-terminal truncated variant of Oas1b as compared to resistant mouse strains, 
which encode full length Oas1b (Fig. 6) (228). Additionally, the Flvr phenotype was restored in 
flavivirus susceptible mouse strains by genetic knock-in with Oas1b capable of expressing full 
length Oas1b, confirming that this phenotype is mediated by Oas1b alone (251). WNV are 
sensitive to RNA degradation by RNase L, however it is clear that deficiency in the enzymatically 
inactive Oas1b protein is detrimental to mouse survival (252, 253). In humans, a single nucleotide 
polymorphism (SNP) in human OAS1 has also shown susceptibility or resistance to flavivirus 
infection (discussed below). These studies suggest that although Oas1b lacks enzymatic activity, 
it could be the functional equivalent to OAS1 and their antiviral activity is independent of RNase 
L (243, 254).   
1.2.2  Oligoadenylate Synthetase 1 
OAS1 is the smallest of the human OAS family proteins with only one catalytically active 
OAS domain in its protein structure (Fig. 6). The catalytic domain of OAS proteins was first 
characterized by Sarkar et al. 1998 by comparing structural models for OAS2 with DNA 
polymerase  which identified a potential catalytic triad of aspartate residues in a highly conserved 
region found in OAS1, OAS2 and OAS3 (235). The presence of this catalytic triad was confirmed 
in OAS1 by analysis of the crystal structure of porcine OAS1 by Hartmann et al. 2003 (236). This 
crystal structure revealed a short N-terminal, followed by the large catalytic domain of OAS 
proteins and a helix-loop linker domain, which connects the catalytic domain to the large C-
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terminal domain of OAS1. Additionally, characterization of the crystal structure of porcine OAS1 
identified several residues required for catalytic activity and RNA binding (236). The crystal 
structure of human OAS1 bound to dsRNA was characterized by Donovan et al. 2013 providing 
more insight into the conformational changes and functionality of OAS1 (Fig.8). The first two 
aspartate residues of the catalytic triad are found on the catalytic domain of OAS1 while the third 
residue is found at the C-terminal domain. These residues come together after dsRNA has bound 
to OAS1, inducing a conformational change that exposes the negatively charged pocket of the 
OAS1 monomer to the ATP ligand (Fig.8A-B). RNA binding is crucial for the activation of OAS1 
and mutation of the lysine and arginine required for RNA binding to negatively charged amino 
acid residues greatly effects activation and function of OAS1 (Fig. 8C left). For optimal binding 
to ATP, two Mg+2 ions are required to bridge the catalytic triad of OAS1 to the ATP ligand and 
catalytic activity is abolished my mutating aspartate to alanine (Fig.8C right).  
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Figure 8. Crystal structure of human OAS1 
Ribbon structure of OAS1 bound to dsRNA and ATP ligand (A). Electrostatic potential surface structure of OAS1 
facing towards the negatively charged pocket of OAS1, which binds to ATP ligand (B). Residues needed for RNA 
binding (left) and residues forming part of the catalytic triad (right) in OAS1 (C). The crystal structure obtained from 
the RCSB protein data base (4ig8) where analyzed by USCF Chimera.  
 
Alternative splicing of the OAS1 gene can lead to the expression of several isoforms: P35, 
P42, P44a, P46, P48 and P52. Interestingly a SNP (rs10774671) found in OAS1 affects the 
expression of these isoforms (255). The SNP rs10774671 is positioned at the acceptor site of exon 
6 and the nucleotides found at this position can vary between adenine or guanine (A or G allele 
A B 
C 
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respectively). The genotype of this SNP can be determined by restriction fragment length 
polymorphism (RFLP) assays using AluI restriction enzyme (developed by Noguchi et al. 2012). 
Although 6 isoforms of OAS1 exists, P42 and P46 isoforms are most abundantly expressed in cells 
that are homozygous for the A or G allele respectively as compared to the other isoforms, 
suggesting that these isoforms are most crucial for mediating antiviral activity (254). However, 
analysis of the OAS1 SNP in patients and healthy cohorts has revealed that the genotype of the 
SNP is crucial for dictating antimicrobial and antiviral protection (246, 254, 256). Heterozygous 
expression of the G allele is sufficient to confer antiviral protection against to flaviviruses and is 
most likely attributed to the predominant expression of the P46 OAS1 isoform, similar to the 
phenotype observed in mice expressing full length Oas1b (Fig. 9). It is crucial to note that 
differences between OAS1 P42 and P46 are restricted to the C-terminal, which is very interesting 
considering that the antiviral phenotype of murine Oas1b is also mediated by differences at the C-
terminus. This suggests that the C-termini of both human and mouse OAS1 are crucial for 
protection against invading pathogens through an RNase L independent mechanism that has yet to 
be described.  
 
Figure 9. OAS1 SNP rs10774671 and Oas1b flavivirus associated alleles 
Exon and intronic structure of human OAS1 p42 and p46 (left) and both truncated and full length Oas1b (right). The 
amino sequence alignment of the C-terminal region of OAS1 p42 and p46 is provided to highlight the differences of 
these two isoforms.  
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1.2.2.1 Antiviral role of OAS1 
 
Early studies overexpressing both human and mouse OAS1 found that these proteins were 
capable of inhibiting viral replication of EMCV and it was thought that this antiviral activity was 
mediated through 2’-5’ synthetase/RNase L activity (257, 258). However, Kristiansen et al. 2010 
showed that extracellular porcine OAS1 was capable of inhibiting EMCV by a RNase L 
independent mechanism (245). Similarly, several studies have eluded to both RNase L dependent 
and independent mechanisms of antiviral activity against flavivirus infection (229, 244, 252, 253). 
Until now the mechanism of OAS1 antiviral activity is still not clear. However, the findings that 
OAS3 is mostly responsible for activation of RNase L and that Oas1b antiviral activity is strictly 
independent of RNase L, are sufficient evidence to hypothesize that human OAS1 is capable of 
restricting virus through an RNase L independent pathway. Additionally, genetic variation of the 
OAS1 SNP rs10774671 influences isoform expression and virus susceptibility (Fig. 9). This SNP 
in OAS1 has been shown to be crucial for the susceptibility of both Hepatitis B and C virus (HBV 
and HCV). Individuals homozygous for the A allele of rs10774671 are more susceptible to HBV 
infection, which can contribute to the development of the autoimmune disease Sjögren’s 
syndrome. On the other hand, the presence of the G allele, which promotes OAS1 p46 expression 
is capable of inhibiting HBV replication (259). Interestingly, this same SNP in OAS1 was 
correlated to response to IFN therapy and disease progression of HCV. Individuals homozygous 
for the A allele were associated with non-responsive therapy as compared to better responses to 
therapy in individuals harboring at least one copy of the G allele (260). A similar trend has also 
been observed for WNV, in which individuals homozygous for the A allele were more susceptible 
to WNV infection as compared to individuals hetero- or homozygous for the G allele (243). These 
 36 
correlative studies between the SNP rs10774671 and viral susceptibility suggest that OAS1 p46 is 
required for the antiviral activity of OAS1. Similarly, studies in murine Oas1b confirm that WNV 
antiviral activity is independent of RNase L.    
1.2.2.2 Antibacterial role of OAS1 
 
In response to bacterial infections host cells secrete IFN, however depending on the 
bacterium, the IFN response can restrict or enhance bacterial growth (102). Traditionally OAS 
family proteins have been shown to restrict virus, however several transcriptomic analysis have 
revealed that OASL is up-regulated in several cell types in response to several intracellular 
pathogens (261, 262). Both probacterial and antibacterial effects has been associated to OASL. 
STING dependent production of OASL was shown to promote survival of Mycobacterium leprae 
by inhibiting expression of antimicrobial peptides and autophagy, and knock-down of OASL 
promoted cGAS dependent autophagy and clearance of M. leprae (263). On the other hand, knock-
down of OASL in the context of M. tuberculosis infection resulted in a decrease of pro-
inflammatory molecules (IL-1, TNF and MCP-1) and increased replication of M. tuberculosis 
(262). In addition to OASL, OAS1 has been associated M. tuberculosis susceptibility. The same 
SNP in human OAS1, which is involved in virus susceptibility, rs10774671, also confers 
protection against M. tuberculosis. A case-control study genotyped whole blood, from TB infected 
patients and healthy cohorts, for the OAS1 rs10774671 SNP and found a correlation between the 
G allele and protection against M. tuberculosis (246). Although correlations between microbial 
protection and OAS family proteins have been established, the mechanisms are yet to be defined.    
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1.3 West Nile Virus 
1.3.1  WNV Prevalence and Pathogenesis  
WNV is a positive single stranded RNA virus belonging to the Flaviviridae family and is 
primarily transmitted through mosquitoes. It is one of the leading causes of mosquito borne 
illnesses in the continental United States (US) and can cause severe neurodegenerative disease in 
immunocompromised individuals. The enzootic cycle of WNV is maintained between mosquitos 
and birds, infected birds develop high titers of virus, which are transmitted from host to host 
through mosquito vectors (264). The disease can be transmitted to mammals through infected 
mosquitos; however, they are considered dead end hosts since they do not develop high levels of 
virus in their blood and are incapable of passing the virus on to uninfected mosquitos. Although 
transmission between mammals is highly unlikely, cases of WNV in the US remain prominent. 
From 1999-2018 the CDC has reported over 50,000 cases of WNV disease, 24,000 cases of WNV 
related neurodegenerative disease and 2300 deaths. Additionally, WNV has played a significant 
impact on the aviary ecosystem of the US causing mortality in over 300 bird species and massive 
population declines in at least 23 species (265, 266).  
WNV was first isolated in Uganda in 1937 and remained endemic in African regions, 
Europe, Asia, Australia and the Middle East (265).  It was first reported in the US in 1999 
following an outbreak in NY, which quickly spread throughout the country.  It reached its peak in 
2003 with several of cases reported in 48 states and registered the largest number of neuroinvasive 
cases related to WNV (264, 267). As of 2004 the number of cases has relatively stabilized, with 
the exception of the 2012 outbreak, the largest outbreak in the US since 2003. The spread of WNV 
throughout the US can be tracked using the open-source tool nextstrain maintained by Grubaugh 
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Lab and James Hadfield (nextstrain.org/WNV/NA). Although the numbers of cases have stabilized 
in the US, there are several individuals at risk for WNV mediated disease and a cost-effective 
vaccine for WNV has yet to be licensed for use in humans. However several vaccines have been 
licensed for horses, another common dead end host of WNV (264). Prevalence of WNV is not 
exclusive to the US, throughout the years WNV spread through the Americas, however the severity 
of disease is not as high that could be related to cross-protection originating from infection with 
other mosquito-borne viruses (265, 268, 269). Outbreaks of WNV have been documented in birds, 
horses and humans in Europe and Eastern Mediterranean region as early as the 1950s (270, 271). 
Phylogenic analysis of WNV strains suggests that the 1999 NY strain originated from Israel and 
spread to the US (265, 270–272). Although WNV has transmitted globally, the level of concern is 
not as high as compared to more infectious and deadly viruses.  
Most individuals infected with WNV remain asymptomatic, some develop common 
symptoms such as fever, aches or digestive problems. Few, such as the elderly, 
immunocompromised or people with chronic illness, can develop severe illness affecting the 
central nervous system, which can lead to encephalitis, meningitis and paralysis (273).  Sejvar 
2016, reviews the clinical manifestations of WNV in great detail (264). There are several genetic 
factors that influence WNV susceptibility, among these are polymorphisms in OAS1, IRF3 and 
MX1 and a homozygous gene deletion found in C-C motif chemokine receptor 5 (CCR5). Mice 
deficient in CCR5 exhibit reduced leukocyte trafficking to the central nervous system, increased 
viral burden and mortality in response to WNV infection. Further studies are needed to determine 
how polymorphisms in IRF3 and MX1 alter their protein expression and also investigate the 
mechanisms of OAS1 WNV antiviral defense (274). Due to the global emergence and spread of 
WNV and the lack of vaccines or effective antiviral therapies, it is important to identify crucial 
 39 
components of the host immune response, required for clearing WNV, which could be used for 
therapy by potentiating the immune response against WNV.     
1.3.2  Molecular Biology of WNV 
WNV belongs to the Flavivirus genus, a group of enveloped positive senses single stranded 
RNA viruses. This genus includes: Zika (ZIKV), Dengue (DENV), Japanese encephalitis virus 
(JEV), Kunjin (KUNV) now considered a subtype of WNV and yellow fever virus among others. 
The WNV genome contains a type 1 cap structure (m7GpppAmp) at the 5’ end and lacks a 3’ poly 
A tail as seen in most flavivirus (275). At both the 5’ and 3’ ends of WNV RNA there are non-
coding regions (NCR) required for folding of RNA into secondary stem loop structures, which are 
conserved among flavivirus and deletions in the stem loop sequence are detrimental in forming 
infectious particles (276).  
The genome of WNV is translated into a single polyprotein, which is proteolytically 
cleaved into three structural proteins (capsid, membrane and envelope proteins) and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). WNV membrane (M) and 
capsid (C) proteins are glycosylated, which allow them to interact with various 
glycosaminoglycans on the cell surface, followed by attachment to C-type lectin receptors and 
endocytosis (276, 277). Additionally, phosphatidylserine binding proteins belonging to the TIM 
family, cellular integrins and laminin-binding proteins have also been shown to facilitate WNV 
entry into host cells (278–280). Once engulfed, viral particles remain associated to endosomes, 
followed by fusion of viral and endosomal membranes, which releases nucleocapsids and virus 
RNA into the cytosol. The viral genome is translated into a single polyprotein and NS2B-NS3 
serine proteases process the polyprotein into mature proteins (281). NS5 or viral RNA-dependent 
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RNA polymerase (RdRp) in conjunction with viral NSPs and host proteins initiates replication of 
negative sense RNA, which serve as templates for the replication of positive sense genome RNAs 
(275, 276, 282). Reorganization and assembly of synthesized genomes and translated proteins 
leads to association with rough ER membranes, where viral particles are packaged followed by 
release of infectious particles into the extracellular environment (276). In addition to their 
structural roles and functions in viral replication, several flaviviral proteins through pathogen-host 
evolutionary arm races, have developed the ability to antagonize host immune responses in order 
to promote virus survival (283). The mechanisms of flavivirus antagonism of host immune 
response is summarized in Fig. 10.  
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Virus Protein Function Reference 
NS1 WNV NS1 binds to RLRs inhibiting IFN induction and 
promoting degradation of RIG-I and MDA5 
(284) 
NS2A The majority of flaviviral NS2A proteins are potent inhibitors of 
IFN promoter driven transcription 
(285) 
NS2B3 DENV NS2B3 interacts with IkK, masking its kinase domain, 
therefore inhibiting IRF3 phosphorylation and activation 
(286) 
NS3 WNV and DENV NS3 bind to 14-3-3e adaptor proteins required 
for translocation of RIG-I to mitochondrial surfaces 
(287) 
NS4A, NS4B DENV NS4A and NS4B have been shown to bind to MAVS 
and disrupt interaction with RIG-I. DENV and WNV NS4B 
have been shown to block TBK1 phosphorylation and 
activation. The majority of flaviviral NS4B proteins have been 
shown to block activation and translocation of STAT1 
(288–290) 
NS5 WNV NS5 has been shown to decrease surface expression of 
IFNAR1 receptors. ZIKV, DENV and YFV NS5 have been 
shown to target and induce degradation of STAT2 
(291–293) 
 
Figure 10. Antagonism of host immune response by flavivirus 
Several flaviviral non-structural proteins have been shown to antagonize RLR signaling and induction of IFNs (left) 
or antagonize IFN receptor signaling (right).  
1.3.3  Host Antiviral Immune Response to WNV 
In order to study pathogenesis and host immune responses to WNV several animal models 
have been developed, for example subcutaneous footpad injections in mice, which mimics 
mosquito delivered virus (274). WNV first replicates in skin keratinocytes and skin residents DCs, 
followed by viral replication in lymph nodes and spread to peripheral tissues and organs (294, 
295). As mentioned above, WNV can cause neuroinvasive disease by infecting neuronal and 
myeloid cells within the CNS and it is believed that WNV crosses the blood brain barrier in order 
to establish infection (296, 297).  
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Control of WNV is dictated by innate antiviral responses that lead to the induction of IFN 
and expression of ISGs required for viral suppression, regulation of apoptosis and viral clearance 
and the establishment of adaptive immunity. WNV dsRNA intermediates are primarily recognized 
by RLRs, resulting in activation of MAVS and IRF3 leading to the induction of type I IFNs. IFN 
signaling leads to the induction of several ISGs known to restrict WNV such as IFITs, PKR, 
viperin, XRN1 and OAS1 (298). IFIT1 has been shown to inhibit virus lacking 2’-O-methylation, 
however several studies have shown that flavivirus, including WNV, exhibit 2’-O-
methyltransferase activities that promote viral evasion of IFIT1 (299). On the other hand, cell type 
specific inhibition of WNV by IFIT2 has been documented in brain tissue of Ifit2-deficient mice 
(300). Similarly, deficiencies of PKR and Viperin or the presence of non-functional Oas1b, greatly 
enhance WNV susceptibility both in-vitro and in-vivo (243, 301, 302). Interestingly, recent studies 
have shown restriction of WNV by the cGAS-STING pathway. cGAS is a cytosolic sensor of DNA 
and the mechanism by which cGAS is activated during RNA virus infections is still unclear. 
However, deficiency of cGAS or STING in mice resulted in higher morbidity after infection with 
WNV suggesting novel functions of cGAS-STING immunity to restrict RNA viruses (303, 304). 
Infection with DENV has also been shown to activate cGAS pathway, and the importance of cGAS 
during infections is alluded by cGAS antagonisms by DENV NS2B (305–307). Currently it is 
proposed that cellular stress during flaviviral infection causes leakage of mitochondrial DNA into 
the cytosol, triggering cGAS activation and IFN induction (305, 308). Another component of 
innate immune responses to WNV include inflammasome signaling pathways that trigger IL-1 
secretion and apoptosis. Deficiencies in NLRP3 inflammasome and IL-1 secretion show 
increased viral susceptibility and it is proposed that IL-1 promotes trafficking of innate and 
adaptive immune cells to sites of WNV infection (309, 310). However, IL-1 signaling has also 
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been implicated in neuropathology. Deficiencies of caspase 3 and 8 during WNV infection, 
increases survival and decreases CNS tissue injury in caspase deficient mice as compared to WT 
mice (311, 312).  
It is clear that several innate immune mechanisms are required for clearing WNV infection, 
but similar to many biological processes a balance between restricting infection and maintaining 
cellular homeostasis is required for host survival. During infection, macrophages and DCs are 
crucial for the establishment of both innate and adaptive cellular immunity through the secretion 
of pro-inflammatory cytokine and cellular chemokines. The role of NK cells and neutrophils 
during WNV infections remains controversial. A small population of  CD3+ T cells are critical 
for eliciting protective immunity against WNV and deficiency of these cells is associated with 
enhanced viral susceptibility and spread to the CNS (274). However, adoptive transfer of IFN 
producing  T cells into TCR-deficient mice restored antiviral immunity to WNV (313). IFN 
signaling, in response to WNV, primes B cell and T cell immunity needed for viral clearance (314, 
315). B cells are important in maintaining passive immunity against WNV. Studies have shown 
that serum from WNV infected mice, is capable of establishing protection against WNV in B cell 
and antibody deficient mice (MT) or in B cell activating factor receptor (BAFFR) deficient mice 
(314, 316). Both CD4+ and CD8+ T cells are required for clearing WNV in the CNS, however 
recent studies suggest that CD4+ T cells help regulate B cell antibody responses and CD8 is 
required for viral clearance (317–319). Determining the mechanisms of WNV pathogenesis and 
antiviral immunity is critical for the development of targeted therapies and protection of 
susceptible individuals amongst the population. As with all viruses, WNV (and other flavivirus) 
have developed several mechanisms of antagonizing host immune responses (reviewed in Fig. 10) 
and understanding the roles of all ISGs, which have been developed through evolutionary arms 
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races, is critical. In this dissertation a novel mechanism of OAS1 WNV antiviral activity is 
described, which explains the RNase L independent protection to WNV provided by murine Oas1b 
and a functional equivalence to human OAS1.   
1.4 Intracellular Bacterial Infections  
Immune responses against bacteria begin with sensing PAMPs of bacterial origin by TLRs 
(Fig. 1), NLRs, AIM-like receptors (ALRs) and cytosolic sensors of both RNA and DNA (Fig. 2). 
However, intracellular bacteria can internalize within the host and avoid immune detection. In 
order to establish an effective infection, intracellular bacteria must first enter host cells through 
phagocytosis, receptor-mediated endocytosis in non-phagocytic cells or through bacterial secretion 
systems that promote actin polymerization and alter membrane integrity (320). Once within cells, 
bacteria thrive in pathogen-containing vacuoles where they evade detection, avoid triggering 
immune responses and can also reprogram both host and bacterial metabolism (321). When 
bacterial growth is saturated in a host cell, they can exit through lysis of existing host in order to 
spread to neighboring cells. Alternatively, some bacteria enter neighboring cells through direct cell 
to cell spread mediated through actin-based motility and formation of membrane protrusions (322). 
Although bacteria have developed sophisticated mechanisms of evading host immune responses, 
they are not full proof, and infection can trigger IFN production and expression of ISGs required 
for bacterial clearance.  
IFN signaling is well established during virus infection, conferring antiviral immunity 
through the expression of ISGs and activation of immune cells needed to clear infection. However, 
the role of IFN during bacterial infections is more complex, in some cases providing protection 
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and in others is detrimental to host survival (7, 102). Beneficial roles of IFN during bacterial 
infection include enhancing tissue integrity, secretion of pro-inflammatory molecules, enhancing 
type II IFN signaling and cellular immunity and secretion of antibacterial peptides, which directly 
disrupt bacteria. On the other hand, infection with some intracellular bacteria, for example L. 
monocytogenes or Francisella tularensis exhibit detrimental effects of IFN signaling. Infection 
can trigger IFN production through cGAS-STING signaling, but induction of IFN in both cases is 
detrimental to the host and deficiencies in IFNAR1 or IRF3 confer protection to mice (102). IFN 
responses to L. monocytogenes have been associated with downregulation of IFN signaling and 
apoptosis of immune cells, which promotes dissemination and proliferation of bacteria (323, 324). 
Induction of IL-17 is required for neutrophil recruitment and clearance of bacterial pathogens. 
However, IFN signaling in response to F. tularensis has been shown to inhibit IL-17A in addition 
to promoting macrophage death, therefore conferring bacterial survival (7, 325). Although 
deficiency in IFNAR1 signaling confers protection against L. monocytogenes and F. tularensis, 
deficiency of AIM2 is detrimental to host survival. It is known that AIM2 activation and 
inflammasome signaling is a critical factor in clearing intracellular bacterial infections (124, 326–
328). The IFN response against M. tuberculosis has shown both protective and detrimental roles 
during infections. Induction of IFN activates macrophages, which can directly inhibit M. 
tuberculosis through the IFN inducible GTPase Irgm1 (or LRG47) (329). Additionally, 
deficiencies in IFN receptor signaling enhance M. tuberculosis mediated disease (330–333).  
Inflammasome activation in response to mycobacterial infections leads to the production 
of IL-1 which is crucial for host defense against infection.  Part of the detrimental roles of IFNs 
during M. tuberculosis infection include downregulation of IL-1 and other pro-inflammatory 
cytokines (334–336). Type I IFN leads to the expression of OAS1, and as previously discussed, 
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an SNP in OAS1 can confer protection to M. tuberculosis suggesting a protective role of type I 
IFNs as well. As the host IFN response to intracellular bacteria is quite complex, with both 
protective and detrimental roles to the host thus understanding these mechanisms can provide 
better insight for the development of therapies. Additionally, the use of intracellular models of 
bacterial infection can be beneficial for studying these mechanisms. In this dissertation, evidence 
is provided for a novel mechanism of OAS1 antibacterial immunity using L. monocytogenes and 
F. novicida as models of gram-positive and gram-negative intracellular infection.  
1.4.1  Model Intracellular Bacteria  
Several intracellular bacteria pose a significant risk for global public health, for example: 
Mycobacterium tuberculosis and leprae, which are associated to lung damage and leprosy 
respectively.  The foodborne pathogen L. monocytogenes, F. tularensis known to cause pneumonic 
tularemia and Salmonella, which affects the intestinal tract, are further examples of intracellular 
bacteria that can cause harm. IFN is a key regulator of autophagy, immune cell function and ISGs 
needed to clear infection, in addition to inflammasome signaling and secretion of pro-
inflammatory cytokines, which are also crucial to controlling infections (337–339). In order to 
study these signaling pathways, several models have been developed both in-vitro and in-vivo, 
which prove beneficial for modelling infections of highly pathogenic or fastidious 
microorganisms. For example, M. tuberculosis is a slow growing pathogen, which is endemic 
globally, and the World Health Organizations estimates 1.5 million tuberculosis associated deaths 
per year. The emergence of antibiotic resistance strains of M. tuberculosis and the lack of effective 
vaccines proves the necessity to further study signaling pathways that can contribute to host 
defense. Therefore, the use of non-virulent or attenuated strains of bacteria, which can easily be 
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cultured or worked on with minimal laboratory restrictions, are great tools for modelling bacterial 
infections and studying host immune responses to a broad spectrum of pathogens.   
1.4.1.1 Listeria monocytogenes 
 
L. monocytogenes is a foodborne gram-positive bacterial pathogen that can lead to 
listeriosis, characterized by fever, diarrhea and gastroenteritis. The CDC reports that older 
individuals, immunocompromised people and pregnant women, where infection can lead to 
miscarriage, are at a higher risk of disease. It is estimated that approximately 1,600 people suffer 
from listeriosis per year and approximately 260 die from the disease. Invasive listeriosis is 
characterized by spread beyond the intestinal tract, which can cause sepsis 
and meningoencephalitis the leading causes of death in high-risk individuals (340). Fortunately, 
listeriosis can be treated with a wide variety of antibiotics, which are effective in clearing infection, 
however the high morbidity of the disease and similarities in immune sensing and signaling to 
other intracellular pathogens is why there are several ongoing research studies to understand the 
host-pathogen interactions of listeriosis.  
In response to L. monocytogenes, IFN is produced from innate immune cells, which 
activate macrophages for early control of infection and prime adaptive immune cells to clear 
bacteria. Therefore, infection with Listeria has been proven useful as a tool to study 
IFN responses to intracellular bacteria both in-vitro and in-vivo. For example, intraperitoneal 
infection of mice with the EDG strain (less virulent) of L. monocytogenes allows researchers to 
study IFN production by innate and adaptive immune cells, spread of bacteria to other organs and 
host survival to infection (341, 342). In fact Listeria has become a widely used model of host-
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pathogen interactions and has provided insight into bacterial gene regulation, bacterial physiology, 
epigenetic modifications, interactions with gut microbiome and induction of innate and adaptive 
immunity (342–344). Studies relating to human infection of listeriosis are limited to 
epidemiological data, due to low incidence and long incubation periods. However, several animal 
models have been developed to effectively study gastrointestinal complications of disease, sepsis, 
neonatal infection and the cell biological and immunological responses to Listeria. Specifics of 
animals used in studies, infection routes, strains and protocols are summarized and reviewed in 
(341, 345–347).   
1.4.1.2 Francisella novicida 
 
Francisella is a genus of gram-negative bacteria, including F. tularensis which is 
associated to Tularemia a disease that varies in severity depending on how the bacteria enters the 
body. Disease can range from mild to life-threatening. Most cases include fever and ulcers at the 
site of infection and in more severe situations can lead to pneumonia, vomiting and diarrhea, 
splenomegaly and hepatomegaly. F. tularensis can enter the body through insect bites (mostly 
ticks), exposure to infected animals, contaminated food or inhaling airborne pathogen and the CDC 
reports hundreds of cases a year. Although infection with F. tularensis can be controlled with 
antibiotics, growing concerns over its high infectious rate and potential use of aerosols in 
bioterrorism has made it a focus for several research groups (348, 349).  
Within the Francisella genus, F. novicida is genetically and biochemically similar to F. 
tularensis and is less pathogenic to humans, making it an ideal model for genetic manipulation and 
studying host-pathogen interactions to Fransicella (350).  Several models have been adapted to 
study Fransicella in order to a gain insight on host immune responses and bacterial virulence 
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factors. Genetic screenings of Drosophila melanogaster infected with F. novicida have been used 
to study host-pathogen interactions and have identified several virulence factors such as transport 
proteins and DNA repair genes that help bacteria survive oxidative stress (351). Similarly, genetic 
screenings of F. novicida transposon mutations in mouse models lead to the identification of 
bacterial ATP synthase and thioredoxin, which when mutated increased host survival (352). Mice 
are highly susceptible to infection with Fransicella offering a unique model to study host-pathogen 
interactions (353). Mice can be infected through several biological routes, which mimic bacterial 
exposure to humans such as respiratory and gastrointestinal tracts, skin and conjunctiva, protocols 
associated with these infection routes are reviewed in (350, 353).  
1.4.2  Host Defense to Intracellular Bacteria  
Innate and adaptive cellular immunity, the induction of IFNs, expression of ISGs and 
inflammasome activation and signaling are all key hallmarks of controlling intracellular pathogen 
infections. Early responses to intracellular bacteria are attributed to the secretion of pro-
inflammatory cytokines (IFN, IL-12 and TNF) resulting in APC activation and enhanced 
oxidative burst and mice lacking these cytokines or respective receptors is associated with 
increased lethality (354, 355). Additionally, host cells can eliminate bacteria trapped in 
autophagosomes through autophagy, when these phagosomes fuse with lysosomes and digests the 
contents of the phagolysosome (356). In addition to maintaining cellular homeostasis and clearing 
pathogens, autophagy promotes MHC I and MHC II antigen presentation through presentation of 
antigens processed in the phagolysosome and enhances CD4+ and CD8+ T cell responses needed 
to clear infection (357).  
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Guanylate binding proteins (GBPs) are a family of IFN inducible proteins known to 
enhance immunity to intracellular pathogens by disrupting their membranes, promoting autophagy 
and enhancing inflammasome signaling (104, 206, 207). Antimicrobial activity to several 
intracellular pathogens by GBPs and immunity-related GTPases (IRGs), another family of IFN 
inducible GTPases, are reviewed in (358). Inflammasome activation in response to intracellular 
pathogens is essential for the production of IL-1 and IL-18, which are crucial for host defense.  
IL-18 regulates induction of IFN in NK and T cells, therefore enhancing the proliferation and 
cytotoxicity of NK and CD8+ T cells in addition to enhancing nitric oxide production in 
macrophages (359). Similarly, IL-1  enhances the induction of several chemokines and cytokine 
and leads to the recruitment of neutrophils to infections sites and stimulates the Th17 response 
(360). AIM2 inflammasome is crucial for the secretion of IL-1 and IL-18 in response to several 
intracellular bacteria, such as L. monocytogenes, Fransicella and M. tuberculosis (361, 362). GBPs 
are crucial for disrupting pathogen-containing vacuoles exposing bacterial ligands to AIM2 sensor, 
and recently the role of IRF1 driven expression of GBPs has been shown in F. novicida (124). 
Type I IFN signaling has been shown to be detrimental to host in response to several intracellular 
bacteria and some suggest that these detrimental effects may outweigh the benefits of AIM2 
inflammasome signaling (102, 363). Additionally, mice lacking type I IFN signaling showed 
protection to F. novicida, however deficiencies in GBPs, IRF1 or AIM2 lead to increased 
susceptibility to infection (363). Therefore, it is likely that enhancing inflammasome signaling 
could prove beneficial in clearing intracellular bacterial infections. This dissertation describes a 
unique mechanism of OAS1 up-regulation of IRF1, which may be required for enhancing the 
transcription of GBPs to clear bacterial infections.   
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1.5 Rationale and Hypothesis  
Studying the role of IFNs and ISGs during viral and bacterial infections is crucial for 
understanding the mechanisms of cellular immunity required to clear infection, providing insight 
into the development of antiviral or antimicrobial therapies. OAS proteins belong to an ancient 
family of NTase proteins described to activate RNase L and suppress global translation, including 
translation of viral mRNA. However, given the fact that OAS3 is sufficient and required for RNase 
L mediated antiviral activity and the existence of antiviral roles of non-catalytically active OAS 
proteins, it is clear that non-canonical mechanisms of host defense exist for OAS family proteins. 
In this dissertation, I report a novel mechanism of human and mouse OAS1 antiviral and 
antimicrobial activity, which is dependent on enhancing the translation of mRNAs related to innate 
immunity. OAS1 enhanced cGAS expression, leading to restriction of WNV mediated by type I 
IFNs. Similarly, IRF1 expression was enhanced by OAS1 and promoted antimicrobial activity 
ahainst L. monocytogenes and F. novicida, most likely mediated through the up-regulation of 
GBPs, inflammasome signaling and induction of IL-1 Taken together, the findings in this 
dissertation clarify several previous findings related to RNase L independent restriction of WNV, 
provides evidence of OAS1 antimicrobial defense to intracellular bacteria, which could explain 
the mechanisms underlying restriction of M. tuberculosis, and overall increases our understanding 
for how OAS1 contributes to host immune responses during infection.  
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2.0 Materials and Methods 
2.1 Materials 
2.1.1  Cell Lines and Reagents  
Table 2. Cell Lines 
Cell Line Description Source 
HEK293 Human embryonic kidney cells immortalized/ transformed by 
adenovirus transduction.  
ATCC® (CRL- 
1573) 
293T HEK293 transformed with the SV40 Large T antigen. Hornung Lab at 
Gene Center 
Munich 
293FT HEK293 transformed with the SV40 Large T antigen and used for 
lentiviral and retroviral packaging. 
Invitrogen (CR700-
07)  
BJ-Tert Foreskin fibroblast cells immortalized with hTERT.  ATCC BJ-5ta 
BJ-Tert Ind. OAS1 
P46 
Doxycycline inducible cell line in WT background generated by 
transduction with OAS1 P46 lentivirus and selected with 1 g/ml 
Puromycin.  
Sarkar Lab  
BJ-Tert Ind. Oas1b  Doxycycline inducible cell line in WT background generated by 
transduction with Oas1b lentivirus and selected with 1 g/ml 
Puromycin. 
Sarkar Lab 
BJ-Tert OAS1-KO OAS1-KO cell line generated by CRISPR/Cas9 editing. Sarkar Lab 
BJ-Tert OAS1-KO 
Ind. OAS1 P42 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with OAS1 P42 lentivirus and selected 
with 1 g/ml Puromycin. 
Sarkar Lab 
BJ-Tert OAS1-KO 
Ind. OAS1 P46 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with OAS1 P46 lentivirus and selected 
with 1 g/ml Puromycin. 
Sarkar Lab 
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Table 2 continued 
BJ-Tert OAS1-KO 
Ind. OAS1 P46 
DADA 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with OAS1 P46 DADA lentivirus and 
selected with 1 g/ml Puromycin. 
Sarkar Lab 
BJ-Tert cGAS-KO cGAS-KO cell line generated by CRISPR/Cas9 editing Sarkar Lab 
BJ-Tert cGAS-KO 
Ind. OAS1 P46 
Doxycycline inducible cell line in cGAS-KO background 
generated by transduction with OAS1 P46 lentivirus and selected 
with 1 g/ml Puromycin. 
Sarkar Lab 
BJ-Tert cGAS-KO 
Ind. Oas1b  
Doxycycline inducible cell line in cGAS-KO background 
generated by transduction with Oas1b lentivirus and selected with 
1 g/ml Puromycin. 
Sarkar Lab 
BJ-Tert IRF1-KO  IRF1-KO cell line generated by CRISPR/Cas9 editing. Sarkar Lab 
BJ-Tert IRF1-KO 
Ind. OAS1 P46 
Doxycycline inducible cell line in IRF1-KO background generated 
by transduction with OAS1 P46 lentivirus and selected with 1 
g/ml Puromycin. 
Sarkar Lab 
BJ-Tert MAVS-KO MAVS-KO cell line generated by CRISPR/Cas9 editing. Sarkar Lab 
BJ-Tert MAVS-KO 
Ind. OAS1 P46 
Doxycycline inducible cell line in MAVS-KO background 
generated by transduction with OAS1 P46 lentivirus and selected 
with 1 g/ml Puromycin. 
Sarkar Lab 
D1-4G2-4-15  B lymphocyte hybridoma cell line of mouse origin, which secretes 
4G2 antibody in culture. 
ATCC HB-112 
Daudi B lymphoblast cell line derived from a patient with Burkitt’s 
lymphoma.  
Change-Moore Lab 
HeLa  Immortalized human adenocarcinoma cell line derived from 
cervical cancer tissue.  
ATCC CCL-2 
HeLa OAS1-KO OAS1-KO cell line generated by CRISPR/Cas9 editing.  Sarkar Lab 
HT1080 Immortalized human fibrosarcoma cell line derived from 
connective tissue. 
ATCC CCL-121 
HT1080 OAS1-KO OAS1-KO cell line generated by CRISPR/Cas9 editing. Sarkar Lab 
HT1080 OAS1-KO 
Ind. OAS1 P42 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with OAS1 P42 lentivirus and selected 
with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 OAS1-KO 
Ind. OAS1 P46 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with OAS1 P46 lentivirus and selected 
with 1 g/ml Puromycin. 
Sarkar Lab 
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Table 2 continued 
HT1080 OAS1-KO 
Ind. OAS1 P46 
DADA 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with OAS1 P46 DADA lentivirus and 
selected with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 OAS1 
RNase L-KO 
RNase L-KO cell line generated by CRISPR/Cas9 editing. Sarkar Lab 
HT1080 
OAS1/RNase L-
DKO 
RNase L-KO cell line on OAS1-KO background generated by 
CRISPR/Cas9 editing.  
Sarkar Lab 
HT1080 
OAS1/RNase L-
DKO Ind. OAS1 P46 
Doxycycline inducible cell line in OAS1/RNase L-DKO 
background generated by transduction with OAS1 P46 lentivirus 
and selected with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 
OAS1/IFNAR1-DKO  
IFNAR1-KO cell line on OAS1-KO background generated by 
CRISPR/Cas9 editing. 
Sarkar Lab 
HT1080 
OAS1/IFNAR1-DKO 
Ind. OAS1 P46 
Doxycycline inducible cell line in OAS1/IFNAR1-DKO 
background generated by transduction with OAS1 P46 lentivirus 
and selected with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 OAS1-KO 
Ind. Oas1b 
K42E/K57E 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with Oas1b K42E/K57E lentivirus and 
selected with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 OAS1-KO 
Ind. Oas1b 
K42E/K57E/K60E 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with Oas1b K42E/K57E/K60E 
lentivirus and selected with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 OAS1-KO 
Ind. Oas1b K60E 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with Oas1b K60E lentivirus and 
selected with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 OAS1-KO 
Ind. Oas1b 
K60E/K191E 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with Oas1b K60E/K191E lentivirus and 
selected with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 OAS1-KO 
Ind. Oas1b K191E 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with Oas1b K191E lentivirus and 
selected with 1 g/ml Puromycin. 
Sarkar Lab 
HT1080 OAS1-KO 
Ind. OAS1 P46 K60E  
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction with OAS1 P46 K60E lentivirus and 
selected with 1 g/ml Puromycin. 
Sarkar Lab 
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Table 2 continued 
Mouse Oas1b-/- 
Fibroblasts 
Mouse fibroblasts isolated from Oas1b-/- tails. Sarkar Lab 
Mouse Oas1b+/+ 
Fibroblasts 
Mouse fibroblasts isolated from Oas1b+/+ tails. Sarkar Lab 
Mouse Oas1b-/- 
BMDM 
Monocytes isolated from Oas1b-/- femur were differentiated into 
BMDMs by culturing in DMEM supplemented with L929 
conditioning media.  
Sarkar Lab 
Mouse Oas1b+/+ 
BMDM 
Monocytes isolated from Oas1b+/+ femur were differentiated into 
BMDMs by culturing in DMEM supplemented with L929 
conditioning media. 
Sarkar Lab 
THP1  Human monocytic cell line derived from the peripheral blood of a 
patient with acute monocytic leukemia.  
Hornung Lab at 
Gene Center 
Munich 
THP1 OAS1-KO OAS1-KO cell line generated by CRISPR/Cas9 editing. Hornung Lab at 
Gene Center 
Munich 
THP1 OAS1-KO 
Ind. OAS1 P42 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction/spinoculation with OAS1 P42 lentivirus 
and selected with 1 g/ml Puromycin. 
Sarkar Lab 
THP1 OAS1-KO Ind. 
OAS1 P46 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction/spinoculation with OAS1 P46 lentivirus 
and selected with 1 g/ml Puromycin. 
Sarkar Lab 
THP1 OAS1-KO Ind. 
OAS1 P46 DADA 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction/spinoculation with OAS1 P46 DADA 
lentivirus and selected with 1 g/ml Puromycin. 
Sarkar Lab 
THP1 OAS1-KO Ind. 
Oas1b 
K42E/K57E/K60E 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction/spinoculation with Oas1b 
K42E/K57E/K60E lentivirus and selected with 1 g/ml 
Puromycin. 
Sarkar Lab 
THP1 OAS1-KO Ind. 
Oas1b K60E 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction/spinoculation with Oas1b K60E 
lentivirus and selected with 1 g/ml Puromycin. 
Sarkar Lab 
THP1 OAS1-KO Ind. 
OAS1 P46 K60E 
Doxycycline inducible cell line in OAS1-KO background 
generated by transduction/spinoculation with OAS1 P46 K60E 
lentivirus and selected with 1 g/ml Puromycin. 
Sarkar Lab 
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Table 2 continued 
Vero  Interferon deficient Kidney epithelial cells isolated from African 
green monkey.  
ATCC CCL-81 
 
293T, 293FT, BJ-Tert, HeLa, HT1080, mouse fibroblast  and Vero cells were cultured with 
DMEM (Fisher Scientific, Catalog number: MT10013CV) supplemented with 10% FBS 
(R&DSystems), 1% Pen-Strep (Fisher Scientific, Catalog number: BW17-602E) and 5g/ml 
Plasmocin (Invivogen, Catalog number: ant-mpt) at 37ºC and 5% CO2. D1-4G2-4-15, Daudi and 
THP1 cells were cultured with RPMI (Fisher Scientific, Catalog number: MT10040CV) 
supplemented with 10% FBS, 1% Pen-Strep and 5g/ml Plasmocin at 37ºC and 5% CO2. BMDMs 
were cultured with DMEM supplemented 10% FBS, 1% Pen-Strep, 5 g/ml Plasmocin and 20% 
L929 conditioning media at 37ºC and 5% CO2. For cell passage of adherent cells, cells were 
incubated with 0.05% Trypsin-EDTA (Fisher Scientific, Catalog number: 25-300-120) at 37ºC 
and 5% CO2 and neutralized with corresponding culture media.  
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2.1.2  Plasmids 
Table 3. Vectors and Plasmids 
Plasmid Description Source 
pENTR D-TOPO Entry vector used for cloning desired gene sequences 
into destination vector by attR and attL driven 
recombination. 
Invitrogen, Topo 
Cloning Kit, 
(K240020) 
pcDNA-DEST47 Destination vector used for expressing protein of 
interest by transfection.  
Invitrogen 
(12281010) 
pLenti CMV Puro DEST (w118-1) Destination vector used for expressing protein of 
interest by transfection. 
Addgene (17452) 
pLenti TRE-DEST-EFpuro-2A-
rTA  
Destination vector used for making doxycycline 
inducible cell lines expressing protein of interest. 
Shuda Lab at the 
University of 
Pittsburgh 
pCMV6-Entry Cloning vector used for expressing protein of interest 
by transfection. Also used for cloning into pENTR D-
TOPO and subsequently other destination vectors.  
Origene  
pCL Ampho Retrovirus packaging vector. Novus Biologicals 
(NBP2-29541) 
psPAX2 Lentiviral envelope expressing plasmid used for 
lentiviral packaging.  
Addgene (12260) 
pMD2.G VSV-G envelope expressing plasmid used for 
lentiviral packaging.  
Addgene (12259) 
OAS1 P42 in pENTR D-TOPO Used to for TOPO Cloning of OAS1 P42 into 
destination vectors. 
TOPO Cloning 
OAS1 P42 in pcDNA-DEST47 Used for expression of OAS1 P42 by transfection. LR reaction 
OAS1 P42 in pLenti TRE-DEST-
Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of OAS1 P42.  
LR reaction 
OAS1 P46 in pENTR D-TOPO Used to for TOPO Cloning of OAS1 P46 into 
destination vectors. 
TOPO Cloning 
OAS1 P46 in pcDNA-DEST47 Used for expression of OAS1 P46 by transfection. LR reaction 
OAS1 P46 in pLenti TRE-DEST-
Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of OAS1 P46.  
LR reaction 
OAS1 P46 DADA in pENTR D-
TOPO 
Used to for TOPO Cloning of OAS1 P46 DADA, 
catalytically inactive mutant, into destination vectors. 
NEB site-directed 
mutagenesis  
 58 
Table 3 continued 
OAS1 P46 DADA in pcDNA-
DEST47 
Used for expression of OAS1 P46 DADA, 
catalytically inactive mutant, by transfection. 
LR reaction 
OAS1 P46 DADA in pLenti TRE-
DEST-Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of OAS1 P46 DADA, catalytically inactive 
mutant.  
LR reaction 
OAS1 P46 K60E in pENTR D-
TOPO 
Used to for TOPO Cloning of OAS1 P46 K60E, 
RNA-binding mutant, into destination vectors. 
NEB site-directed 
mutagenesis 
OAS1 P46 K60E in pcDNA-
DEST47 
Used for expression of OAS1 P46 K60E, RNA-
binding mutant, by transfection. 
LR reaction 
OAS1 P46 K60E in pLenti TRE-
DEST-Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of OAS1 P46 K60E, RNA-binding mutant.  
LR reaction 
Oas1a in pCMV6 Used for expression of Oas1a by transfection. Origene  
Oas1b in pCMV6 Used for expression of Oas1b by transfection. Origene  
Oas1g in pCMV6 Used for expression of Oas1g by transfection. Origene  
Oas1h in pCMV6 Used for expression of Oas1h by transfection. Origene  
Oas1b in pENTR D-TOPO Used to for TOPO Cloning of Oas1b into destination 
vectors. 
TOPO Cloning 
Oas1b in pLenti CMV Puro DEST Used for expression of Oas1b by transfection. LR reaction 
Oas1b in pLenti TRE-DEST-
Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of Oas1b.  
LR reaction 
Oas1b K42E/K57E pENTR D-
TOPO 
Used to for TOPO Cloning of Oas1b K42E/K57E, 
RNA-binding mutant, into destination vectors. 
NEB site-directed 
mutagenesis 
Oas1b K42E/K57E in pLenti CMV 
Puro DEST 
Used for expression of Oas1b K42E/K57E, RNA-
binding mutant, by transfection. 
LR reaction 
Oas1b K42E/K57E in pLenti TRE-
DEST-Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of Oas1b K42E/K57E, RNA-binding 
mutant.  
LR reaction 
Oas1b K42E/K57E/K60E pENTR 
D-TOPO 
Used to for TOPO Cloning of Oas1b 
K42E/K57E/K60E, RNA-binding mutant, into 
destination vectors. 
NEB site-directed 
mutagenesis 
Oas1b K42E/K57E/K60E in 
pLenti CMV Puro DEST 
Used for expression of Oas1b K42E/K57E/K60E, 
RNA-binding mutant, by transfection. 
LR reaction 
Oas1b K42E/K57E/K60E in 
pLenti TRE-DEST-Efpuro-2A-
rTA 
Used for making cell lines with doxycycline inducible 
expression of Oas1b K42E/K57E/K60E, RNA-
binding mutant.  
LR reaction 
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Table 3 continued 
Oas1b K60E pENTR D-TOPO Used to for TOPO Cloning of Oas1b K60E, RNA-
binding mutant, into destination vectors. 
NEB site-directed 
mutagenesis 
Oas1b K60E in pLenti CMV Puro 
DEST 
Used for expression of Oas1b K60E, RNA-binding 
mutant, by transfection. 
LR reaction 
Oas1b K60E in pLenti TRE-
DEST-Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of Oas1b K60E, RNA-binding mutant.  
LR reaction 
Oas1b K60E/K191E pENTR D-
TOPO 
Used to for TOPO Cloning of Oas1b K191E, RNA-
binding mutant, into destination vectors. 
NEB site-directed 
mutagenesis 
Oas1b K60E/K191E in pLenti 
CMV Puro DEST 
Used for expression of Oas1b K191E, RNA-binding 
mutant, by transfection. 
LR reaction 
Oas1b K60E/K191E in pLenti 
TRE-DEST-Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of Oas1b K191E, RNA-binding mutant.  
LR reaction 
Oas1b K191E pENTR D-TOPO Used to for TOPO Cloning of Oas1b K60E/K191E, 
RNA-binding mutant, into destination vectors. 
NEB site-directed 
mutagenesis 
Oas1b K191E in pLenti CMV Puro 
DEST 
Used for expression of Oas1b K60E/K191E, RNA-
binding mutant, by transfection. 
LR reaction 
Oas1b K191E in pLenti TRE-
DEST-Efpuro-2A-rTA 
Used for making cell lines with doxycycline inducible 
expression of Oas1b K60E/K191E, RNA-binding 
mutant.  
LR reaction 
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2.1.3  Virus and Bacterial Strains  
Table 4. Virus 
Virus Description Source 
WNV-KUN Less virulent WNV subtype (364). Used for all in-
vitro infection assays.  
Diamond Lab, grown and 
maintained in Sarkar Lab 
WNV-NY Strain responsible for the 1999 New York outbreak 
(365). Used for in-vivo experiments with Oas1b-KI 
mice.  
Diamond Lab 
POWV Tickborne Flavivirus (366). Used for in-vivo 
experiments with Oas1b-KI mice. 
Diamond Lab 
 
Table 5. Bacteria 
 
Bacteria Description Source 
Francisella tularensis 
subsp. Novicida, 
Strain Utah 112 
 
Intracellular gram-negative bacteria with rare disease 
occurrence in humans as compared to Francisella 
tularensis (366). However, mice are susceptible to F. 
novicida (367),therefore we used F. novicida as a 
model for our in-vivo experiments in Oas1b-KI mice. 
BEI Resources (NR-13) 
Listeria 
monocytogenes, Strain 
10403s 
 
Foodborne intracellular gram-positive bacteria 
extensively used as a model for characterizing 
bacterial and host factors for pathogenicity (368, 
369).  Used for in-vivo experiments with Oas1b-KI 
mice. 
BEI Resources (NR-13223) 
DH5 Competent E. 
coli 
Used for bacterial transformation of pENTR D-
TOPO and pcDNA plasmids. 
Made in Sarkar Lab 
NEB 5-alpha 
Competent E. coli 
Used for bacterial transformation of plasmids altered 
by site-directed mutagenesis.  
Purchased from NEB (C2988J) 
STBL3 Competent E. 
coli 
Used for bacterial transformation of lentiviral 
plasmids.  
Made in Sarkar Lab 
TOP10 Competent E. 
coli 
Used for bacterial transformation of pENTR D-
TOPO plasmids. 
Included in TOPO Cloning Kit 
(K240020) 
 61 
2.1.4  Restriction Digest and Molecular Cloning Enzymes  
Table 6. Enzymes 
Enzyme Purpose Company Catalog Number 
AluI Genotyping of OAS1 A/G allele of 
rs10774671 SNP by RFLP assay. 
NEB R0137S 
BamHI Restriction digest of Oas1b and OAS1 
plasmids. 
NEB R3136S 
BspEI Genotyping of Oas1b-KI mice. NEB R0540S 
KpnI Restriction digest of Oas1b and OAS1 
plasmids. 
NEB R3142S 
NotI Restriction digest of Oas1b and OAS1 
plasmids. 
NEB R3189S 
DpnI  Digestion of methylated DNA. NEB R0176S 
KLD Enzyme Mix  Kinase, Ligase and DpnI enzyme mix used 
in NEB site directed mutagenesis kit. 
NEB M0554S 
LR Clonase II Molecular cloning of target sequence from 
entry plasmid to destination plasmid by attR 
and attL driven recombination. 
Fisher Scientific 11791020 
OneTaq Hot Start 
Quick Load 2x 
Master Mix 
DNA Polymerase with inert tracking dye. 
Used for most OAS1 and Oas1b genotyping 
assays.  
NEB M0489S 
Q5 Hot-Start High-
Fidelity 2x Master 
Mix 
DNA Polymerase. Used for all non-
genotyping PCR reactions.  
NEB M0494S 
Topoisomerase I Cloning of target sequence into pENTR/D-
TOPO 
ThermoFisher 
Scientific 
Included in TOPO 
Cloning Kit 
(K240020) 
 
All restriction enzymes were used with instructed buffers: 10X CutSmart Buffer (NEB, Catalog 
number: B7204S) or 10X NEBuffer 3.1 (NEB, Catalog number: B7203S). Topo cloning was 
performed with TOPO Cloning Kit (ThermoFisher Scientific, Catalog Number: K240020). 
Gateway cloning of desired sequence from pENTR/D-TOPO to destinations vectors was 
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performed with Gateway LR Clonase II Enzyme Mix (Fisher Scientific, Catalog number: 
11791029). Site directed mutagenesis of desired sequence was performed using Q5 Site-Directed 
Mutagenesis Kit (NEB, Catalog number: E0554S).  
2.1.5  Cytokines  
Table 7. Cytokines 
Cytokine Working Concentration Company Catalog Number 
hIFN 1000-2000 U/ml Prescription drug 
obtained from 
Kalinsky Lab  
NDC 0085-0571-02 
hIFN 200-500 U/ml Miltenyl Biotec 130-096-873 
mIFN 100 ng/ml BioLegend 575306 
 
2.1.6  Antibodies  
Table 8. Antibodies 
Target Dilution Company Catalog 
Number 
4G2 1:50 IF Grown from D1-4G2-4-15 
hybridoma cells from ATCC 
ATCC HB-112 
-Tubulin  1:1000 WB Cell Signaling Technologies 3873S 
-Actin 1:1000 WB Santa Cruz Biotechnology  Sc-47778 
Calnexin 1:1000 WB, 1:100 IF Cell Signaling Technologies 2679S 
Calnexin 1:200 IF Novus Biologicals  NBP2-36571SS 
cGAS 1:500 WB Cell Signaling Technologies 15102S 
cGAS (D-9) 1:500 WB, 1:50 IP Santa Cruz Sc-515777 
FLAG 1:1000 WB, 1:200 IF Cell Signaling Technologies 2368S 
FLAG M2 1:1000 WB, 1:200 IF Millipore Sigma F1804 
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Table 8 continued 
Goat anti-mouse IgG 
AF488 
1:500-1000 ThermoFisher Scientific A-11017 
Goat anti-mouse IgG 
AF594 
1:500-1000 ThermoFisher Scientific A-32742 
Goat anti-rabbit IgG 
AF488 
1:500-1000 ThermoFisher Scientific A-32731 
Goat anti-rabbit IgG 
AF594  
1:500-1000 Cell Signaling Technologies 8889S 
Goat anti-rabbit IgG 
AF594  
1:500-1000 ThermoFisher Scientific A-11072 
IFNAR1 1:500 WB Abcam Ab124764 
IRF1 1:1000 WB, 1:50 IP Cell Signaling Technologies 8478S 
IRF1 1:1000 WB, 1:200 IF  Santa Cruz Sc-514544 
IRF1-PE 1:50 IF Cell Signaling Technologies 12732S 
MYC 1:1000 WB, 1:200 IF  OriGene  TA100010 
J2 1:200 IF Gift from Coyne Lab at the 
University of Pittsburgh 
N/A 
OAS1 1:250 WB, 1:50 IP, 
1:100 IF 
Cell Signaling Technologies 14498S 
Rabbit mAb IgG Isotype 
Control-PE 
1:50 IF Cell Signaling Technologies 5742S 
RNase L 1:1000 WB Cell Signaling Technologies 27281S 
Phosphor-Stat1 (Tyr701) 1:1000 WB Cell Signaling Technologies 7649S 
STAT3 1:200 WB R&D Systems 1799 
STAT5 1:1000 WB Cell Signaling Technologies 25656S 
EDD (UBR5) 1:1000 WB Santa Cruz Sc-515494 
XRN1 1:1000 WB Santa Cruz Sc-165985 
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2.1.7  Transfection Reagents  
Table 9. Transfection Reagents 
Reagent Company Catalog Number 
Lipofectamine 2000 ThermoFisher Scientific 11668027 
Lipofectamine 3000 ThermoFisher Scientific L3000008 
Turbofect  ThermoFisher Scientific  R0531 
X-tremeGene HP  Millipore Sigma 6366244001 
 
2.1.8  CRISPR  
Table 10. CRISPR guide RNAs and Plasmids 
Plasmids gRNA Target Sequence Purpose 
pLKO_OAS1_gRNA_SINGLE_BB GATCAGTTAAATCGCCG Generate OAS1-deficient cells 
pLKO_RNaseL_gRNA_SINGLE_BB GGGGGTTGTTATGATCCC Generate RNase L-deficient cells 
Retro_cGAS_DOUBLE_BB_CMV AACTTTCCCGCCTTAGGCA Generate cGAS-deficient cells 
Retro_IFNAR1_DOUBLE_BB_CMV CAGGAGCGATGAGTCTGTC Generate IFNAR1-deficient cells 
Retro_IRF1_DOUBLE_BB_CMV GCCCAGCTCCGGAACAAAC Generate IRF1-deficient cells 
Retro_MAVS_DOUBLE_BB_CMV ACTTCATTGCGGCACTGAG Generate MAVS-deficient cells 
pRZ_CAS9_mCherry N/A Co-expressed with SINGLE_BB 
plasmids  
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2.1.9  PCR Primers and Probes  
Table 11. qPCR Primer Sequence 
Gene Primer / Probe Sequence  Source   
cGAS (SYBR) FWD 5’- TTCAAAACTGGCTTTCAGCA -‘3 
REV 3’- TAGCCGCCATGTTTCTTCTT -‘5 
Integrated DNA 
Technologies  
cGAS (Taqman) Primer + Probe Mix Biorad (qHsaCEP0053484) 
GAPDH (SYBR) FWD 5’- TGCACCACCAACTGCTTAGC -‘3 
REV 3’- GGCATGGACTGTGGTCATGAG -‘5 
Integrated DNA 
Technologies 
GAPDH (Taqman) Primer + Probe Mix  Biorad (qHsaCEP0041396) 
IRF1 (SYBR) FWD 5’- AAAAGGAGCCAGATCCCAAGA -‘3 
REV 3’- CATCCGGTACACTCGCACAG -‘5 
Integrated DNA 
Technologies 
IRF1 (Taqman) Primer + Probe Mix Biorad (qHsaCEP0051342) 
STAT1 (SYBR) FWD 5’- TCACTATAGTTGCGGAGAGT –‘3 
REV 3’- ATAGGGTCATGTTCGTAGGT –‘5 
Integrated DNA 
Technologies 
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2.2 Methods 
2.2.1  Restriction Length Polymorphism Assay 
Genotyping of all cell lines for OAS1 SNP rs10774671 was done by RFLP adapted from 
Noguchi et al. 2012 (370). Genomic DNA was isolated from 105-6 cells using Wizard Genomic 
DNA Purification Kit (Promega, Catalog number: A1120). Genomic DNA (100 ng) was amplified 
by PCR using Q5 Hot-Start High-Fidelity 2x Master Mix and OAS1 specific primers containing 
the rs1077467 SNP (FWD: 5’-TCACAGTGTCTACCGTAAATGCTC-3’ REV: 5’-
AGAAAGTCAAGGCTGGAATTTCAT-3’). Samples were denatured at 95ºC for 30 seconds, 
followed by 45 cycles of amplification as follows: 98ºC for 15 seconds, 55ºC for 15 seconds, 68ºC 
for 30 seconds, and finally 68ºC for 5 minutes. First PCR reaction results in low yield of PCR 
product, therefore 2 l of 1st PCR reaction was used as template for a second round of PCR 
amplification. 10 l of product from the 2nd PCR reaction (1-2 g DNA) was digested with 0.5 
U/l AluI overnight at 37ºC and analyzed by DNA electrophoresis on a 3% agarose gel. 
2.2.2  Virus Stock and Purification  
Stocks of WNV-KUN were obtained from Dr. Michael Diamond and were expanded and 
titered in Vero cells. Cells were cultured in Falcon Tissue Culture Treated 150cm2 flasks (Fisher 
Scientific, Catalog number: 08-772-48) until 85% confluent and then split into three T150 cm2 
flasks containing 15ml 2% FBS DMEM. After 24 hours cells were infected with WNV-KUN at a 
MOI of 0.05 and incubated for 48 hours at 37ºC, CO2. Supernatant was harvested and spun at 3500 
rpm for 10 minutes at 4ºC. Cell free supernatant containing virus was then purified by 
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ultracentrifugation using a SW32 rotor on a Sorvall LYNX 4000 Ultracentrifuge. Ultra-tubes 
(Beckman Coulter, Catalog number: 344058) were prepared by adding 6ml cold 25% glycerol in 
TNE buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl and 1 mM EDTA at a final pH of 8) layered 
by virus-containing supernatant without exceeding 35 ml. Samples were spun at 30,000 rpm for 4 
hours at 4ºC. After centrifugation, the top layer of TNE was removed leaving approximately 1 ml 
of TNE. Virus pellet was then re-suspended with 5 ml TNE and sonicated for 1 round of 20% 
power, 2 second pulses for a total of 30 seconds. Virus was aliquoted and stored at -80ºC and viral 
titer was quantified by FFU assay.  
2.2.3  Florescent Foci Assay 
For quantification of virus focus forming units, Vero cells were plated in 96-well plates 
with DMEM and infected when 80-90% confluent with serial dilutions (using DMEM containing 
no FBS) of virus supernatant for 2 hours with gentle shaking every 15 minutes at 37ºC, 5% CO2. 
Following virus adsorption, virus supernatant was removed and fresh 2% FBS DMEM was added 
to sample wells. After 24 hours post infection, media was removed and wells were washed with 
PBS (Fisher Scientific, Catalog number: BW17512F12). Cells were fixed with a 1:1 ratio of 
Methanol:Acetone for 10 minutes at room temperature, followed by washing with PBS. Cells were 
then incubated with 1:50 4G2 antibody with gentle shaking for 1 hour at room temperature or 
overnight at 4ºC. Cells were washed and incubated with goat anti mouse AF488 secondary 
antibody in the dark with gentle shaking for 1 hour at room temperature, followed by washing with 
PBS and incubation with 1:200 DAPI containing PBS. FFUs were visualized and counted by 
fluorescent microscopy to calculate viral titers. The lowest virus concentration we were able to 
detect reliably in these virus growth measurements was 25 FFU/ml.  
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2.2.4  WNV Plaque Assay 
For quantification of virus plaque forming units, Vero cells were plated in 6-well plates 
with DMEM and infected when 80-90% confluent with serial dilutions (using DMEM containing 
no FBS) of virus supernatant for 1 hour at 37ºC, 5% CO2.  After incubation, 2x MEM media, 
supplemented with 8% FBS, 2% Pen-strep, 2% HEPES (Fisher Scientific, Catalog number: 15-
630-080) and 1% sodium bicarbonate, was combined 1:1 with 2% low melting point agarose 
(Invitrogen, Catalog number: 15517-022) and applied to samples in the 6-well plate until agarose 
solidified at room temperature. Cells were incubated for 72 hours at 37ºC, 5% CO2. Cells were 
fixed with 10% paraformaldehyde for 45 minutes and stained with crystal violet. Plaques were 
visualized and counted to calculate viral titers. The lowest virus concentration we were able to 
detect reliably in our virus growth measurement was 20 PFU/ml.  
2.2.5  In-vivo infection of mice with WNV and POWV 
WT and Oas1b-KI mice were infected with WNV-NY and POWV by footpad injection 
and survival was monitored over a course of 3 weeks. Mice were infected with 100 PFU/ml WNV-
NY and 100 FFU/ml POWV. Additionally, viral burden from serum, brain, spinal cord and spleen 
was measured by plaque assay after harvesting tissue or serum 2, 4 or 7 days post WNV-NY 
infection.  
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2.2.6  Bacterial stocks and culture  
L. monocytogenes was grown in Brain Heart Infusion (BHI) broth with 200 rpm shaking 
at 37ºC or BHI-agar plates at 37ºC for individual colonies. Broth and agar were prepared from 
BHI powder (Millipore Sigma, Catalog number: 53286). F. novicida was grown in Mueller Hinton 
(MH) broth 200rpm shaking at 37ºC or MH-agar plates at 37ºC for individual colonies. Broth and 
agar were prepared from MH powder (Millipore Sigma, Catalog number: 70192).  
2.2.7  Gentamicin Protection Assay 
All in-vitro bacterial infections were analyzed by Gentamicin Protection Assays. L. 
monocytogenes was used as a model of gram-positive bacterial infection and F. novicida as a 
model of gram-negative bacterial infection. Prior to the day of infection, adherent cells were seeded 
at a cell number of 1.5 x 105 in 12-well plates and bacterial suspensions were prepared in 5 ml of 
culture medium and left to grow overnight with 200 rpm shaking at 37ºC. The following day, the 
optical density at 600 nm (OD600) of bacterial cultures was measured to determine bacterial 
concentration. Bacterial cultures were diluted in infection medium, DMEM + 1% heat inactivated 
FBS, added directly to cells at indicated MOI, centrifuged at 2000 rpm for 5 minutes and incubated 
for 1 hour at 37ºC, 5% CO2. After bacterial adsorption, wells were washed with DMEM containing 
10% FBS and 50 g/ml gentamycin, followed by incubation with fresh gentamycin-containing 
media at 37ºC, 5% CO2. At 4 or 8 hours post incubation, cells were washed with PBS and lysed 
with 1% Triton X-100 (USBiological, Catalog number: 9002-93-1) diluted in PBS. Cell 
suspensions were collected, serial diluted in PBS, plated on appropriate agar plates and incubated 
for 18-20 hours for Listeria or 48 hours for Francisella at 37ºC, 5% CO2. Lastly, bacterial colonies 
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were counted in order to calculate bacterial burden (CFU/ml). For infection of suspension cells, 
cells were grown at a cell density of 0.5-1 x 106 cells/ml, 1 x 106 cells were added to 2 ml of 
infection medium in 6-well plates at the intended MOI, centrifuged at 3500rpm for 5 minutes for 
attachment of bacteria to the cells and incubated for 1 hour at 37ºC, 5% CO2. After bacterial 
adsorption, cells were collected in tubes, spun at 1500rpm for 5 minutes, washed with gentamycin 
containing media, re-suspended in gentamycin containing media and incubated for 4 or 8 hours at 
37ºC, 5% CO2. At desired time points post incubation, cells were collected in microcentrifuge 
tubes, spun down at 5000rpm for 5 minutes, washed once in PBS and lysed with 1% Triton X-100 
diluted in PBS. Cell suspensions were collected, serial diluted in PBS, plated on appropriate agar 
plates and incubated as described previously. Lastly, bacterial colonies were counted in order to 
calculate intracellular bacteria and expressed as CFU/ml.  
2.2.8  In-vivo infection of mice with L. monocytogenes and F. novicida  
WT and Oas1b-KI mice were infected with L. monocytogenes intraperitoneally or F. 
novicida by subcutaneous injection. Mice were infected with 1 x 105 CFU/ml L. monocytogenes 
and 1 x 104 CFU/ml F. novicida. Survivability and body weight were monitored for 10 or 13 days 
respectively.   
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2.2.9  Immunoblot  
For all WB analysis, protein concentration of WCL (prepared with standard lysis buffer: 
0.1% sodium deoxycholate, 1% Triton X-100, 20 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM 
MgCl2, 2 mM EGTA, 2 mM DTT, 10 mM NaF, 12.5 mM -glycerophosphate, 1 mM Na3VO4, 1 
mM PMSF and protease inhibitor [Millapore Sigma, Catalog number: 5892970001]) was 
measured by Bradford Assay (Bio-Rad, Catalog number: 500-0006). Samples were prepared with 
equal amounts of protein extract and resolved on 10% or 12% SDS-polyacrylamide gels by SDS-
PAGE. Proteins were then transferred to Polyvinylidene difluoride (PVDF) membranes (Fisher 
Scientific, Catalog number: IPVH00010). Protein membranes were blocked with 5% dry milk 
(Bio-rad, Catalog number: 170-6404) made in Tris-buffered saline with 1X Tween 20 (TBST) 
(Santa Cruz, Catalog number: sc-362311) for 1 hour at room temperature with gentle shaking. 
Afterwards, membranes were incubated with primary antibody diluted in 5% dry milk and 0.02% 
sodium azide (Millapore Sigma, Catalog number: S2002) in TBST overnight with gentle shaking 
at 4ºC. Antibody concentrations for desired proteins are listed in Table 8. Membranes were then 
washed three times with 1X TBST and incubated with horseradish peroxidase-conjugated anti-
mouse or anti rabbit immunoglobulin G (IgG) (Rockland, Catalog numbers: 610-1302 and 6111-
103-122 respectively) diluted 1:10,000 in 5% dry milk in TBST. After 1hour secondary body 
incubation, membranes were washed three times with 1X TBST and developed by 
chemiluminescence using Clarity or Clarity Max ECL Western Blotting Substrates (Bio-rad, 
Catalog numbers: 1705061 and 1705062 respectively).  
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2.2.10  Immunofluorescence  
In order to determine subcellular localization of target proteins, cells were treated with IFN, 
expressed by transfection or inducibly expressed with doxycycline and analyzed by fluorescent 
confocal microscopy. Prior to treatment, cells were seeded overnight in 4-well chamber slides 
(ThermoFisher Scientific, Catalog number: 154526PK). After treatment or transfection, cells were 
fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Catalog number: 15710) diluted 
in PBS for 15 minutes at room temperature, rinsed 3 times with PBS and incubated in 100% 
methanol for 10 minutes at -20ºC. After methanol permeabilization, cells were rinsed once in PBS 
and blocked with blocking buffer (5% FBS and 1% BSA in 1X PBS) for 1 hour at room 
temperature. After blocking, cells were incubated with primary antibody diluted 1:100-200 in 
antibody dilution buffer (1% BSA and 0.3% Triton X-100 in 1X PBS) overnight shaking at 4ºC. 
Cells were rinsed 3 times with PBS and incubated with filtered fluorochrome-conjugates 
secondary antibodies (Listed in Table 8) diluted 1:500 in antibody dilution buffer for 1-2 hours in 
the dark at room temperature. Cells were rinsed 3 times with PBS and mounted with Vectashield 
mounting medium with DAPI (Vector Laboratories, Catalog number: H-1500). Glass clover slips 
were placed over chamber slides and sealed with nail polish. Samples were then analyzed by 
confocal microscopy.  
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2.2.11  Molecular Cloning, Bacterial Transformation and Plasmid Preparation 
2.2.11.1 TOPO Cloning  
 
For insertion of desired PCR product into pENTR/D-TOPO vectors, primers were designed 
as instructed by TOPO Cloning Kit instructions. Forward orientations primers contained a 5’ 
CACC overhang sequence to allow directional cloning of PCR product into the TOPO vector. PCR 
was performed with Q5 Hot-Start High-Fidelity 2x Master Mix under the following PCR cycle 
conditions: denaturation at 95ºC for 2 minutes, followed by 30 cycles of: 95ºC for 15 seconds, 60-
65ºC for 30 seconds, 72ºC for 45 seconds, and finally 72ºC for 10 minutes. Approximately 2-5 l 
of PCR product was analyzed by DNA electrophoresis on a 1% agarose gel to verify successful 
amplification and purity of product, PCR Clean-up was performed if needed using QIAquick PCR 
Purification Kit (QIAGEN, Catalog number: 28104). PCR product was then digested with DpnI at 
a final concentration of 1 U/l for 1 hour at 37ºC, followed by heat inactivation for 20 minutes at 
80ºC. Next, the TOPO reaction was performed by combining DpnI digested product with TOPO 
vector as described in the TOPO Cloning Kit for 1 hour or overnight at room temperature. TOP10 
cells were then transformed with the TOPO reaction and plated on 50 g/ml Kanamycin LB agar 
plates for selection. Individual bacterial colonies were screened by colony PCR using the same 
PCR cycle parameters for the original product and DNA gel electrophoresis with 1% agarose gel. 
Colonies with successful incorporation of product into TOPO vector were expanded and plasmid 
DNA was isolated by Mini Prep (Qiagen, Catalog number: 27106).  
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2.2.11.2 Site Directed Mutagenesis  
 
Site directed mutagenesis was performed using NEB Site Directed Mutagenesis Kit. 
Primers used for nucleotide substitutions were designed using NEB’s web-based tool NEBase 
Changer. PCR was performed with Q5 Hot-Start High-Fidelity 2x Master Mix under the following 
PCR cycle conditions: denaturation at 98ºC for 30 seconds, followed by 25 cycles of: 98ºC for 10 
seconds, 62-69ºC for 20 seconds, 72ºC for 1 minute, and finally 72ºC for 2 minutes. Approximately 
5l of PCR product was analyzed by DNA electrophoresis on a 1% agarose gel to verify successful 
amplification and purity of product. 1 l of PCR product was incubated with KLD enzyme mixture 
for 5 minutes at room temperature, KLD reaction mixture was transformed in NEB 5-alpha 
Competent E. coli and plated on LB agar plates containing appropriate antibiotics for selection. 
Individual colonies were picked and grown in antibiotic containing 2X LB broth overnight 
followed by isolation of plasmid DNA by Mini Prep. Plasmid DNA was then analyzed by 
restriction digestion by incubating DNA-enzyme mixture for 2 hours at 37ºC followed by DNA 
electrophoresis on a 1% agarose gel. Finally, approximately 500-800 ng of DNA was sent to 
GENEWIZ for sequencing using GENWIZ universal primers M13-40FOR (5’-
GTTTTCCCAGTCACGAC-3’) and T7 (5’-TAATACGACTCACTATAGGG-3’). Sequence and 
chromatogram were aligned to the original plasmid sequence in order to verify successful 
nucleotide substitution by mutagenesis.  
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2.2.11.3 LR Cloning  
 
Cloning of pENTR/D-TOPO entry vectors into desired destinations vectors was done by 
gateway cloning using LR Clonase II. 50-100 ng of entry vector was combined with 150 ng of 
destination vector and incubated with Tris-EDTA buffer and LR Clonase II overnight at room 
temperature. LR reaction was terminated by addition of Proteinase K (Fisher Scientific, Catalog 
number: BP1700-100) for 10 minutes at 37ºC. LR reaction mixture was transformed in DH5 or 
STBL3 Competent E. coli and plated on 50 g/ml ampicillin LB agar plates for selection. 
Individuals colonies were picked and grown in ampicillin containing 2X LB broth overnight 
followed by isolation of plasmid DNA by Mini Prep. Plasmid DNA was then analyzed by 
restriction digestion by incubating DNA-enzyme mixture for 2 hours at 37ºC followed by DNA 
electrophoresis on a 1% agarose gel. To obtain higher yields of plasmid DNA, bacterial broth from 
positive clones was cultured overnight in 100 ml ampicillin containing 2X LB broth followed by 
plasmid Midi Prep (Qiagen, Catalog number: 12143).  
2.2.11.4 Bacterial Transformation  
 
All plasmid DNA was transformed into appropriate competent bacteria by adding 5-10 l 
(after cloning reactions) or 1-2 l (for expanding purified plasmid) to 50 l of competent bacteria 
followed by incubation for 30 minutes on ice. Bacterial cells were then heat-shocked for 30-45 
seconds at 42ºC. Heat-shocked cells were chilled on ice for 5 minutes and 450 l of 2X LB or 
SOC medium was added to the mixture. Bacterial cultures were incubated for 1 hour with shaking 
at 37ºC and spread on LB agar plates containing Kanamycin or Ampicillin for selection 
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(designated by antibiotic resistant gene expression in plasmid). Bacterial plates were incubated 
overnight at 37ºC.  
2.2.11.5 Plasmid Mini and Midi Prep 
 
For isolation of plasmid DNA, bacterial cultures were processed by QIAPrep Spin 
Miniprep Kit or QIAGEN Plasmid Midi Kit (QIAGEN, Catalog numbers: 27106 and 12143 
respectively). Plasmid DNA was then analyzed by restriction digestion by incubating DNA-
enzyme mixture for 2 hours at 37ºC followed by DNA electrophoresis on a 1% agarose gel to 
ensure successful isolation of intended plasmid DNA. Expression of proteins pertaining to genes 
of interest in plasmid sequence was validated by transfection of cells with plasmid DNA using 
Turbofect or X-tremeGene HP followed by WB analysis.  
2.2.12  Production of High Titer lentivirus and Transduction  
All lentivirus and retrovirus were made in high titer for the purpose of transducing cells. 
Prior to transfection with viral plasmids, 2 x 106 293FT cells were seeded in 10 cm2 tissue culture 
dishes (Fisher Scientific, Catalog number: 08-772-4F) and were grown overnight. Lentiviral 
transfection mix was assembled with 5 g lentiviral plasmid, 3.75 g psPAX2 and 1.25 g 
pMD2.G in 500 l Opti-MEM (Fisher Scientific, Catalog number: 31-985-070) and retroviral 
transfection mix was assembled with 5 g retroviral plasmid and 5 g pCL Ampho in 500 l Opti-
MEM. 30 l Lipofectamine 2000 was diluted in 500 l Opti-MEM and incubated for 5 minutes. 
Afterwards the DNA and Lipofectamine 2000 solutions were combined and incubated for 20 
minutes at room temperature. Transfection mix was then applied dropwise to 293FT cells with 7 
 77 
ml DMEM and incubated for 6 hours at 37ºC, 5% CO2. After 6 hours, media was replaced with 
fresh DMEM and incubated for 72 hours at 37ºC, 5% CO2 for lentivirus and 32ºC, 5% CO2 for 
retrovirus. At 72 hours post transfection, virus containing supernatant was filtered through 0.45m 
filters, aliquoted and kept at -80ºC.  
For transducing adherent cells, cells were seeded the day before infection in 10 cm2 dishes 
or 6-well plates. 1ml virus was added to the cells in a total volume of 5 ml or 2 ml (10 cm2 or 6well 
plate) with 6 g/ml polybrene (Millipore Sigma, Catalog number: TR-1003) and incubated for 24 
hours at 37ºC, 5% CO2. The following day media was replaced with fresh media (DMEM or 
RPMI) and cells were incubated for an additional 72 hours at 37ºC, 5% CO2. After incubation, 
media was replaced with fresh media containing specific antibiotics (designated by eukaryotic 
antibiotic resistance genes) and incubated for 72-96 hours at 37ºC, 5% CO2 if using Puromycin 
(InvivoGen, Catalog number: ant-pr-1) or 1-2 weeks at 37ºC, 5% CO2 if using Geneticin (G418) 
(InvivoGen, Catalog number: ant-gn-1). After selection, cells were validated for expression of 
desired protein by WB analysis.  
For transducing suspension cells, cells were infected with virus by spinoculation. In a 12-
well plate 2 x 105 cells were infected with 1 ml virus in a total volume of 2 ml with 8 g/ml 
polybrene. Cells were spun at 2500 rpm for 1 hour, cells were re-suspended in the same medium 
and transferred to 15 ml conical tubes (Fisher Scientific, Catalog number: 14-959-70C). Cells were 
spun at 1500 rpm for 5 minutes, supernatant was discarded, cells were re-suspended in media at a 
cell density of 50,000 cells/ml in 4 ml volume and transferred to a 6-well plate. Cells were 
incubated for 72 hours at 37ºC, 5% CO2. After incubation, cells were spun at 1500 rpm for 5 
minutes, supernatant discarded and cells were re-suspended in 4 ml of antibiotic selection media 
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for 72-96 hours at 37ºC, 5% CO2, if using puromycin or 1-2 weeks at 37ºC, 5% CO2, if using 
Neomycin. After selection cells were validated for expression of desired protein by WB analysis. 
2.2.13  Generation of Knockout Cell Lines 
All KO cell lines generated in Sarkar Lab (Table 2) were done by transfection using 
Lipofectamine 2000, Lipofectamine 3000 or X-tremeGene HP of single (SBB) or double backbone 
(DBB) CRISPR/Cas9 plasmids, with co-transfection of Cas9 for SBB plasmids expressing GFP. 
Alternatively, transduction of CRISPR plasmids was performed if cell lines are difficult to 
transfect, for example BJ-Tert cells. After 24 hours of transfection or 48-72 hours of transduction, 
cells were observed by fluorescent microscope in order to determine transfection or transduction 
efficiency. Cells were then sorted for GFP and mCherry double positive cells (for SBB plasmids) 
or mCherry positive cells (for DBB plasmids). Following clonal selection, cells were expanded 
and analyzed by WB for deficiency of the protein of interest.  
2.2.14  Generation and Characterization of Doxycycline Inducible Cell Lines  
All doxycycline inducible cell lines generated in Sarkar Lab (Table 2) were made by 
transduction of lentivirus. First Gateway cloning of pENTR vectors listed in Table 3 into pLenti 
TRE-DEST-EFpuro-2A-rTA destination vector was performed and plasmids were then packaged 
into lentivirus and transduced into target cells. After antibiotic selection, cells were treated with 
increasing concentrations of doxycycline (ranging from 0-5 g/ml of doxycycline) for 24-48 hours 
and analyzed by WB for inducible expression of desired proteins. 24 hours of doxycycline 
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treatment is sufficient for expression of proteins, however optimal expression is achieved at 48 
hours.  
2.2.15  Genotyping of Oas1b-KI Mouse Model  
A mouse model expressing full length Oas1b was obtained by restoring Oas1b by CRISPR 
homology driven repair, replacing the stop codon responsible for truncated Oas1b with an Arginine 
residue (X253R). Additionally, a new BspEI restriction site was inserted to allow genotyping of 
Oas1b-KI mice. To genotype these mice, tail snips were collected from mice and digested 
overnight at 55ºC with a tissue lysis mixture consisting of 120 l 0.5 M EDTA, pH 8.0, 500 l 
Nuclei Lysis Solution (from Wizard Genomic DNA Purification Kit) and 40 mg/ml of Proteinase 
K. Next samples were treated with 10 mg/ml  RNase and incubated for 15 minutes at 37ºC. 
Samples were cooled to room temperatures and protein precipitation solution was added and DNA 
isolation continued as instructed in Wizard Genomic DNA Purification Kit. Concentration of 
genomic DNA was quantified by NanoDrop and 50-100 ng of DNA was amplified by PCR using 
OneTaq Hot Start Quick Load 2x Master Mix and Oas1b specific primers (FWD: 5’-
TGACTGGGTGTGACAGTGTG-3’, REV: 5’-AGGGCTGTAGGACCTCATGT-3’). PCR cycle 
conditions were as following: denaturation at 95ºC for 30 seconds, followed by 45 cycles of: 58ºC 
for 15 seconds, 55ºC for 15 seconds, 68ºC for 30 seconds, and finally 68ºC for 5 minutes. PCR 
product was digested with 250 U/ml BspEI overnight at 37ºC and 20l of digested PCR product 
was analyzed by DNA electrophoresis on a 2% agarose gel. DNA from WT mice resulted in a 500 
bp undigested product and DNA from Oas1b-KI mice resulted in a 250 bp product after digestion.  
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2.2.16  Isolation of Mouse Fibroblasts and Bone Marrow Derived Macrophages 
2.2.16.1 Isolation of Mouse Fibroblasts from tails  
 
To isolate fibroblasts from mouse tails, mice were sacrificed, and tails were collected after 
dissection. Tails were sliced into smaller pieces in PBS using a razor blade under sterile conditions 
and collected in a 15 ml conical tube containing 1 ml of 1:1 PBS and Pen-Strep. 1 ml of collagenase 
(ThermoFisher Scientific, Catalog number: 17104019) was added to samples at a final 
concentration of 1000 U/ml and incubated for 30 minutes with repeated shaking at 37ºC. Cells 
were spun at 1200 rpm for 5 minutes; pellets were washed with 1.5 ml Hank’s Balanced Salt 
Solution (HBBS) (Millipore Sigma, Catalog number: 55021C) and again spun at 1200 rpm for 5 
minutes. Cell pellets were incubated with 2-3 ml 0.05% Trypsin-EDTA for 20 minutes with 
repeated shaking at 37ºC. DMEM containing 20% FBS was added to mixture prior to a final spin 
at 1200 rpm for 5 minutes. Cells were re-suspended in DMEM containing 20% FBS, transferred 
to 10 cm2 plates and incubated at 37ºC, 5% CO2. After cells became confluent tail pieces were 
removed and cells were split for freezing and continued culture.  
2.2.16.2 Isolation and differentiation of BMDMs from femur 
 
To obtain BMDMs from mice, mice were sacrificed, dissected and monocytes were 
isolated from femurs. Cells were differentiated in DMEM with 20% L929 conditioning media. 
Excess tissue was removed from collected femurs and cells inside were flushed out with DMEM 
using a 25-gauge needle. Cells were collected in a 15 ml conical tube and spun down at 500 rpm 
for 1 minute, to remove tissue debris, and supernatant was transferred to a new 15 ml conical tube 
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and spun at 1000 rpm for 10 minutes. Cell were resuspended in DMEM containing 20% 
conditioning media, transferred to 10 or 60 cm2 tissue culture plates and incubated at 37ºC, 5% 
CO2 with changing of media every 2 days. After 7 days of culture, cells differentiated into 
macrophages and were frozen or used for experiments. 
2.2.17  ELISA  
To measure apical secretion of IFN from mouse BMDMs, cell supernatants were 
collected from cells transfected with poly (dA:dT) or p(I):p(C) and cells infected with Herpes 
Simplex Virus (HSV) or Sendai Virus (SeV). Samples were frozen at -80ºC until analyzed. IFN 
ELISA was adapted from Banerjee et al. 2018 (371). 96-well plates were first coated with rat anti-
mouse IFN capture antibody (Santa Cruz, Catalog number: sc-57201) diluted 1:500 in coating 
buffer (0.1 M Sodium Carbonate pH  9.5) followed by overnight incubation at 4ºC. Wells were 
washed 3 times with wash buffer (0.05% Tween-20 in PBS), blocked with assay diluent (10% FBS 
in PBS) for 1 hour at room temperature and washed an additional 3 times with wash buffer prior 
to the addition of ELISA standards and samples to the plate. Standard and samples were incubated 
overnight at 4ºC, washed 5 times with wash buffer, and incubated with rabbit anti-mouse 
IFN detection antibody (R&D Systems, Catalog number: 32400-1) diluted 1:2000 in assay 
diluent for 3 hours at room temperature. Wells were washed 5 times with wash buffer and 
incubated with goat anti-rabbit HRP-linked secondary antibody (CST, Catalog number: 7074) 
diluted 1:2000 in assay diluent for 2 hours at room temperature. Wells were washed 7 times with 
wash buffer and incubated with Tetramethylbenzidine chromogenic substrate (BD Biosciences, 
Catalog number: 555214) in the dark for 15 minutes at room temperature. Chromogenic reaction 
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was terminated by the addition of Stop Solution 2N Sulfuric Acid (Millipore Sigma, Catalog 
number: 258105) and the absorbance at 450 nm of samples was read within 30 minutes of stopping 
the reaction.  
2.2.18  RNA extraction and RT-qPCR  
Total RNA from cells was extracted using Macherey-Nagel Nucleospin RNA Kit (Fisher 
Scientific, Catalog number: NC9581114), according to manufacturer’s instructions, or with 
TRIzol reagent (ThermoFisher Scientific, Catalog number: 15596018). For RNA isolation using 
TRIzol, cell pellets were re-suspended with 0.5 ml TRIzol followed by addition of Chloroform 
(Fisher Scientific, Catalog number: AC423555000) and vigorous mixing by vortex. Samples were 
centrifuged at 12000 rpm for 5 minutes and the upper aquatic phase was transferred to 
microcentrifuges tubes containing 250 l isopropanol for 10 minutes at room temperature, 
followed by RNA precipitation by centrifugation at 12000 rpm for 5 minutes. Samples were 
washed with 75% ethanol and centrifuged at 12000 rpm to remove excess salts. Supernatant was 
removed, RNA pellets were air-dried for 10-20 minutes and re-suspended in RNase-free H2O. 
RNA concentration was measured by NanoDrop and 0.5-1 g RNA was used for synthesis of 
complementary DNA (cDNA) using iScript cDNA Synthesis Kit (Bio-Rad, Catalog number: 
1708891). cDNA was diluted 1:2 in water and gene expression was evaluated by RT-qPCR using 
SsoFast EvaGreen Supermix (Bio-Rad, Catalog number: 172-5200) or Sso Advanced Advanced 
Universal Probes Supermix (Bio-Rad, Catalog number: 172-5281) for Taqman probed-based 
qPCR. Primers used for amplification of target genes are listed on Table 11.   
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2.2.19  RNA sequencing  
2 x 106 WT and OAS1-KO THP1 cells in T75cm2 flasks were treated with 500 U/ml IFN 
for or 0, 1, 2, 4 and 8 hours, harvested and RNA sequencing was performed (Health Sciences 
Sequencing Core at the UPMC Children’s Hospital of Pittsburgh). RNA was extracted using 
RNeasy Plus Mini kit (Qiagen, Catalog number: 74134) following manufacturer’s instructions. 
Total RNA input was enriched for mRNA and fragmented. Random primers initiated first strand 
and second strand cDNA synthesis. Adenylation of 3’ends was followed by adapter ligation and 
library amplification with indexing. Sequencing was performed on an Illumina NextSeq 500. 
RNAseq FASTQ data were processed and mapped to the human reference genome (hg19) using 
CLC Genomics Workbench 11 (Qiagen). The mean RPKM values, with a cutoff of WT RPKM > 
1, from the RNaseq data from two biological replicates was used to calculate the ratio of WT to 
OAS1-KO RPKM values. Heatmaps of RPKM ratios ranging from 0.55 to 1.75 were generated 
using pheatmap package in R studio (rstudio.com).  
2.2.20  SILAC Analysis  
WT and OAS1-KO THP1 cells were cultured at a cell density of 2-5 x 105 cells/ml for 8 
generations in media containing heavy (13C-6 15N-2 L-Lysine 2HCl and 13C-615N-4 L-Arginine 
HCl) or light (L-Lysine 2HCl and L-Arginine HCl) isotope containing amino acids respectively. 
Cells were treated with 500 U/ml IFN for 0, 4 and 8 hours, harvested and SILAC analysis 
performed (MS Bioworks). Cell lysates were analyzed for incorporation efficiency (99.6%),  
followed by fractionation on SDS-PAGE, trypsin digestion and LC/MS/MS analysis. The mass 
spectrometer was operated in data-dependent mode, with MS and MS/MS performed in the 
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Orbitrap at 70,000 FWHM and 17,500 FWHM resolution, respectively. Data was processed and 
analyzed in MaxQuant software 1.6.0.16 (www.maxquant.org). Peptides with and FDR of 0.01 
and Q-value (posterior error probability) of ≤ 0.05 were normalized and filtered by removing all 
proteins with less than 2 unique peptides throughout all the readings, with the exception of those 
proteins with 1 unique peptide across multiple reads. The average peptide ratios for 0, 4 and 8 
hours were calculated from two experiments and the ratio values were transformed to log2 values. 
Further filtering was performed to remove proteins with no significant log2 (ratio) fold change 
[0.99 > log2 (peptide ratio) > -0.99]. Next the RPKM values of the corresponding proteins was 
imported from our RNAseq data into the same worksheet. Proteins with RPKM values < 1 in WT 
samples or RPKM WT/OAS1-KO ratios not within 0.55-1.75 were removed from the dataset. 
From this final list of proteins, the top 10 post transcriptionally upregulated proteins in WT from 
each timepoint were used to generate heatmaps of log2 (peptide ratio) and RPKM ratios ranging 
from 0.55 to 1.75 using pheatmap package in R studio (Chapter 3). From this list of post 
transcriptionally regulated proteins, a few bacterial infection related cellular proteins were detected 
and RPKM values were represented in heatmaps (Chapter 4). To identify IFN-inducible genes 
transcriptionally regulated by OAS1, the dataset was filtered to create a list of proteins up-
regulated 2 fold at 4 and 8 hours post treatment. Next the log2 fold change of WT to OAS1-KO 
RPKM ratio was calculated and genes up-regulated [log2 (RPKM ratio) ≥ 1] or down-regulated 
(RPKM ratio) ≤ -1) in WT cells were compiled into a list (Appendix B.2, Table 14). Additionally, 
functional annotation of several gene lists was performed using The Database for Annotation, 
Visualization and Integrated Discovery (DAVID) bioinformatics tool (372, 373).  
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2.2.21  Ribosome Profiling  
Ribosome profiling was performed on THP1 WT and OAS1-KO cells after 0 or 4 hours of 
500 U/ml IFN treatment, followed by incubation with 100 g/ml cycloheximide in PBS for 5 
minutes at 37ºC, 5% CO2. Cells were washed twice in PBS and harvested with polysome lysis 
buffer (50 mM Tris-HCL pH 7.5, 100 mM KCL, 12 mM MgCl2, 1% NP-40, 1 mM DTT, 1X 
HALT protease inhibitor, 100 g/ml cycloheximide). Lysate was cleared by centrifugation at 8000 
g for 10 minutes at 4ºC, supernatants were layered on 10-50% sucrose gradient and spun at 230,000 
g for 2.5 hours at 4ºC. Gradients were fractionated while monitoring absorbance at 254 nm. Total 
RNA was isolated from fractions using Direct-zol 96 RNA Kit (Zymo Research, Catalog number: 
R2054), according to manufacturer’s instructions. RNA was used for synthesis of cDNA using 
iScript cDNA Synthesis Kit and gene expression was evaluated by RT-qPCR using Sso Advanced 
Advanced Universal Probes Supermix. Expression of cGAS and IRF1 mRNA in polysome 
fractions was carried out using TaqMan primers and probes listed on Table 11.   
2.2.22  Radiation pulse-chase of nascent protein synthesis  
Nascent protein synthesis was analyzed in THP1 WT and OAS1-KO cells by radiolabeling 
with 35S-labeled amino acids (EasyTag EXPRESS 35S Protein Labeling Mix, Perkin-Elmer, 
Catalog number: NEG772014MC), protein immunoprecipitation and SDS-PAGE. For analysis of 
IRF1 protein levels, 10 million cells per time point were grown at a cell density of 2-5 x 105 
cells/ml and treated with 500 U/ml IFN for 2 hours. Cells were harvested by centrifugation at 
1600 rpm for 3 minutes, re-suspended in 30 ml starvation media (RPMI without methionine, 
cystine or L-glutamine, Millipore Sigma, Catalog number: R7513) containing 4 mM L-glutamine 
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and 500 U/ml IFN for 10 minutes at room temperature followed by centrifugation at 1600 rpm 
for 3 minutes and re-suspension with 12 ml starve media containing 0.08 mCi/ml 35S labelling 
mix. Cells were labeled for 30 minutes at room temperature and radiolabeled pulse samples were 
collected at different time points. The remaining cells were spun at 1600 rpm for 3 minutes, re-
suspended in 15 ml chase media: standard RPMI media without FBS, 1% Pen-Strep, 5mM L-
methionine (Millipore Sigma, Catalog number: M5308), 5 mM L-cystine (Millipore Sigma, 
Catalog number: C6852), 10 mM HEPES and chase samples were collected at different time 
points. Samples were kept on ice, centrifuged at 13000 rpm for 1 minute and lysed with lysis buffer 
containing 1% Triton X-100. For analysis of cGAS protein levels, 6 million cells per time point 
were grown at a cell density of 2-5 x 105 cells/ml. Cells were harvested by centrifugation at 
1600rpm for 3 minutes, re-suspended in 20 ml starvation media containing 4 mM L-glutamine for 
10 minutes at room temperature followed by centrifugation at 1600 rpm for 3 minutes and re-
suspension with 12 ml starvation media containing 0.08 mCi/ml 35S labelling mix. Cells were 
labeled for 30 minutes at room temperature and radiolabeled pulse samples were collected at 
different time points. The remaining cells were spun at 1600 rpm for 3 minutes, re-suspended in 
6ml chase media and chase samples were collected at different time points. Samples were kept on 
ice, centrifuged at 13000 rpm for 1 minute and lysed with lysis buffer containing 1% Triton X-
100. All samples were then immunoprecipitated with IRF1 or cGAS antibody by incubation with 
1:50 antibody for 1 hour with rotation at 4ºC followed by incubation with Protein A/G Agarose 
Beads (Santa Cruz, Catalog number: sc-2003) overnight with rotation at 4ºC. Samples were spun 
down at 2000 rpm for 30 seconds, washed 3 times with IP buffer (standard lysis buffer without 
proteinase inhibitor) and after a final PBS wash, re-suspended in 1X sample buffer (Bio-Rad, 
Catalog number: 1610747). Pulse-chase and total protein samples were separated on 12% SDS-
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polyacrylamide gels by SDS-PAGE, gels were dried for 45 minutes at 70ºC using a gel dryer and 
gels were placed in a phosphorimager plate for 3-5 days until analyzed by phosphorimaging using 
a Typhoon Biomolecular Imager. Gel images were analyzed using ImageQuant.  
2.2.23  RNA Immunoprecipitation  
Protein-RNA interactions of OAS1 was analyzed by RNA IP (RIP) after formaldehyde 
crosslinking, followed by RNA extraction and RT-qPCR analysis. Cells were harvested after 
treatment with or without 500 U/ml IFN for 2-4 hours. Cells were spun down at 1500 rpm for 10 
minutes, washed twice in PBS and re-suspended in a 1:1 mix of PBS and 1% formaldehyde. Cell 
suspension was incubated for 10 minutes at room temperature followed by addition of cold 1M 
glycine (Bio-Rad, Catalog number: 56-40-6) and incubation for 10 minutes at room temperature. 
Cells were centrifuged at 1500 rpm for 10 minutes and cell pellets were flash frozen in liquid 
nitrogen and stored at -80ºC until analyzed. Samples were re-suspended in buffer B (0.5% NP-40, 
0.25% sodium deoxycholate, 0.1% SDS, 10 mM EDTA, 50 mM Tris-HCL pH 8, 1X protease 
inhibitor, 40 U/ml RNase inhibitor) and incubated for 30 minutes with rotation at 4ºC. Samples 
were spun down and lysate was sonicated for 15 cycles of 30 seconds on and 30 seconds off. 
Sonicated lysate was centrifuged at 10000 rpm for 3 minutes and supernatant was pre-cleared by 
the addition of pre-washed Protein A/G agarose beads. RIP buffer (0.5% NP-40, 1.2 mM EDTA, 
16.7 mM Tris-HCL pH 8, 167 mM NaCl, 1X protease inhibitor, 40 U/ml RNase inhibitor) was 
added to bead + lysate mixture and incubated for 45-60 minutes with rotation at 4ºC. After pre-
clearing, samples were centrifuged at 10000 rpm for 3 minutes, supernatant was transferred to new 
microcentrifuge tubes and brought to 1 ml volume with RIP buffer. Samples were divided in three 
parts: 100 l for input, 450 l for IP with IgG isotype control and 450 l for IP with OAS1/FLAG 
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antibody. IP was performed by adding 1 g antibody and RNase inhibitor to the samples followed 
by incubation overnight with rotation at 4ºC. Samples were centrifuged at 10000 rpm for 3 
minutes, supernatant was added to Protein A/G agarose beads and incubated for 2 hours with 
rotation at 4ºC. Again, samples were centrifuged at 10000 rpm for 3 minutes, supernatant was 
discarded, and beads were washed with 300 l RIP buffer. Similar to RIP buffer washes, beads 
were washed with 300 l High Salt Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCL pH 8 and 500 mM NaCl) and then washed with TE buffer (1 mM EDTA and 10 mM 
Tris-HCL pH 8). After final washes, supernatant was discarded, and RNA was eluted from beads 
by incubation with 100l Elution buffer (5 mM Tris-HCL pH 8, 150 mM NaCl, 1 mM MgCl2, 1% 
SDS, 40 U/ml RNase inhibitor and 20 g Proteinase K) for 5 minutes at 55ºC. Samples were spun 
down, elution was collected in a new microcentrifuge tube, RNA elution of beads was repeated 
once more with 200 l Elution buffer without proteinase K for 25 minutes at 55ºC. Eluted samples 
from IgG and OAS1 IP were de-crosslinked with 12 l 5 M NaCl and input sample was de-
crosslinked with 4 l 5 M NaCl followed by incubation for 2 hours at 65ºC. RNA was then isolated 
from samples using Macherey-Nagel Nucleospin RNA Kit, according to manufacturer’s 
instructions. cDNA was synthesized from isolated RNA using iScript cDNA Synthesis Kit. 
Expression of mRNA associated to the protein of interest was evaluated by RT-qPCR using 
SsoFast EvaGreen Supermix and primers specific to target mRNA (listed on Table 11).   
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2.2.24  Statistics  
For in-vitro experiments, statistical significance was calculated as indicated in the Figure 
Legends and represented as * p < 0.05, ** p < 0.002, *** p < 0.001 and **** p < 0.0001 using 
GraphPad PRISM 8.0. For all in-vivo survival experiments, statistical significance was calculated 
using a Mantel-Cox test.  
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3.0 OAS1 enhances cGAS protein synthesis and restricts WNV replication 
3.1 Introduction 
WNV remains widespread throughout the globe and has become the leading cause of 
mosquito-borne disease in the United States since it was first detected in New York in 1999 (268). 
Although approximately 80% of individuals infected with WNV remain asymptomatic, 
neuroinvasive disease can develop in older or immunocompromised individuals resulting in death 
(264). WNV neuroinvasive disease is established once WNV gains access to the CNS by crossing 
the blood-brain barrier and replicating efficiently in neurons and myeloid cells. Unfortunately, 
cost-effective vaccines against WNV have yet to be developed for human use, sparking a need to 
study the pathogenesis of WNV and host immunity in order to identify individuals susceptible to 
WNV infection and therapies to clear infection. Early cell-intrinsic immunity and induction of type 
I IFN is needed for control of WNV followed by adaptive humoral and T cells responses needed 
to clear infection (274). However, WNV among other flavivirus have developed several 
mechanisms of antagonizing IFN induction and signaling to establish persistent infection in the 
host (Fig. 10). Therefore, it is crucial to understand the mechanisms of host immunity in response 
to WNV to identify IFN inducible proteins needed to clear infection. A SNP located at the C-
terminal of human OAS1 (rs10774671) has been associated to WNV antiviral resistance and 
influences the expression of OAS1 isoforms (243, 254). In mice, WNV resistance has been mapped 
to enzymatically inactive Oas1b (228). Laboratory strains mice susceptible to WNV have been 
shown to contain an early stop codon at exon 4 of Oas1b resulting in a truncation of Oas1b, 
whereas resistant mice express full length Oas1b. Additionally, recent studies have confirmed that 
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RNase L activity is not required for Oas1b mediated resistance to WNV and In humans OAS3 has 
been shown to primarily activate RNase L, with little contribution of OAS1 and OAS2  (17, 253). 
OASL, another enzymatically inactive OAS protein, has been shown to confer antiviral resistance 
by potentiating RIG-I signaling, making it clear that non-catalytic antiviral activities exist for OAS 
family proteins (238).   
In this chapter we investigate the role of human and mouse OAS1 during WNV infection 
and clarify the mechanisms by which these proteins restrict WNV replication. The G allele of 
OAS1 SNP rs10774671 was shown to be protective to WNV through expression of OAS1 P46 and 
antiviral protection was independent of OAS1 enzymatic activity and activation of RNase L. We 
demonstrate that OAS1 post transcriptionally increases protein levels of several basal and IFN 
inducible proteins by binding to their mRNA and enhancing protein synthesis. Among these 
proteins, cGAS was shown to mediate OAS1 and Oas1b antiviral activity to WNV through type I 
IFN signaling. Lastly, an RNA binding residue of OAS1 and Oas1b was identified as a critical 
factor of WNV antiviral activity and impaired post transcriptional regulation of IRF1 and cGAS 
protein. Overall these studies identify a new mechanism of OAS1 and Oas1b antiviral activity to 
WNV and confirm that non-canonical roles exist for OAS family members.   
 
 
 
 92 
3.2 Results 
OAS1 SNP rs10774671 influences isoform splicing and antiviral activity against WNV, 
but the mechanisms of WNV antiviral activity by OAS1 are not well understood. This SNP is 
located at the 3’ end of human OAS1 and isoform expression is dependent on the expression of the 
G/A allele at this site (Fig. 11 A). Homozygous expression of the A allele incorporates an 
additional Alu I digestion site allowing for genotyping of human cell lines by RFLP assay. 
Therefore, we genotyped several commonly used human cell lines and found that 293T and HeLa 
cells have homozygous A/A; THP1, HT1080 and BJ-Tert have heterozygous G/A; and Daudi has 
homozygous G/G genotypes (Fig. 11 B). Expression of OAS1 after IFN treatment was 
determined in order to validate the expression of OAS1 P42 and P46 isoforms corresponded to the 
genotype of the A/G allele (Fig. 11 C). As expected, HeLa cells (A/A) expressed P42 as compared 
to THP1, HT1080 and BJ-Tert cells (G/A), which all expressed P46 primarily after IFN treatment. 
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Figure 11. Human OAS1 SNP rs10774671 genotyping and isoform expression 
Schematic of OAS1 rs10774671 SNP and RFLP Assay design. Presence of the A allele leads to an additional AluI 
digestion site allowing for differentiating A genotypes from G genotypes (A). Human cell lines were genotyped for 
the A or G allele of OAS1 SNP rs10774671 by RFLP Assay using AluI restriction enzyme (B). WT and OAS1-KO 
THP1, HeLa, HT1080 and BJ-Tert cells were treated with 1500 U/ml of IFN overnight and expression of OAS1 was 
examined by immunoblotting of whole cell lysates (C).  
 
Given that WNV resistance has been linked to expression of the G allele in OAS1 (243), 
we assessed the isoform-specific functions of OAS1 by creating multiple OAS1-deficient (OAS1-
KO) cell lines either in homozygous A/A (HeLa) or heterozygous G/A (THP1, HT1080 and BJ-
Tert) background using CRISPR/Cas9 gene editing (Fig. 11 C) and infected these cells WNV 
Kunjin strain (WNV-KUN) (Fig. 12 A-C).  Heterozygous G/A cell lines (HT1080 and BJ-Tert), 
expressed P46 and were capable of restricting WNV-KUN replication, which was impaired in 
OAS1-deficient cells (Fig. 11 C, Fig. 12 B-C) as compared to homozygous A/A HeLa cells, which 
did not restrict WNV-KUN. (Fig. 12 A). This suggests that the antiviral activity of OAS1 against 
WNV-KUN is associated with the expression of OAS1 P46 isoform.  
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Figure 12. Cell lines with G allele and OAS1 P46 expression inhibit WNV infection 
WT and OAS1-KO HeLa (A), HT1080 (B) and BJ-Tert (C) cells were infected with WNV-KUN at a MOI of 1. 
Culture supernatants collected at indicated time points post infection were quantified for infectious virus particles by 
florescent foci assay (FFU assay) on Vero cells. For each timepoint, supernatants from two independent infections 
were used to infect Vero cells in duplicates, mean and SEM of the calculated FFU/ml were plotted. Statistical 
significance of OAS1-KO cells compared to WT cells was assessed using a two-way ANOVA with Sidak’s multiple 
comparison test.   
 
We validated our previous finding by inducibly expressing P42 and P46 in OAS1-KO 
HT1080 cells (Fig. 13 A), followed by infection with WNV-KUN. Doxycycline (Dox) inducible 
expression of OAS1 P46, but not P42, was capable of inhibiting WNV-KUN growth (Fig. 13 B-
C), indicating that the protective role of OAS1 to WNV infection results from the rs10774671 G 
genotype and expression of the P46 isoform.  
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Figure 13. Inducible expression of OAS1 P46 inhibits WNV infection 
HT1080 OAS1-KO, OAS1-KO inducible OAS1 P42 and OAS1 P46 were pre-treated with 2.5 and 1 g/ml 
Doxycycline (Dox) respectively for 24 h and then infected with WNV-KUN at a MOI of 1. Cell lysates were prepared 
24 h post Dox treatment and analyzed by immunoblotting with OAS1 and Actin antibody (A). Culture supernatants 
were collected 24 and 48 h post infection and infectious particles were quantified by FFU assay on Vero cells as 
described previously. Mean and SEM were calculated from two dilutions of duplicate samples. Significance of Dox 
treated cells compared to untreated cells was assessed using a two-way ANOVA with Sidak’s multiple comparison 
test.   
 
We next examined whether the NTase activity of OAS1 was necessary for the antiviral 
activity of P46. Previous studies had identified critical Asp residues, composing a catalytic triad 
in the active site of OAS enzymes. These Asp residues are needed for NTase activity and mutations 
of these residues abolish catalytic function (235, 236). We inducibly expressed an enzymatically 
inactive mutant of P46 D75A/D77A (DADA) in HT1080 (Fig. 14 A). Both WT and P46 DADA 
mutant restricted WNV replication to the same degree (Fig. 14 B-C) and these results were 
validated in BJ-Tert cells by inducibly expressing P42, P46 and P46 DADA (Fig. 14 D). Similarly, 
WT P46 and P46 DADA mutant inhibited viral growth (Fig. 14 E-F), confirming that enzyme 
activity is not required for the antiviral activity of P46.  
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Figure 14. OAS1 antiviral activity against WNV is independent of its NTase activity 
HT1080 OAS1-KO cells expressing inducible OAS1 P46 and OAS1 P46 D75A/D77A (DADA) mutant were pre-
treated with 1g/ml Dox for 24 h and infected with WNV-KUN at a MOI of 1. Cell lysates were prepared 24 h post 
Dox treatment and analyzed by immunoblotting with OAS1 and Actin antibody (A). Culture supernatants were 
collected at indicated time points followed by FFU assay on Vero cells as described before (B-C). BJ-Tert OAS1-KO 
inducibly expressing OAS1 P42, OAS1 P46 and OAS1 P46 D75A/D77A (DADA) were pre-treated with 5, 2 and 5 
µg/ml Dox respectively for 24 h and then infected with WNV-KUN at a MOI of 1. Cell lysates were collected 24 h 
post Dox treatment and analyzed by immunoblotting with OAS1 and Actin antibody (D). Culture supernatants were 
collected 24 and 48 h post infection and infectious particles were quantified by FFU assay on Vero cells (E-F). Mean 
and SEM values were determined as in Fig. 13. Statistical significance of Dox treated cells compared to untreated 
cells was assessed using a two-way ANOVA with Sidak’s multiple comparison test. 
 
The NTase activity OAS proteins, responsible for the production of 2’-5’ oligoadenylates, 
is required for activation of RNase L and suppression of global RNA translation, including viral 
RNA (162, 374).  Given that P46 restricted WNV independent of NTase activity, we hypothesized 
that RNase L was not required for OAS1 P46-specific WNV antiviral activity. Therefore, we 
generated RNase L-deficient (RNase L-KO), and OAS1/RNase L-double deficient (OAS1/RNase 
L-DKO) HT1080 cells, in which we inducibly expressed P46 (Fig. 15 A). These cells were infected 
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with WNV-KUN. As expected, WT and RNase L-KO cells inhibited viral growth as compared to 
OAS1-KO cells and inducible expression of P46 in OAS1/RNase L-DKO cells had reduced virus 
production in a manner equivalent to its ectopic expression in WT and RNase L-KO cells (Fig. 15 
B-C). Together this data confirms that OAS1 P46 inhibits WNV replication through a novel 
mechanism independent of NTase activity and RNase L activation.  
 
 
Figure 15. OAS1 antiviral activity against WNV is independent of RNase L activation 
Expression of OAS1 and RNaseL was validated by treating the indicated cells overnight with 1000 U/ml of IFN. 
Inducible expression of OAS1 was validated by treating OAS1/RNaseL-DKO inducible OAS1 P46 cells with 1 g/ml 
Dox for 24 h.  Cell lysates were analyzed by immunoblotting with RNaseL, OAS1 and Actin antibody (A). HT1080 
WT, OAS1-KO, RNaseL-KO, OAS1/RNaseL-DKO and OAS1/RNaseL-DKO inducible OAS1 P46 (pre-treated with 
1g/ml Dox for 24 h) were infected with WNV-KUN at a MOI of 1. Culture supernatants for each cell line were 
collected 24 and 48 h post infection and infectious particles were quantified by FFU assay on Vero cells as. Mean and 
SEM were plotted as described previously and the statistical significance of all groups was assessed using a one-way 
ANOVA with Turkey’s multiple comparison test.   
 
To define the mechanistic bases of OAS1 antiviral activity, we characterized type I and 
type II IFN signaling in THP1 and BJ-Tert OAS1-deficient cells. The levels of IFIT1 and IFIT3 
protein was comparable between WT and OAS1-deficient cells (Fig. 16 A-C), concluding that 
OAS1 does not affect IFN signaling. On the contrary, a significant loss of IRF1 protein was 
observed after treatment of THP1 and BJ-Tert OAS1-deficient cells with IFN as compared to WT 
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cells (Fig. 16 D). Additionally, IRF1 protein levels were unaffected in RNase L-deficient THP1 
cells indicating that the phenotypic loss of IRF1 is independent of RNase L activation (Fig. 16 E).  
 
 
 
Figure 16. Type I and Type II IFN signaling in OAS1-deficient cells 
WT and OAS1-KO THP1 cells were treated overnight with 100 and 1000 U/ml IFN. Cell lysates were collected 
after treatment and analyzed by immunoblotting with IFIT1 and Actin antibody (A). WT and OAS1-KO THP1 and 
BJ-Tert cells were treated overnight with 1000 U/ml IFN. Cell lysates were collected after treatment and analyzed 
by immunoblotting with IFIT1, IFIT3 and Actin antibody (B-C). WT and OAS1-KO BJ-Tert and THP1 cells were 
treated with 500 U/ml of IFN for 4 h (D). WT, RNAse L-KO and OAS1-KO THP1cells were treated with 500 U/ml 
of IFN for 4 h. Cell lysates were prepared after treatment and analyzed by immunoblotting with IRF1 and Actin 
antibody (E).  
 
To explore the defects in type II IFN signaling observed in OAS1-KO cells, we examined 
STAT1 phosphorylation and IRF1 mRNA induction in WT and OAS1-KO THP1 cells following 
IFN treatment. The lack of OAS1 did not affect IFN mediated STAT1 phosphorylation at Tyr701 
(Fig. 17 A) or STAT1 and IRF1 mRNA induction (Fig. 17 B-C), suggesting that IRF1 is regulated 
by OAS1 post transcriptionally.  
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Figure 17. Deficiency in type II IFN signaling is downstream of transcription and STAT1 activation 
THP1 WT and OAS1-KO cells were treated overnight with 1000 U/ml IFN or 1000 U/ml IFN for 4 h. Cell lysates 
were analyzed by immunoblotting with STAT1, phospho-STAT1, IRF1 and Actin antibody (A). As indicated, THP1 
WT and OAS1-KO cells were treated overnight with 1000 U/ml IFN or 500 U/ml IFN for 4 h. Total RNA was 
extracted from cells and STAT1 and IRF1 mRNA were quantified by RT-qPCR. Mean and SEM were calculated for 
each treatment from three replicates. 
 
In order to determine the effect of OAS1 loss on cellular physiology and IFN response we 
simultaneously characterized the proteasome and transcriptome of OAS1-deficient THP1 Cells. 
WT and OAS1-KO THP1 cells were treated with IFN and analyzed by RNA sequencing 
(RNAseq) and Stable Isotope Labeling by/with Amino acids in Cell culture (SILAC). WT cells 
were grown in the presence of heavy isotope labeled amino acids and analyzed for incorporation 
efficiency (99.6%).  OAS1-KO cells were grown in the presence of light isotope labeled amino 
acids. Cells were treated with IFN for different durations and analyzed by liquid chromatography-
tandem mass spectroscopy analysis. Similarly, treated cells were analyzed in parallel by RNAseq. 
Because our findings showed that OAS1 post transcriptionally regulated IRF1, we focused our 
analysis on proteins with altered levels without significant differences in corresponding mRNA 
levels. This strategy limits the detection of proteins for which levels were altered due to changes 
in transcription resulting from up-regulation of upstream transcription factors, for example IRF1. 
We then filtered the data set with FDR (p < 0.01) and determined the ratio of peptide intensities 
between WT and OAS1-KO cells at each time point and sorted from highest to lowest fold change 
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(detailed in Methods, Section 2.2.21). Similar ratio of RPKM (Reads Per Kilobase of transcript, 
per Million mapped reads) values of the corresponding genes below 1.7-fold indicated whether the 
mRNA for the same gene was not altered. We detected total 87 proteins (Appendix B, Table 12) 
that were post transcriptionally reduced more than 2-fold in OAS1-KO cells at any time point and 
Fig. 18 A highlights the top 30 proteins affected by the loss OAS1. Several proteins were up-
regulated in WT cells at the basal level (0 h), including cGAS, compared to OAS1-KO cells and 
there were no significant differences in corresponding mRNA levels (Fig. 18A). Similarly, several 
IFN inducible proteins with known antiviral activity such as IRF1, UBR5 (375), XRN1 (376), 
TAP2 (377) and several STAT proteins were reduced in OAS1-KO cells without significant 
reduction of corresponding mRNAs (Fig. 17A). Few proteins were up-regulated in OAS1-KO cells 
(Appendix B, Table 13), however none were associated with known cellular antiviral response 
pathways. We validated these findings by immunoblotting of select proteins in THP1, BJ-Tert and 
HT1080 WT and OAS1-KO cells (Fig. 18 B).  
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Figure 18. OAS1 deficiency leads to a loss of steady state protein levels 
THP1 WT and OAS1 KO cells were cultured for 8 generations in media containing heavy isotope amino acids (13C-6 
15N-2 L-Lysine, and 13C-6 15N-4 L-Arginine) and light isotope amino acids (L-Lysine and L-Arginine) respectively. 
Cells were then treated with 500 U/ml IFN for 0,4 and 8 h for SILAC analysis. In parallel, cells grown in regular 
media were treated with 500 U/ml IFN for 0, 1, 2, 4 and 8 h and analyzed by RNAseq analysis. Following filtering 
(STAR Methods) of the SILAC data peptide ratios were scaled for each protein and represented by heatmap. 
Corresponding mRNA RPKM values were plotted in the heatmap as fold change without scaling (A). WT and OAS1-
KO THP1, BJ-Tert and HT1080 cells were treated with 500 U/ml of IFN for 0, 2 and 4 h. Cell lysates were analyzed 
by immunoblotting with indicated antibodies (B).  
 
Next we confirmed that OAS1 P46 was responsible for post transcriptional regulation of 
target proteins by measuring protein levels of cGAS and IRF1 after inducible expression of WT 
P46 and P46 DADA mutant in OAS1-deficient THP1 cells. Expression of both WT P46 and P46 
DADA were capable of rescuing cGAS protein expression (Fig. 19 A) and similarly rescued IRF1 
and STAT3 protein levels in IFN treated cells (Fig. 19 B). Additionally, P42 was not capable of 
restoring IRF1 or STAT3 (Fig. 19 B) indicating that P46 is responsible for regulating levels of 
specific proteins at a post transcriptional level.  
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Figure 19. Inducible expression of OAS1 P46 rescues cGAS, IRF1 and STAT3 protein levels 
THP1 OAS1-KO inducible OAS1 P46 and P46 DADA cells were treated with 0.5, 1, 2.5 and 5 g/ml Dox. Cell lysates 
were analyzed by immunoblotting with cGAS, OAS1 and Actin antibody (A). THP1 OAS1-KO inducible OAS1 P42, 
P46 and P46 DADA cells were treated with 2.5, 1 and 1 g/ml Dox respectively for 48 h followed by treatment with 
1000 U/ml IFN for 4 h. Cell lysates were prepared after treatment and analyzed by immunoblotting with IRF1, 
STAT3, OAS1 and Actin antibody (B).  
 
Our findings that OAS1 P46 regulates the expression of cGAS and IRF1 at a protein level 
without affecting steady state levels of their mRNA, suggesting that P46 regulates the translation 
of target mRNA. To further understand the mechanism, we measured protein synthesis in THP1 
WT and OAS1-KO cells. First, we performed polysome profiling on these cells, a powerful tool 
used to monitor subsets of actively translating mRNAs in a cell, by sucrose gradient separation of 
polysomes associated to mRNA (378). Polysome profiling of WT and OAS1-KO THP1 cells with 
or without IFN treatment showed that the peak of IFN induced IRF1 mRNA was shifted towards 
the monosome fractions in the OAS1-KO cells compared to the WT cells (Fig. 20). Similarly, the 
polysome-associated fraction of cGAS mRNA was reduced in OAS1-KO cells (Fig. 20). 
Association with polysomes is an indicator of active translation of bound mRNA, therefore notable 
shifts of IRF1 and cGAS mRNA towards the monosome fractions in OAS1-KO cells suggests that 
OAS1 augments translation of these mRNAs.  
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Figure 20. OAS1 shits target mRNA to polyribosome fractions 
Polysome profiling was performed on THP1 WT and OAS1-KO cells after 0 or 4 h of 500 U/ml IFN treatment. 
Following translational arrest with 100 g/ml cycloheximide cell lysates were fractionated on a 10-50% sucrose 
gradient at 230,000g for 2.5 h. Total RNA from each fraction were isolated followed by RT-qPCR analysis for cGAS 
and IRF1 mRNA. 
 
To validate the results from our polysome profiling, we measured the rate of protein 
synthesis and decay using pulse-chase 35S labeling followed by immunoprecipitation (IP) of IRF1 
and cGAS. There were no apparent differences in the levels of total protein synthesis (Fig. 21 A, 
first two lanes), however IRF1 and cGAS accumulation was reduced in OAS1-KO cells (Fig. 21 
A, IP lanes). In order to determine the rate of IRF1 and cGAS translation and protein decay, 35S 
labeled IRF1 and cGAS band intensities were fitted with linear regression during the pulse period 
or by fitting the band intensities with a single-phase exponential decay equation and quantifying 
the half-life of the exponential decay during the chase period  (Fig. 21 B). Analysis revealed that 
the rate of translation (determined by the slope of the linear regression) was reduced by 6- and 3-
fold for IRF1 and cGAS respectively, in OAS1-KO cells. However, the half lives of IRF1 between 
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WT (16.4 min) and OAS1-KO (12.1 min) cells were quite similar and cGAS band intensity did 
not diminish during this period (Fig. 21 B). Together the results of polysome profiling and pulse-
chase experiments indicate that OAS1 does not regulate the decay of these proteins, but instead 
enhances their synthesis.  
 
 
Figure 21. Effect of OAS on IRF1 and cGAS protein synthesis and decay 
WT and OAS1-KO THP1 cells were pulse labelled with 35S-L-methionine and 35S-L-cysteine mixture for 30 min, 
followed by chase with cold amino acids for 60 min. Cell lysates were immunoprecipitated with IRF1 or cGAS 
antibodies and analyzed by SDS-PAGE and autoradiography with a Typhoon imager (A). IRF1 and cGAS band 
intensities were quantified, plotted and fitted with a linear regression for protein synthesis or fitted with a single 
exponential decay equation to measure protein degradation (B). Representative figures from at least twice repeated 
experiments are shown.  
 
Having established that P46 enhances the translation of IRF1 and cGAS mRNA, we sought 
to determine the molecular mechanism of OAS1 translational regulation by OAS1 using RNA-
immunoprecipitation (RIP) experiments. During RIP analysis, cells are subjugated to 
formaldehyde treatment to generate protein-RNA cross-links between proximal molecules 
followed by immunoprecipitation of proteins of interest. Reverse cross-linking of the IPed protein 
and RNA complexes allows recovery of the associated RNA that is and quantified by RT-qPCR 
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(379). In order to determine if OAS1 directly bound to IRF1 and cGAS mRNA, we performed RIP 
analysis on IFN treated HT1080 OAS1-deficient cells inducibly expressing P42 and P46. Only 
P46 induced by Dox showed enrichment of cGAS mRNA as compared to P42, which did not show 
any association with cGAS mRNA. Additionally, the control GAPDH mRNA was not enriched in 
P46 expressing cells (Fig. 22 A). Similarly, IRF1 mRNA was enriched in cells expressing P46 
after IFN induction, but not in cells expressing P42 (Fig. 22 B). These results indicate that human 
P46 associates with specific mRNA to enhance their translation.  
 
 
Figure 22. OAS1 P46 binds directly to target mRNA 
THP1 OAS1-KO expressing inducible OAS1 P42 and P46 cells were treated with 1.5g/ml Dox for 48 h. 
Formaldehyde crosslinked cell lysates were prepared followed by RNA-immunoprecipitation (RIP) with OAS1 and 
control IgG antibody. GAPDH and cGAS mRNA was quantified in input and RIP samples by RT-qPCR. Percent 
enrichment of specific mRNA were calculated with respect to the input mRNA. Mean and SEM of the fold enrichment 
values with respect to the control IgG were plotted from three replicates. 
 
Given that OAS1 P46 restricts WNV and regulates the translation of several antiviral 
proteins, we hypothesize that OAS1 antiviral activity was mediated downstream through a specific 
protein or pathway regulated by P46. As both cGAS and IRF1 have been shown to restrict WNV 
(380, 381), we used cGAS-KO and IRF1-KO BJ-tert cells to inducibly express P46 and examine 
the antiviral activity of these cells to WNV. Additionally, we included WT, OAS1-KO and MAVS-
KO BJ-Tert cells as controls. All cell lines were verified for the loss of expression of the target 
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protein and inducible expression of P46 in each cell line (Fig. 23 A) followed by infection with 
WNV-KUN in the absence or presence of doxycycline. Viral titers in individuals cell lines without 
inducible expression of P46 showed the expected patterns of enhanced virus replication in IRF1, 
MAVS and OAS1-KO cells confirming their antiviral roles. However, expression of P46 restricted 
viral growth in all cell lines except cGAS-KO cells (Fig. 23 B) establishing a requirement for 
cGAS to mediate downstream antiviral effects of P46. The antiviral activity of cGAS to WNV was 
confirmed by ectopically expressing FLAG-tagged cGAS and measuring WNV replication (Fig. 
23 C-D).  
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Figure 23. OAS1 antiviral activity is mediated through cGAS 
BJ-Tert WT, cGAS-KO, IRF1-KO, MAVS-KO and OAS1-KO cells with inducible P46 expression were pre-treated 
with 2g/ml Dox for 24 h and then infected with WNV-KUN at a MOI of 1. Cell lysates collected 24 h post Dox 
treatment, were analyzed by immunoblotting with cGAS, IRF1, MAVS, OAS1 and Actin antibody (A). Culture 
supernatants from each KO cell line were collected 24 h post infection and infectious particles were quantified by 
FFU assay on Vero cells (B). Mean and SEM were plotted from as before followed by statistical analysis using a two-
way ANOVA with Sidak’s multiple comparison test. HT1080 cells were transfected with pcDNA-Flag-cGAS 
overnight, followed by infection with WNV-KUN at a MOI of 1. Cell lysates were prepared from transfected samples 
and analyzed by immunoblotting with Flag and Actin antibody (C). Culture supernatants were collected 24 h post 
infection and virus particles were quantified by FFU assay on Vero cells as before (D). Statistical significance of 
cGAS transfected cells compared to pcDNA transfected cells was assessed using an Unpaired t test. 
 
cGAS senses cytosolic DNA resulting in the production of the second messenger cGAMP 
and subsequent activation of STING in order to induce transcriptional activation of type I IFNs 
and ISGs needed to restrict viral growth (382). However, cGAS has also been implicated in 
restricting RNA virus infection and it is thought that cGAS is activated due to leakage of 
mitochondrial DNA during virus infection (308, 383).  Our findings that cGAS is required for the 
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antiviral activity of OAS1 to WNV suggests that intact IFN signaling is needed to inhibit virus. 
We examined this hypothesis using IFN-receptor-deficient (IFNAR-KO) cells. We infected 
OAS1/IFNAR1-DKO BJ-Tert cells with or without inducible expression of P46 (Fig. 24 A). 
OAS1/IFNAR1-DKO cells were incapable of repressing WNV-KUN replication, as compared to 
WT cells, and inducible expression of P46 did not inhibit virus (Fig. 24 B-C), suggesting that 
downstream IFN signaling presumably through cGAS is required for the antiviral activity of P46.  
 
 
Figure 24. OAS1 antiviral activity requires cGAS mediated IFN signaling 
Expression of OAS1 and IFNAR1 was validated by treating HT1080 WT, OAS1-KO and OAS1/IFNAR1-DKO with 
1000 U/ml of IFN overnight. Inducible expression of OAS1 was validated by treating OAS1/IFNAR1-DKO 
inducible OAS1 P46 cells with 2g/ml Dox for 24 h. Cell lysates were analyzed by immunoblot with IFNAR1, OAS1 
and Actin antibody (A). HT1080 WT, OAS1-KO, OAS1/IFNAR1-DKO and OAS1/IFNAR1-DKO inducible OAS1 
P46 (pre-treated with 2g/ml Dox for 24 h) were infected with WNV-KUN at a MOI of 1. Culture supernatants were 
collected 24 and 48 h post infection and infectious particles were quantified by FFU assay on Vero cells (B-C). Mean 
and SEM values were plotted as described before. Statistical significance of KO cells compared to WT cells was 
assessed using a one-way ANOVA with Dunnett’s multiple comparison test.  
 
Having established that OAS1 antiviral activity against WNV is mediated through cGAS 
and IFN signaling, we proceeded to characterize murine Oas1 proteins in order to identify the 
functional equivalent to human OAS1. There are 8 Oas1 genes (Fig. 5) of which only Oas1a and 
Oas1g exhibit NTase activity. Oas1b is the only variant linked to restricting WNV lacking NTase 
activity and this protection has been shown to be independent of RNase L activation (228, 253, 
384). In order to determine the antiviral activity of several enzymatically active (NTase+) and 
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inactive (NTase-) Oas1 genes, we used our human HT1080 OAS1/RNase L-DKO cell system and 
tested WNV growth in these cells. As expected, expression of Oas1b (NTase-) robustly inhibited 
viral replication, as compared to Oas1g (NTase+), which inhibited virus to a small degree, and 
Oas1a (NTase+), which had no effect on viral growth (Fig. 25. A-B). Poor expression of Oas1h 
(NTase-) cDNA precluded us from determining the effects of Oas1h on viral growth (Fig. 25 A). 
This data validates that Oas1b WNV antiviral activity is NTase and RNase L independent.  
 
 
Figure 25. Mouse Oas1b restricts WNV replication in-vitro 
HT1080 OAS1/RNaseL-DKO cells were transfected with pCMV6-Oas1-Flag-MYC constructs carrying various Oas1 
isoforms (Oas1a, Oas1b, Oas1g, Oas1h) overnight, followed by infection with WNV-KUN at a MOI of 1. Cell lysates 
were prepared from transfected samples and analyzed by immunoblotting with MYC and Tubulin antibody (A). 
Supernatants from transfected cells were collected 24 h post infection and infectious particles were quantified by FFU 
assay on Vero cells (B). Vero cells were infected in duplicate and mean FFU and SEM was calculated from two 
dilutions corresponding to each replicate. Statistical significance of Oas1b transfected cells compared to pCMV6 
transfected cells was assessed using a one-way ANOVA with Dunnett’s multiple comparison test.   
 
To determine if the antiviral activity of Oas1b protein is related to cGAS signaling, we 
inducibly expressed Oas1b in WT and cGAS-KO BJ-Tert cells (Fig. 26 A) and infected these cells 
with WNV-KUN. As seen with human OAS1, inducible expression of Oas1b was incapable of 
restricting virus in the absence of cGAS protein (Fig. 26 B), indicating that Oas1b mediated 
antiviral activity requires cGAS and IFN signaling to confer protection. These results suggest that 
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murine Oas1b is functionally equivalent to human OAS1 and clarify the mechanism of Oas1b 
WNV antiviral reported in previous studies.   
 
 
Figure 26. Murine cGAS is required for Oas1b mediated WNV antiviral activity 
BJ-Tert WT and cGAS-KO cells with inducible Oas1b expression were treated with 0, 1 and 2 g/ml Dox for 24 h 
followed by immunoblotting with MYC and Actin antibody (A). Similarly treated cells with 1g/ml Dox for 24 h 
were infected with WNV-KUN as indicated followed by FFU assay on Vero cells (B). Mean and SEM were calculated 
as before. Statistical significance of Dox treated cells compared to untreated cells was assessed using an Unpaired t 
test.  
 
To establish if cGAS mediated antiviral activity of Oas1b was mechanistically similar to 
human OAS1, we performed RIP analysis on OAS1-deficient HT1080 cells inducibly expressing 
Oas1b. Previous studies have identified several residues within the positively charged surface of 
OAS1 (Fig. 8) as essential for binding dsRNA and have been confirmed by mutagenesis (236, 
385). We used cells expressing two Oas1b RNA binding mutants (K42E/K57E/K60E and K60E) 
(Fig. 27 A) in our RIP analysis in order to determine if mutations of these residues impaired mRNA 
association with Oas1b. We first established the specificity of Oas1b in our RIP experiments by 
inducibly expressing FLAG tagged Oas1b and showed that only Dox treated samples were 
enriched in cGAS mRNA after anti-FLAG IP compared to IgG control, whereas control GAPDH 
mRNA was not enriched (Fig. 27 B). We then proceeded to characterize our RNA binding mutants 
and showed that enrichment of cGAS mRNA observed in WT Oas1b was lost in both mutants 
 111 
(Fig. 27 C). These results suggest that similar to human OAS1, Oas1b enhances protein synthesis 
of cGAS by directly binding its mRNA and the K60 residue is critical for this interaction.  We 
validated these results in OAS1-deficient THP1 cells inducibly expressing WT Oas1b and Oas1b 
K60E (Fig. 27 D). We showed significant enrichment of cGAS and IRF1 mRNA, but not control 
GAPDH mRNA, confirming that Oas1b also targets IRF1 mRNA (Fig. 27 E). Similarly, 
enrichment of cGAS mRNA was lost in THP1 OAS1-KO cells inducibly expressing Oas1b K60E 
as compared to WT Oas1b (Fig. 27 F). Overall this data indicates that murine Oas1b, similar to 
human OAS1, associates to specific mRNAs, including IRF1 and cGAS, in order to enhance their 
translation. Together this data suggests that Oas1b is mechanistically similar to human OAS1 in 
terms of regulating protein synthesis and antiviral activity.  
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Figure 27. Murine Oas1b binds directly to target mRNA 
HT1080 OAS1-KO inducible Oas1b, Oas1b K42E/K57E/K60E and Oas1b K60E cells were characterized by 0, 1 and 
2 µg/ml Dox treatment for 48 h. THP1 OAS1-KO cells with inducible Oas1b and Oas1b K60E expression were treated 
with 0, 1 and 2 g/ml Dox for 48 h. Cell lysates were prepared post treatment and analyzed by immunoblotting with 
OAS1 and Actin antibody (A, D). HT1080 OAS1-KO inducible Oas1b cells were treated with 1.5 µg/ml Dox for 48 
h and cell lysates were subjected to RNA-immunoprecipitation with FLAG antibody and control IgG antibody, 
followed by quantitation of GAPDH and cGAS mRNA by RT-qPCR (B-C). THP1 OAS1-KO inducible Oas1b cells 
were treated with 1.5g/ml Dox for 48 h followed by treatment with 500 U/ml IFN for 4 h. Formaldehyde crosslinked 
cell lysates were prepared followed by RNA-immunoprecipitation (RIP) with FLAG and control IgG antibody. 
GAPDH, IRF1 and cGAS mRNA was quantified in input and RIP samples by RT-qPCR (E-F) Percent enrichment of 
specific mRNA were calculated with respect to the input mRNA.  Mean and SEM were calculated from three technical 
replicates (B-C, E-F). 
 
We have shown that a specific residue in Oas1b (K60) is needed for binding to IRF1 and 
cGAS mRNA, to enhance protein synthesis and confer antiviral protection. To establish the 
necessity of K60 of OAS1/Oas1b for WNV antiviral activity, we ectopically expressed several 
Oas1b mutants targeting consensus RNA binding residues in HT1080 OAS1-KO cells followed 
by infections with WNV-KUN (Fig. 28 A). Analysis of viral titers revealed that the K60E mutant 
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abolished the antiviral activity of Oas1b (Fig. 28 B). Similarly, the same K60 mutation in human 
P46 resulted in a loss of antiviral activity against WNV (Fig. 28 C-F). This data indicates that K60 
of both P46 and Oas1b is essential for regulating the translation of cGAS mRNA needed confer 
antiviral protection against WNV, establishing the functional equivalence between human and 
murine OAS1.  
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Figure 28. Oas1b and OAS1 K60 residue is essential for WNV antiviral activity 
HT1080 OAS1-KO cells were transfected overnight with different pLenti-Oas1-Flag-MYC Oas1b WT and RNA 
binding mutants (Oas1b, Oas1b K42E, Oas1b K42E/K57E/K60E, Oas1b K60E, Oas1b K60E/K191E) or different 
pcDNA3-OAS1 isoforms (OAS1 P46, OAS1 P46 K60E, OAS1 P42)for 24 h, followed by WNV-KUN infection at 1 
MOI. Cell lysates were prepared from transfected samples and analyzed by immunoblotting with MYC and Actin 
antibody (A) or OAS1 and Actin antibody (C). Cell supernatants were collected 24 h post infection and infectious 
particles were quantified by FFU assay on Vero cells (B, D). Mean and SEM were calculated from two dilutions of 
duplicate samples. Statistical significance of Oas1b transfected cells compared to pLenti transfected cells and OAS1 
transfected cells compared to pcDNA transfected cells was assessed using a one-way ANOVA with Dunnett’s multiple 
comparison test. HT1080 OAS1-KO inducible OAS1 P46 and OAS1 P46 K60E were pre-treated with 2 µg/ml Dox 
for 24 h and infected with WNV-KUN at a MOI of 1. Cell lysates were prepared 24 h post Dox treatment and analyzed 
by immunoblotting with OAS1 and Actin antibody (E). Supernatants were collected 24 h post infection and infectious 
particles were quantified by FFU assay on Vero cells (F). Mean and SEM were calculated as in panel B and D. 
Statistical significance of Dox treated cells compared to untreated cells was calculated using a two-way ANOVA with 
Sidak’s multiple comparison test.   
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Although we have shown that OAS1 enhances the synthesis of several proteins by binding 
to their respective mRNA, the mechanism by which translation is enhanced by OAS1 remains 
unknown.  It is known that translation of mRNA is compartmentalized between cytosolic and ER-
bound ribosomes and previous ribosome profiling suggested that ER-associated ribosomes play an 
important role in global mRNA translation (386). The C-terminal domain of OAS1 P46, but not 
P42, harbors a conserved CAAX motif, important for prenylation and membrane association (387–
389). Additionally, a transmembrane domain at the C terminus of Oas1b (a.a. 354-371) has been 
shown to anchor Oas1b to the ER and is important for WNV antiviral activity (384). Notably this 
transmembrane domain is missing in truncated Oas1b, found in laboratory strain mice (Fig.6), 
suggesting that the localization of Oas1b mediates its antiviral activity. To determine if OAS1 
similar to Oas1b is localize to the ER, we used fluorescent confocal microscopy to determine the 
cellular localization of inducibly expressed OAS1 P42 and P46 in addition to ectopically expressed 
Oas1b and Oas1g. We first determined the specificity of our assay by immunofluorescent staining 
of IFN treated HT1080 WT and OAS1-KO cells using OAS1 specific antibody followed by 
visualization using confocal microscopy. OAS1 signal was detected in WT cells but not in OAS1-
KO cells and OAS1 seemed to localize around the nucleus (Fig. 29 A, left panel). In order to 
determine the isoform specific localization of human OAS1, we inducible expressed P46 and P42 
in OAS1-deficient HT1080 cells and stained these cells with OAS1 and Calnexin (ER marker) 
antibodies. Additionally, we ectopically expressed FLAG-tagged Oas1b and Oas1g in HT1080 
OAS1-KO cells and analyzed these cells with FLAG and Calnexin antibodies. We found that 
OAS1 P46 and Oas1b co-localize to the ER, P42 and Oas1g were diffused throughout the cells 
(Fig. 29), suggesting that like Oas1b, P46 localization to the ER is needed for antiviral activity. 
Our previous characterization of OAS1 post transcriptional regulation in combination with our 
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localization results, suggests that OAS1 and Oas1b localization might be important for enhancing 
protein synthesis and restricting virus. We hypothesize that OAS1 binds to and directs mRNA to 
the ER for association with polyribosomes and effective translation, although we have yet to define 
how the localization of OAS1 impacts mRNA translation. This hypothesis will be explored in 
future studies.  
 
Figure 29. Subcellular localization of human and mouse OAS1 
Validation of -OAS1 antibody staining of endogenous OAS1 in IFN treated HT1080 cells. WT and OAS1-KO 
HT1080 cells were treated with IFN followed by immunofluorescence (IF) staining with anti-OAS1 antibody (left 
column). HT1080 OAS1-KO P46 and P42 cells were inducibly expressed with Dox followed by anti-OAS1 (green) 
and anti-Calnexin (ER, red) staining (Top). HT1080 OAS1-KO cells were transfected with FLAG-tagged Oas1b and 
Oas1g followed by anti-FLAG (green) and anti-Calnexin (ER, red) staining. Imaging was done using an Olympus 
confocal microscope. Scale bars = 10 m.  
 
Lastly, to define the in-vivo role of Oas1b to WNV, we generated mice expressing full 
length Oas1b. Several strains of laboratory mice, including C57BL/6 and BALB/c mice, carry a 
premature stop codon at the C-terminal Oas1b coding region resulting in truncation of Oas1b 
protein and WNV sensitivity (228, 251). Using CRISPR/Cas9-based gene editing, we created an 
Oas1b-knockin (Oas1b-KI) mouse restoring the full-length Oas1b expression in C57BL/6J 
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background (Fig. 30. A-C). The premature stop codon was replaced with Arg, which allowed full 
length expression of Oas1b (Fig. 30 A, highlighted in red), in addition to several nucleotide 
substitutions giving rise to a BspE I restriction site, which facilitated genotyping of mice (Fig. 30 
C).  
 
Figure 30. Oas1b-KI Mouse Model 
Oas1b-KI mouse model generated by CRISPR/Cas9 homology directed repair. Sequence of the WT C56BL/6J mice 
and Oas1b-KI mice showing the targeted nucleotides (highlighted in red) in the Oas1b locus (A). Representative 
sanger sequencing traces (B) and sample genotyping (C) with BspEI from WT, Oas1b-KI heterozygous and 
homozygous mice.  
 
Primary fibroblasts were obtained from WT and Oas1b-KI mice and infected with WNV-
KUN. Fibroblasts from Oas1b-KI mice showed resistance to WNV growth as compared to cells 
from WT mice (Fig. 31 A). Previously we showed that inducible expression of Oas1b in BJ-Tert 
OAS1-KO cells conferred cGAS mediated antiviral activity to WNV (Fig. 26 B). Therefore, to 
confirm the effect of Oas1b on cGAS function, we examined primary BMDMs derived from WT 
and Oas1b-KI mice. Basal expression levels of cGAS were higher in BMDMs derived from Oas1b-
KI mice as compared to WT BMDMs (Fig. 31 B, inset). Additionally, treatment of the BMDMs 
with DNA (poly(dA:dT)) or DNA virus (Herpes simplex virus, HSV) but not RNA (poly(I:C)) or 
RNA virus (Sendai virus, SeV) resulted in increased IFN induction (Fig. 31 B). These results 
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demonstrate that like human OAS1, Oas1b enhances synthesis of cGAS protein, which restricts 
WNV replication in a type I IFN dependent manner.  
 
 
Figure 31. Oas1b Primary Fibroblasts and BMDMs confer protection to WNV 
Primary fibroblasts from WT and Oas1b-KI mice were infected with WNV-KUN at a MOI of 1. 24 h post infection 
virus particles were quantified by FFU assay on Vero cells. Mean and SEM were calculated from two dilutions of 
duplicate infections on Vero cells. Statistical significance of Oas1b-KI cells compared to WT cells was assessed using 
a two-way ANOVA with Sidak’s multiple comparison test (A). Bone Marrow Derived Macrophages (BMDMs) from 
WT and Oas1b-KI mice were transfected with poly dA:dT or p(I):p(C) (pI:C)(0.5 µg/ml for both) or infected with 
Herpes Simplex Virus (10 MOI) or Sendai Virus (80HAU/ml). Culture supernatants were analyzed for IFN 
production by ELISA (B). Statistical significance of Oas1b-KI cells compared to WT cells was assessed using multiple 
unpaired t test per condition. Inset: Cell lysates from WT (1) and Oas1b-KI (2) were collected and analyzed by 
immunoblotting with cGAS and Actin antibody.  
 
Using a subcutaneous infection model with WNV (New York 1999 strain, WNV-NY) and 
Powassan virus (POWV), another neurotropic tick-transmitted flavivirus, we assessed the in-vivo 
role of Oas1b. Oas1b-KI mice infected with WNV-NY, were completely protected from lethality 
(Fig. 32 A) and analysis of viral burden in different organs of these mice revealed markedly 
reduced virus infection in the Oas1b-KI mice compared to WT mice (Fig. 32 B). Similarly, Oas1b-
KI mice were completely resistant to lethal infection with POWV as compared to WT mice (Fig. 
32 C). Taken together, these results confirm that mouse Oas1b confers resistance to flavivirus 
infection in-vitro and in-vivo in a RNase L independent manner.  
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Figure 32. Oas1b confers protection to WNV and Powassan virus in-vivo 
Survival and virus burden in tissue of WT and Oas1b-KI mice infected with WNV-NY (100 PFU/ml) by footpad 
infection. Mouse survival was measured for 21 days (A). Statistical significance of Oas1b-KI survival compared to 
WT mice was assessed using a Mantel-Cox test. WNV-NY virus burden in the brains, spinal cords, spleens and serum 
of WT and Oas1b-KI mice was determined by plaque assay of samples from mice at days 2, 4 and 7 post infection 
(B). Mean and SEM of viral loads from tissue were plotted and statistical significance of Oas1b-KI compared to WT 
mouse tissue titers was assessed using a Mann-Whitney test. Survival of WT and Oas1b-KI C57BL/6 mice infected 
with POWV (100 FFU) by footpad injection. Mouse survival was measured for 21 days. Statistical significance of 
Oas1b-KI survival compared to WT mice was assed using a Mantel-Cox test (C).  
 
 
 
 
 
W
T
O
as
1b
-K
I
(h
et
)
– + – + – + BspEI
513 (WT)
264 (Oas1b-KI)
500
200
O
as
1b
-K
I
(h
om
)
WT
Oas1b-KI (het)
Oas1b-KI (hom)
* * * * * * *
A
B
C
C POWV (footpad injection)
0 7 14 21
0
20
40
60
80
100
Days Post Infection
P
e
rc
e
n
t
s
u
rv
iv
a
l
Oas1b-KI (n=5)
WT (n=4)
p-value < 0.0009
7
0
2
4
6
8
10
Brain
**
lo
g
1
0
P
F
U
/g
W
N
V
-N
Y
WT Oas1b-KIB
Days Post Infection
7
2
4
6
8
10
Spinal cord
**
2 4
2
4
6
Spleen
**
2 4 7
1
2
3
4
5
Serum
*
*
A
WNV-NY (footpad injection)
0 7 14 21
0
20
40
60
80
100
Days Post Infection
P
e
rc
e
n
t
su
rv
iv
a
l
Oas1b-KI (n=8)
WT (n=10)
p-value < 0.0001
24 hpi 48 hpi
104
105
Mouse Fibroblast, WNV-KUN
MOI of 1, 24 and 48 hpi
W
N
V
-K
U
N
(f
fu
/m
l)
WT
Oas1b-KI
**** ****
A
Mock pdA:dT pI:C HSV SeV
0
25
50
75
100
200
300
400
500
IF
N
b
(p
g
/m
l)
*
**
WT
Oas1b-KI
cGAS
Actin
1 2
BMDM
B
 120 
3.3 Discussion 
WNV remains endemic around the world and is the leading cause of mosquito-borne 
disease in the USA. Although infection with WNV may not present serious disease progression in 
healthy individuals, it can cause neuroinvasive disease in the elderly and immunocompromised. 
Among the flavivirus family, several have been associated with severe disease progression, for 
example hemorrhagic dengue fever and congenital birth defects by ZIKV infection (390, 391). 
Structural and non-structural proteins are conserved among flavivirus, therefore understanding the 
host immune response against these viruses is crucial for the development of therapies and 
vaccines. Flavivirus RNA is detected by cytosolic sensors, leading to the induction of IFN and 
ISGs. However, flavivirus have developed several mechanisms of antagonizing IFN induction and 
signaling in order to efficiently replicate in host cells (284, 284, 287, 291–293, 392–394). Among 
these mechanisms of IFN antagonism, reports of degradation of cGAS by DENV NS2B, suggests 
that cGAS may play a role during flaviviral infection (306). Although flavivirus are RNA virus, it 
has been shown that virus infection can lead to cellular stress and mitochondrial damage allowing 
leakage of mitochondrial into the DNA and activation of cGAS-STING pathways (298, 304–306, 
308). These studies suggest that cGAS plays an important role during flaviviral infection and in 
this chapter, we confirmed that the WNV antiviral activity of OAS1 is mediated through cGAS 
protein.  
A SNP in human OAS1 has been shown to influence isoform expression and confer 
protection against WNV (243), which lead us to investigate the isoform specific function of OAS1 
to WNV. We showed that cells carrying the G haplotype, responsible for expression of OAS1 P46, 
conferred protection against WNV. Inducible expression of OAS1 P46, but not P42, restricted 
WNV replication confirming that the G haplotype and P46 is protective to WNV. Given that the 
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antiviral activity of enzymatically inactive Oas1b is independent of RNase L and other studies 
have shown that OAS3 is required and sufficient for RNase L activation (17, 253), we investigated 
if the catalytic activity of OAS1 was necessary for inhibiting WNV. Using a catalytically inactive 
mutant of P46, we demonstrated that the enzyme activity of OAS1 was not necessary for restricting 
WNV. Similarly, using viral growth assays in RNAse L-deficient cells we confirmed that RNAse 
L is not required for OAS1 antiviral activity against WNV. In order to determine the mechanism 
by which OAS1 restricts WNV, we performed proteomic and transcriptome analysis on OAS1-
deficient cells. These analyses revealed that OAS1 post transcriptionally regulated basal 
expression and IFN mediated induction of several antiviral genes. Using polysome profiling, we 
determined that OAS1 shifted target mRNAs towards polysome fractions and analysis of nascent 
protein synthesis by radiolabeling revealed enhanced synthesis of cGAS and IRF1 protein. RIP 
analysis revealed that OAS1 P46 associated with mRNA suggesting that this association of P46 
isoform with target mRNA is needed for enhancing the translation of these mRNAs. Taken 
together these results suggest that P46 regulates the translation of several proteins that may be 
needed for antiviral defense against WNV. Through inducible expression of OAS1 in cells 
deficient in several antiviral genes, we showed that cGAS and downstream IFN signaling was 
primarily responsible for the antiviral activity of OAS1. Similarly, Oas1b antiviral activity was 
shown to require cGAS expression.   
Several studies have described critical residues in the positively charged region of OAS1 
needed for RNA binding, however these were done in the context of dsRNA binding required to 
trigger OAS1 2’-5’ enzymatic activity and RNase L activation (236, 237, 385). In this study we 
show that K60 residue, conserved in mouse and human (Appendix A, Fig. 43), is essential for 
binding target mRNA in order enhance protein synthesis and confer antiviral protection. Although 
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we have established that OAS1 associates with mRNA and enhances their translation, the 
mechanism by which this occurs is not completely understood. Subcellular localization of human 
and mouse OAS1 revealed that these proteins localize in the ER and it is possible that OAS1 binds 
to and directs mRNA to ER-associated polyribosomes in order to mediate their translation (386, 
395). However, this hypothesis is yet to be tested and will be addressed in the future. In our final 
experiments, we show that full length Oas1b restored protection against WNV, as described before 
(251) and BMDMs derived from Oas1b-KI mice revealed that cGAS protein levels and IFN 
signaling were enhanced as compared to WT mice. Together these results indicate that Oas1b is 
functionally equivalent to human OAS1 and enhances cGAS synthesis to confer antiviral 
protection through IFN signaling. This study provides a non-canonical mechanism of OAS1 
antiviral activity and clarifies the mechanism by which Oas1b restricts WNV. Additional studies 
have shown that the G haplotype and expression of P46 is protective against HCV and DENV 
(229, 260), suggesting that OAS1 may provide protection to a broad range of viral pathogens 
through the translational regulation of host antiviral mRNAs.  
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4.0 OAS1 mediates intracellular bacterial infection  
4.1 Introduction 
Several bacterial ligands are recognized through TLRs and intracellular receptors that lead 
to IFN induction and activation of inflammatory pathways. However, the roles of IFNs during 
bacterial infections remains challenging to interpret. Type I IFN signaling may be beneficial or 
detrimental to the host, dependent on the bacterial species (7, 102). Type II IFN signaling is crucial 
for mediating immunity towards intracellular pathogens and deficiencies in IFN signaling leads 
to enhanced susceptibility to several bacteria, including mycobacteria and L. monocytogenes (341). 
IFN enhances MHC I and II processing, induces secretion of chemokines and other inflammatory 
molecules, promotes immune cell differentiation and enhances the antibacterial functions of 
several innate and adaptive immune cells, which altogether is required for bacterial clearance (103, 
333, 396, 397). IFNs also regulate the expression of several ISGs, however their role in bacterial 
pathogenesis remains unclear. OAS family proteins are ISGs, first described to promote antiviral 
protection through activation of RNase L and suppression of translation. However, the 
characterization of OASL and Oas1b enzyme independent mechanisms of antiviral activity (238, 
253), in addition to the results presented in this dissertation for human OAS1, reveal that non-
canonical roles exist for OAS family members. In chapter 3 we showed that OAS1 enhanced 
protein synthesis of several basal and IFN inducible proteins. Among these proteins, cGAS was 
responsible for conferring antiviral protection to WNV independent of RNase L activation. 
Additionally, the levels of several antimicrobial related proteins were elevated, including IRF1, 
suggesting potential antibacterial roles of OAS1. To my knowledge, mechanisms of antibacterial 
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activity for OAS proteins have not been described, however the same SNP in OAS1 that confers 
resistance to WNV has been associated with protection against M. tuberculosis (246). We used L. 
monocytogenes and F. novicida (herein referred to as Lm and Fn respectively) to model 
intracellular infections both in-vitro and in-vivo as tools for studying host responses to bacterial 
infection (341, 345, 347, 351, 353, 398).  
In this chapter, we explore the role of OAS1 during bacterial infections. Similar to the 
antiviral role of OAS1, protection against Lm and Fn is related to the expression of OAS1 isoform 
P46 and is independent of enzyme activity. OAS1 post transcriptionally regulates IRF1 and we 
show that P46 antibacterial activity is mediated through IRF1. Proteomic and transcriptome 
analysis revealed that the transcription of several IFN-regulated genes was down-regulated in 
OAS1-deficient cells. OAS1 enhances the synthesis of several proteins without directly altering 
mRNA levels. Therefore, it is likely that these OAS1 regulated transcripts are dependent on 
transcription factors post-transcriptionally regulated by OAS1. Among these transcription factors, 
IRF1 is known to regulate the expression of several IFN-inducible genes and it is likely that IRF1 
regulated proteins contribute to bacterial defense. Lastly, we demonstrate that Oas1b can confer 
protection to Lm and Fn in-vitro and in-vivo establishing OAS1 as a critical component of host 
antibacterial activity to these pathogens.  
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4.2 Results 
Previously I described a novel mechanism of OAS1 antiviral activity against WNV, which 
was dependent on the expression of P46 isoform. P46 was capable of binding target mRNAs and 
enhanced the synthesis of basal and IFN-inducible proteins. Given that the same SNP, which 
promotes P46 expression, also confers protection to M. tuberculosis, we hypothesized that OAS1 
might contribute to antibacterial defense through the same translational mechanism described 
before. First, to determine the susceptibility of OAS1-deficient cells to intracellular bacterial 
infections, we used the gram-positive bacteria Lm as a model. We infected THP1 and BJ-Tert WT 
and OAS1-KO cells with Lm at different MOI and analyzed intracellular bacterial growth by 
Gentamicin protection assay (Fig. 33 A-D). At 8 h post infection, bacterial burden was 
significantly higher in both THP1 and BJ-Tert OAS1-deficient cells (Fig. 33 A-B and C-D 
respectively), suggesting that OAS1 is protective against Listeria.  
 126 
 
 
Figure 33. OAS1 confers protection against L. monocytogenes 
WT and OAS1-deficient THP1 (A-B) and BJ-Tert (C-D) cells were infected with Lm at a MOI of 1 and 10. Following 
bacterial adsorption for 1 h, cells were incubated in medium containing 50 µg/ml Gentamycin for 4 or 8 h. Cells were 
collected, lysed and plated on BHI-agar plates. After 18-20 h, CFU/ml were determined. Data points represent 
duplicate averages taken from two biological replicates. Statistical significance of OAS1-KO cells to WT was 
determined with two-way ANOVA with Sidak’s multiple comparison test.  
 
To validate the antibacterial activity of OAS1, we inducibly expressed P42, P46 and P46 
DADA in THP1 OAS1-KO cells, followed by infections with Lm. Dox inducible expression of 
OAS1 P46, but not P42, was capable of restricting intracellular bacterial growth (Fig. 34 A-B). 
Additionally, expression of the enzymatically inactive mutant P46 DADA was able to suppress 
bacterial growth similar to P46 (Fig. 34 A-B). Together these results indicate that P46, expressed 
through the rs10774671 G allele, provides protection against Listeria, which is independent on 
NTase activity.  
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Figure 34. OAS1 P46 and P46 DADA inhibit L. monocytogenes growth 
THP1 OAS1-KO, OAS1-KO inducible P42 and P46 were pre-treated with 2 µg/ml Dox for 48 h, followed by infection 
with Lm at a MOI of 1 and 10. After adsorption, cells were grown in 50 µg/ml Gentamycin containing media for 8 h. 
Cells were lysed and plated on BHI-agar plates. After 18-20 h, CFU/ml were determined. Duplicate averages taken 
from two biological replicates were plotted and statistical significance between Dox-treated and untreated cells was 
assessed using Multiple t tests (A-B).  
 
To study the antibacterial role of OAS1 in another model organism, we infected THP1 and 
BJ-Tert OAS1-KO cells with the gram-negative bacterium Fn. Similar to infection with listeria, 
bacterial load was higher in OAS1-KO cells at 8 h post infection (Fig. 35 A-D). These findings 
confirm that OAS1 confers protection against several intracellular pathogens through expression 
of OAS1 P46. This suggests that protection against M. tuberculosis through the G genotype is most 
likely mediated through P46 as well.  
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Figure 35. OAS1 confers protection against F. novicida 
WT and OAS1-KO THP1 (A-B) and BJ-Tert (C-D) cells were infected with Fn at a MOI of 10 and 25. After 
adsorption, cells were incubated in medium containing 50 µg/ml Gentamycin for 4 or 8 h. Cells were collected, lysed 
and plated on MH-agar plates. After 18-20 h, CFU/ml were determined, and statistical significance was assessed as in 
Fig. 32.  
 
Previously we have shown Type I IFN signaling was not affected in OAS1-deficient cells, 
however Type II IFN signaling and expression of IRF1 was impaired in OAS1-KO cells (Fig. 16). 
IFN induction is critical for restricting the replication of several intracellular pathogens and 
deficiencies in IFN signaling lead to increased susceptibility to bacterial infections (333, 399). 
Therefore, to characterize the mechanism by which OAS1 inhibits bacterial growth, we filtered 
our proteomic and transcriptomic data (described in Chapter 3 and Appendix B) to include IFN-
regulated proteins that were post transcriptionally regulated by OAS1. This analysis revealed a 
few IFN inducible proteins down-regulated in OAS1-KO cells with potential antibacterial 
4 hrs 8 hrs
104
105
F
n
(C
F
U
/m
l)
THP1,
F. novicida MOI of 25
WT
OAS1-KO
***
*
IRF1
ANKRD17
IFI30
WARS
-1
-0.5
0
0.5
1
IRF1
ANKRD17
IFI30
WARS
0.6
0.8
1
1.2
1.4
1.6
1.8
2
WT/OAS1-KO Protein (log2 fold
change in intensity scaled)
WT/OAS1-KO mRNA (fold change
in RPKM no scaling)
RPKM ratio
0 4 8 IFNg (h) 0 21 4 8 IFNg (h)
THP1 cells
4 hrs 8 hrs
103
104
105
THP1,
F. novicida MOI of 10
F
n
(C
F
U
/m
l)
WT
OAS1-KO
**
4 hrs 8 hrs
103
104
105
BJ-Tert,
F. novicida MOI of 10
F
n
(C
F
U
/m
l)
WT
OAS1-KO
*
****
4 hrs 8 hrs
103
104
105
106
BJ-Tert,
F. novicida MOI of 25
F
n
(C
F
U
/m
l)
WT
OAS1-KO
****
– + – +
WT KO
BJ-Tert Cells
– + – +
WT KO
IFNg
THP1 Cells
IRF1
Actin
IRF1
Actin
THP1 WT
Listeria (h)
MOI 10
0 4 8
A B
C D
A
B C
 129 
properties, including IRF1 (124, 400), ankyrin repeat domain 17 (ANKRD17) (401) (Fig. 36 A), 
gamma-interferon-inducible lysosome thiol reductase (IFI30) (402) and tryptophanyl-tRNA 
synthetase (WARS) (403). The expression of IRF1 was validated in both BJ-Tert and WT cells 
after IFN treatment. Similar to our proteomic data, IRF1 was down regulated in cells deficient in 
OAS1 (Fig. 36 B). Additionally, infection with Lm induced a dose dependent increase in IRF1 
protein levels (Fig. 36 C). This suggests that in response to bacterial infection, OAS1 enhances the 
synthesis of IRF1 protein required for controlling bacterial growth.  
 
 
 
Figure 36. OAS1 regulates levels of several antibacterial proteins 
THP1 WT and OAS1 KO cells were cultured for 8 generations in media containing heavy isotope amino acids (
13
C-
6 
15
N-2 L-Lysine, and 
13
C-6 
15
N-4 L-Arginine) and light isotope amino acids (L-Lysine and L-Arginine) 
respectively. Cells were then treated with 500 U/ml IFN for 0, 4 and 8 h for SILAC analysis. In parallel, cells grown 
in regular media were treated with 500 U/ml IFN for 0, 1, 2, 4 and 8 h and analyzed by RNAseq analysis. Following 
filtering of the SILAC data (Section 2.2.21), peptide ratios were scaled for each protein and represented by heatmap. 
Corresponding mRNA RPKM values were plotted in the heatmap as fold change without scaling (A). WT and OAS1-
KO BJ-Tert and THP1 cells were treated with 500 U/ml IFN 4 h and cell lysates were analyzed by immunoblotting 
with IRF1 and Actin antibody (B). WT THP1 cells were infected with Lm at a MOI of 10 for 0, 4 and 8 h followed 
by immunoblotting with IRF1 and Actin antibody.  
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To test the hypothesis that OAS1 antibacterial activity is mediated through IRF1 protein, 
we first confirmed the requirement of IRF1 in regulating bacterial infection. We infected BJ-Tert 
WT, OAS1-KO and IRF1-KO cells with Lm and determined the bacterial burden in these cells. 
As seen before, OAS1-KO cells were more susceptible to infection and IRF1-KO cells showed a 
significantly higher bacterial load as compared to WT cells (Fig. 37 A). Next, we assessed whether 
IRF1 was essential for OAS1 mediated antibacterial protection by inducibly expressing OAS1 P46 
in WT and IRF1-deficient cells, followed by infection with Lm and Fn. Inducible expression of 
P46 was capable of restricting bacterial growth in WT cells, but not in the absence of IRF1 (Fig. 
37 B-C). These results establish the requirement for IRF1 to mediate the downstream antibacterial 
effects of P46.  
 
 
Figure 37. IRF1 is required for OAS1 mediated antibacterial activity 
BJ-Tert WT, OAS1-KO and IRF1-KO cells were infected with Lm at a MOI of 1 and 10 (A). BJ-Tert OAS1-KO and 
IRF1-KO inducible P46 were pre-treated with 2 µg/ml Dox for 48 h, followed by infection with Lm at a MOI of 1 and 
10 (B) or Fn at a MOI of 10 and 25 (C). Following bacterial adsorption, cells were incubated in 50 µg/ml Gentamycin 
containing media for 8 h. Cells infected with Lm were lysed and plated on BHI-agar plates for 18-20 h (B). Cells 
infected with Fn were lysed and plated on MH-agar plates for 48 h. CFU/ml were determined as described before and 
data points represent duplicate averages taken from two biological replicates. Statistical significance between WT, 
OAS1-KO and IRF1-KO cells was determined with two-way ANOVA with Sidak’s multiple comparison test (A). 
Statistical significance between Dox-treated and untreated cells was assessed two-way ANOVA with Tukey’s multiple 
comparison test (B-C). 
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IRF1 is a transcription factor known to regulate the expression of several genes following 
IFN treatment to inhibit infection through these ISGs. Additionally, IRF1 can enhance T cell 
differentiation needed to clear infection and IRF1-deficient mice show impaired Th1 responses to 
Listeria (404). During Francisella infection, IRF1 has been shown to promote the expression of 
GBPs needed for disrupting bacteria-containing vacuoles exposing bacterial DNA to AIM2 and 
promoting inflammasome activation (124, 363). These previous studies suggest a critical role of 
IRF1 in regulating intracellular bacterial infections through GBPs and inflammasome signaling. 
To establish if IRF1 regulated proteins were downregulated in OAS1-KO cells, we filtered our 
SILAC and RNAseq data sets to represent genes that were transcriptionally regulated after IFN 
treatment. The heatmaps in Fig. 38 represent genes in which mRNA was down-regulated in OAS1-
KO cells as compared to WT, resulting in a decrease in protein expression. The RPKM and peptide 
intensity values of several genes known to enhance immunity were decreased in OAS1-deficient 
THP1 cells (Fig. 38). Several GBP proteins were shown to be enhanced by OAS, which is likely 
dependent on IRF1 signaling. Together these results suggest that OAS1 antibacterial activity is 
mediated through downstream signaling of IRF1.  
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Figure 38. OAS1 upregulates transcription of several IFN-induced genes and protein levels 
THP1 WT and OAS1-KO cells were analyzed by SILAC and RNAseq as described in Fig. 4. Following filtering of 
SILAC data for transcriptionally regulated genes (Section 2.2.21), RPKM and peptide intensity values were scaled 
and represented by heatmaps. 
 
In Chapter 3 of this dissertation, we established murine Oas1b as the functional equivalent 
to human OAS1. Oas1b was capable of binding cGAS and IRF1 mRNA and conferred protection 
to WNV and POWV through cGAS induction of type I IFNs. To determine if mouse Oas1b plays 
a role during bacterial infections, we infected BMDMs collected from WT and Oas1b-KI mice 
with Listeria. BMDMs from Oas1b-KI mice showed a significant reduction in bacterial burden at 
both 4 and 8 h (Fig. 39 A-B), confirming that Oas1b is capable of restricting bacterial growth. 
These findings suggest that both human OAS1 and Oas1b have dual roles in restricting both virus 
and bacterial growth through a common mechanism dependent on enhancing the translation of 
several immune related proteins needed to clear infection.  
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Figure 39. Oas1b confers antibacterial protection to L. monocytogenes 
BMDMs from WT and Oas1b-KI mice were infected with Lm at a MOI of 1 and 10. Following adsorption, cells were 
incubated in media containing 50 µg/ml Gentamycin. After 4 and 8 h post infections cells were collected, lysed and 
plated on BHI-agar plates. CFU/ml were calculated 18-20 h after plating. Duplicate averages taken from two biological 
replicates were plotted. Statistical significance between WT and Oas1b-KI BMDMs was determined with two-way 
ANOVA with Sidak’s multiple comparison test.  
 
Finally, we assessed the in-vivo role of OAS1 by measuring the survival of WT and Oas1b-
KI mice following infection with Lm or Fn. Mice were infected intraperitoneally with Lm or 
subcutaneously with Fn and survival was measured for 10 and 13 days respectively. All WT mice 
succumbed to infection with Lm, however most Oas1b-KI survived infection (Fig. 40 A). 
Similarly, WT mice presented a heavy loss of body weight after infection with Fn as compared to 
Oas1b-KI mice (Fig. 40 B). Consequently, all the WT mice died after infection, whereas 90% of 
Oas1b-KI mice survived. Our results confirm that Oas1b confers a protective phenotype to both 
Listeria and Francisella.  Together the results presented in this chapter suggest that OAS1 and 
Oas1b, in addition to their antiviral role, are protective against intracellular bacteria.  
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Figure 40. Oas1b confers protection to mice against L. monocytogenes and F. novicida in-vivo 
Oas1b-KI and WT mice were infected with 1 x 105 CFU/ml L. monocytogenes intraperitoneally and survival was 
measured for 10 days (A). A separate group of mice was infected with 1 x 104 CFU/ml F. novicida subcutaneously 
and survival was measured for 13 days (B). Statistical significance of Oas1b-KI survival compared to WT mice was 
assessed using a Mantel-Cox test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
ed Se
v
EH
E
C Fn
Sh
ig
Li
st
1u
l
Li
st
2u
l
Li
st
5u
l
0
500
1000
1500
2000
2500
BMDM, IFNb, Day 6
IF
N
(p
g
/m
l)
WT
Oas1b-KI
****
**** ****
** *
M
ed Se
v
EH
E
C Fn
S
hi
g
Li
st
1u
l
Li
st
2u
l
Li
st
5u
l
0
1000
2000
3000
BMDM, IFNb, Day 8
IF
N
(p
g
/m
l)
WT
Oas1b-KI
****
****
*
**
M
ed
Pa
m
3
pI
C
hm
w
LP
S
(1
:1
K)
LP
S
(1
:1
0K
)
R
83
7
pd
Ad
T
D
M
XA
A
0
500
1000
1500
BMDM, IFNb, Day 6
IF
N
(p
g
/m
l)
WT
Oas1b-KI
****
*
M
ed
Pa
m
3
pI
C
hm
w
LP
S
(1
:1
K)
LP
S
(1
:1
0K
)
R
83
7
pd
Ad
T
D
M
XA
A
0
200
400
600
800
1000
BMDM, IFNb, Day 8
IF
N
(p
g
/m
l)
WT
Oas1b-KI
****
****
*
0 5 10 15
0
20
40
60
80
100
F. novicida
Days post-infection
P
e
rc
e
n
t
s
u
rv
iv
a
l
WT (n=10)
Oas1b-KI (n=10)
p-value < 0.0001
0 5 10 15
0
20
40
60
80
100
L. monocytogenes
Days post-infection
P
e
rc
e
n
t
s
u
rv
iv
a
l
WT (n=6)
Oas1b-KI (n=5)
p-value = 0.0304
B C
0 5 10 15
70
80
90
100
110
F. novicida
Days post-infection
%
C
h
a
n
g
e
o
f
b
o
d
y
w
t.
Oas1b-KI
WT
subcutaneouslyintraperitoneal
E
F
not sure if to show or
not, as of now i wont
A
 135 
4.3 Discussion 
OAS are family of ancient proteins first described to inhibit viral replication through the 
synthesis of 2’-5’ oligoadenylates and activation of RNase L. These proteins have no known 
antibacterial functions, however some studies have associated OAS proteins with progression of 
M. tuberculosis (246, 261–263, 405). The G genotype of the SNP rs10774671 in OAS1 has been 
associated with resistance to M. tuberculosis (246). In this chapter, we explored the antibacterial 
role of OAS1 using Lm and Fn as models of intracellular bacterial infection. Several of these 
microorganisms have been associated with disease progression. M. tuberculosis in particular, 
remains the leading cause of death worldwide from a single infectious agent (406). Listeria is a 
foodborne pathogen and is one of the leading causes of hospitalization due to foodborne illness 
(345). Although listeriosis is rare, it can cause severe disease to developing fetus in pregnant 
women leading to miscarriage. It can also lead to sepsis or infection of the brain in older or 
immunocompromised individuals. F. tularensis can cause tularemia, a disease which ranges from 
mild to life-threatening, and needs to be handled under biosafety level 3 (BSL-3) conditions, 
making it a challenging pathogen to study. F. novicida U112 (Fn U112) is an attenuated strain of 
Francisella with a high genetic identity to F. tularensis. Additionally, Fn U112 is easily genetically 
manipulated, can infect macrophages in-vitro and mice infected with this strain exhibit illness, 
making it an excellent model to study the pathogenesis of F. tularensis (353, 407). The immune 
response to intracellular bacteria is quite complicated. IFNs have been shown to be both beneficial 
and detrimental during infection (7, 102, 324, 333). Therefore, understanding the mechanisms 
behind bacterial host-pathogen interactions is important in defining critical components of host 
immunity required for antibacterial defense.  
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Previously, we described how OAS1 confers antiviral protection through enhancing the 
protein synthesis of cGAS. In this chapter, we show that the antibacterial activity of OAS1 is 
mediated through another OAS1 regulated protein, IRF1. We first measured the bacterial burden 
in OAS1-deficient cells infected with Lm and Fn. We confirmed that in the absence of OAS1, 
bacterial growth was significantly increased, suggesting that OAS1 is protective during bacterial 
infection. Since the G allele of the SNP rs10774671 was related to susceptibility to M. tuberculosis, 
we believed that the antibacterial activity of OAS1 was mediated through P46 isoform. Inducible 
expression of P42 did not inhibit bacterial growth, however expression of P46 and NTase-deficient 
P46 DADA significantly reduced bacterial burden. This confirmed that the isoform-specific 
antibacterial activity of P46 was independent of catalytic activity and RNase L activation. To 
determine the specific proteins or pathways required for OAS1 mediated antibacterial protection 
we re-evaluated our proteomic and transcriptome data. Our data revealed that some antibacterial 
related proteins were post transcriptionally regulated by OAS1, in addition to IRF1. These proteins 
included ANKRD17, IFI30 and WARS. ANKRD17 functions as a binding partner of NLRs, 
required for pathogen sensing and induction of inflammatory pathways (408), and deficiency in 
ANKRD17 resulted in decreases cytokine secretion during Shigella flexneri infection (401).  IFI30 
is a thiol reductase expressed in the lysosomes of antigen-presenting cells and is crucial for MHC 
antigen processing and presentation (402, 409). WARS (or WRS) is secreted rapidly during 
infection and primes innate immune responses by binding myeloid differentiation factor 2 (MD2) 
on macrophages inducing phagocytosis and chemokine production (403, 410). The antibacterial 
role of IRF1 has been well established, promoting immune cell differentiation and activation of 
inflammasome pathways (121, 124, 404). This led us to investigate the role of IRF1 during Listeria 
and Francisella infection. As expected, IRF1-deficient cells were more susceptible to infection, 
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similar to OAS1-deficient cells. To determine if OAS1 antibacterial activity was mediated through 
IRF1, we inducibly expressed P46 in WT and IRF1-KO cells and found that the antibacterial 
activity of OAS1 was abolished in the absence of IRF1.  
Since IRF1 is known to regulate the expression of a variety of IFN-inducible genes (125, 
411), we filtered our SILAC and RNAseq data to represent the RPKM and peptide intensity of 
genes that were transcriptionally downregulated in the absence of OAS1. We found several IFN 
inducible genes, with known antibacterial functions, that were downregulated in OAS1-deficient 
cells resulting in a loss of protein. Among these, we found RIG-I and MDA5 transcription was 
elevated by OAS1, which are well established sensors of viral RNAs and have also been shown to 
elicit IFN signaling in response to bacterial ligands (412–416). ISG15 was up-regulated in WT 
cells, a well-established antiviral ISG that has also been shown to restrict Listeria and is associated 
with M. tuberculosis disease severity (175, 200, 417, 418). C3 complement protein was also up-
regulated in our analysis, which is crucial for restricting several intracellular pathogens through 
activation of complement pathways, including Listeria and M. tuberculosis (419–422). 
Additionally, the pro-inflammatory chemokine CXCL10 was up-regulated in WT cells, which is 
known to promote chemotaxis, cell growth and apoptosis during infection (423). CXCL10 has 
been shown to restrict Lm growth and CXCL10 is highly induced during infection with M. 
tuberculosis and has been proposed as a biomarker of active tuberculosis (424–426). Lastly, the 
transcription of several GBPs was up-regulated in WT type cells compared to OAS1-KO cells. 
This family of GTPases is known to promote antimicrobial defense through disruption of pathogen 
containing vacuoles or direct disruption of bacterial membranes to release antigens into the cytosol 
and induce activation of inflammasome pathways (104, 205, 207, 427). Inflammasome signaling 
leads to the processing of pro-inflammatory cytokines such as IL-1 and IL-18 crucial for clearing 
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bacteria (334, 359, 428). Altogether, our proteomic and RNAseq analysis revealed that several 
antibacterial genes are transcriptionally enhanced in the presence of OAS1. OAS1 has not been 
described to bind DNA, suggesting that the transcriptional regulation of these genes is mediated 
by transcription factors regulated by OAS1. IRF1 is known to drive the expression of GBPs and 
promotes inflammation activation, suggesting that the antibacterial activity of OAS1 could be 
mediated downstream of the IRF1 signaling pathway (124, 363, 427).  
Finally, we explored the in-vitro and in-vivo role of Oas1b during bacterial infections. 
BMDMs collected from Oas1b-KI infected with Lm showed a decreased bacterial burden as 
compared to WT cells. Additionally, Oas1b-KI mice infected with Lm and Fn exhibited increased 
survival as opposed to WT mice, establishing that murine Oas1b confers the same antibacterial 
activity as human OAS1. The results presented in this chapter establish that OAS1 and Oas1b are 
capable of restricting intracellular bacterial growth. This inhibition of bacterial replication is most 
likely mediated through IRF1, which is post transcriptionally regulated by OAS1. Additionally, 
we hypothesize that downstream signaling of IRF1, leading to the transcription of ISG15, GBPs 
and other IFN-inducible proteins (429–431), is required for the antibacterial phenotype of OAS1. 
This hypothesis is yet to be confirmed. The role of OAS family proteins during bacterial infections 
is currently being investigated in our laboratory.  
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5.0 Conclusions and Future Perspectives  
OAS family proteins were discovered over 40 years ago, and were first described to 
synthesize 2’-5’ oligoadenylates required for RNAse L activation and suppression of virus 
replication (211, 213, 217). Several residues in the negatively charged active site of OAS were 
shown to be crucial for NTase activity, required for OAS antiviral activity (235, 236). However, 
the discovery of enzyme independent mechanisms of antiviral activity in Oas1b and OASL have 
made it clear that there are alternative mechanisms of OAS mediated antiviral immunity (13, 228, 
230, 237, 253). Furthermore, among human NTase+ OAS proteins, OAS3 was sufficient and 
necessary for the activation of RNase L with no contribution from OAS1 and OAS2 (17). 
Additional studies have shown that OAS3 engages longer dsRNA, requires lower concentrations 
of RNA to become active as compared to OAS1, and synthesizes longer 2’-5’ oligoadenylates, 
which may be required for efficient activation of RNase L (432, 433). Overexpression of OAS1 
and OAS2 have been associated with lower viral titers of several flavivirus (229, 434, 435), 
suggesting potential RNase L independent roles of enzymatically active OAS proteins. In this 
study, we investigate NTase independent antiviral and antibacterial roles of OAS1.  
An SNP (rs10774671) located at the C-terminal domain of OAS1, has been shown to 
influence isoform expression and susceptibility to WNV (243, 389). We confirmed that cells 
containing the G haplotype of the rs10774671 SNP, were resistant to WNV replication. Inducible 
expression of OAS1 isoform P46, but not P42, was necessary for restricting viral replication. 
Furthermore, inducible expression of the NTase-deficient mutant D75A/D77A (DADA) was also 
capable of restricting WNV to the same extent as P46, suggesting that OAS1 enzyme activity is 
not required for antiviral activity to WNV. Similarly, inducible expression of P46 in OAS1/RNase 
 140 
L-double deficient cells restricted viral growth, confirming that OAS1 restricts WNV through a 
novel mechanism independent of RNase L activation. We next performed proteomic and 
transcriptome analysis to determine which proteins or pathways may be required for mediating the 
antiviral of OAS1. We found that OAS1 regulated the expression of several basal and IFN-
inducible proteins. Our dataset confirmed that 105 proteins were post-transcriptionally regulated 
by OAS1 (Appendix B, Table 12-13), meaning that protein levels were enhanced or decreased 
without significant changes in mRNA expression. This led us to hypothesize that OAS1 regulated 
the translation of target mRNAs. Through polysome profiling and radiolabeling of nascent protein 
synthesis we revealed that OAS1 enhanced the synthesis of cGAS and IRF1 protein. Additionally, 
through RIP analysis we showed that OAS1 and Oas1b directly bound to cGAS and IRF1 mRNA. 
K60 residue found on the positively charged face of OAS1, conserved between human OAS1 and 
mouse Oas1b (Appendix A), was shown to be essential for binding mRNA and conferring antiviral 
resistance to WNV.  We next sought to identify which well-known cellular antiviral proteins may 
be required for the WNV antiviral activity of OAS1, by inducible expressing P46 in OAS1-, IRF1-
, cGAS- and MAVS-deficient cells lines. We observed that P46 antiviral activity was abolished in 
cGAS-KO cells, suggesting that inhibition of WNV by OAS1 was mediated through cGAS. 
Similarly, inducible expression of Oas1b in cGAS-KO cells was not capable of restricting virus, 
establishing a functional equivalence between human OAS1 and mouse Oas1b. We also 
demonstrated that the antiviral activity of OAS1 was abolished in IFNAR1-KO cells, therefore 
indicating that cGAS must restrict WNV through the induction of Type I IFNs. Furthermore, 
mouse cGAS protein levels were increased in BMDMs isolated from Oas1b-KI mice (expressing 
full length Oas1b) as compared to WT (expressing truncated Oas1b), which consequently 
enhanced type I IFN signaling in response to DNA stimuli or HSV infection. In-vivo data using 
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our Oas1b-KI mouse model revealed less viral load and enhanced survival in response to WNV 
infection as compared to WT mice, confirming that Oas1b is protective to WNV as reported 
previously (248, 251, 253).  Together our results clarify the mechanism of OAS1 antiviral activity 
to WNV. We establish that OAS1 P46 and Oas1b enhance the synthesis of cGAS protein, which 
through IFN signaling suppresses WNV replication.  
Having established the role of OAS1 during WNV infection, we next explored the potential 
antibacterial role of OAS1. The functions of OAS family proteins have mostly been confined to 
suppressing virus replication. However, some studies have correlated OAS1 and OASL with 
suppression of M. tuberculosis (246, 261–263). Similarly, the same SNP in OAS1, which confers 
resistance to WNV has also been associated to restriction of M. tuberculosis (246), suggesting that 
OAS1 P46 may confer protection to intracellular bacterial infection through a similar mechanism. 
To explore this hypothesis, we used in-vitro and in-vivo models of L. monocytogenes (Lm) and F. 
novicida (Fn) infection to investigate the antibacterial activity of OAS1 and Oas1b. We first 
showed that OAS1-deficient cells were more susceptible to infection with both Lm and Fn, 
confirming that OAS1 confers protection to intracellular bacteria. Similarly, inducible expression 
P46 and P46 DADA mutant, but not P42, restricted Lm, confirming that the antibacterial activity 
of OAS1 is conferred through isoform P46 and is independent of RNase L activation. Having 
previously established that OAS1 enhanced the synthesis of several proteins and cGAS was needed 
for OAS1 antiviral activity, we screened our dataset for antibacterial proteins regulated by OAS1. 
This strategy allowed us to identify IRF1 as an essential protein required to mediate the 
antibacterial activity of OAS1, since inducible expression of P46 in IRF1-deficient cells resulted 
in a complete loss of antibacterial activity. Our transcriptome and proteomic analysis had also 
identified 145 genes that were transcriptionally regulated by OAS1, resulting in enhanced protein 
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levels after IFN treatment (Appendix B, Table 14). OAS1 has not been described to bind DNA, 
therefore it is unlikely that OAS1 is directly enhancing the transcription of these genes. Given that 
several transcription factors were post-transcriptionally regulated by OAS1 (Appendix B, Fig. 44), 
it is likely that these transcription factors are responsible for enhancing the transcription of OAS1 
regulated genes. Among these proteins were GBPs, known to be regulated by IRF1 and promote 
inflammasome signaling. Given that GBPs and inflammasome signaling have been shown to 
restrict intracellular bacteria (104, 204–207, 356, 363, 427), we hypothesize that IRF1 mediated 
antibacterial activity of OAS1 requires the expression of GBPs in order to promote inflammasome 
signaling. Lastly, we established the in-vivo phenotype of OAS1 antibacterial activity by infecting 
WT and Oas1b-KI mice with Lm and Fn. Survival experiments revealed that all WT mice 
succumbed to infection as compared to Oas1b-KI, which showed a significant increase in survival. 
Together these results establish the antibacterial phenotype of OAS1 and Oas1b, mediated through 
IRF1, which regulates the expression of several IFN-inducible genes required for controlling 
intracellular bacterial infections.  
We have established that OAS1 confers protection to both virus and bacterial infections by 
regulating the protein levels of cGAS and IRF1 needed to restrict virus and bacterial growth 
respectively. We showed that OAS1 and Oas1b directly bound to cGAS and IRF1 mRNA and 
established that this binding is mediated through K60 residue in both human and mouse. OAS1 
has previously been described to bind ssRNA and microRNA (miRNA) in order to promote OAS1 
enzyme activity (436–438). However, we show that OAS1 binds cellular mRNA and influences 
their translation independently of NTase activity. Regulation of translation by OAS family proteins 
has been reported before. Oasl1 has been shown to suppress the translation of IRF7 mRNA by 
binding to the 5’ untranslated region (UTR) of IRF7 (439), and our study provides another example 
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of translational modulation by OAS proteins. Given that the location of K60 residue in OAS1 and 
Oas1b is not towards the C-terminal region of these proteins (Appendix A, Fig. 43), it alone does 
not describe the isoform specific functions of human OAS1 or clarify the antiviral phenotypes 
between full length or truncated mouse Oas1b. Previous studies have identified a CaaX motif in 
OAS1 P46, not found in P42, that is required for prenylation and membrane association (440, 441). 
Similarly, a transmembrane domain in Oas1b, not present in truncated Oas1b, has been shown to 
anchor Oas1b to the ER (384). Therefore, we investigated the subcellular localization of OAS1 
P42/46 and Oas1b/g and confirmed that both OAS1 and Oas1b localized to the ER. There are 
several ribosomes associated to the ER surface, and through polysome profiling have been shown 
to serve a global role in mRNA translation (386, 395). It is likely that OAS1/Oas1b binds to and 
traffics mRNA to the ER where they are effectively translated by ER membrane-bound ribosomes. 
Previous studies have shown that under stress RNase L reprograms mRNA translation by 
promoting global suppression of host mRNA (442). However, several immune related mRNAs are 
able to escape RNase L mediated decay, allowing for enhanced translation of these specific 
mRNAs, including IFNs (374, 442, 443).  Therefore, another possibility is that OAS1 localizes to 
the ER and sequesters mRNA, providing protection to RNase L mediated degradation and allowing 
for the synthesis of antiviral or antibacterial proteins. Although we have not yet identified sequence 
motifs within these mRNAs that could be targeted by OAS1, our transcriptome and proteomic 
analysis serve as a starting point to identify these structural elements and clarify the mechanism 
by which OAS1 enhances mRNA translation.  
The mechanisms of OAS1 mediated antiviral and antibacterial activity described in this 
study provide explanations for the WNV and M. tuberculosis resistant phenotypes observed in the 
G allele of OAS1 SNP rs10774671. We have confirmed that cells with the G genotype primarily 
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express P46 and this isoform is responsible for enhancing the translation of target mRNAs, 
resulting in protection to WNV, Lm and Fn. Additionally, we have shown that OAS1 regulates the 
transcription of several antiviral genes, for examples IFIT proteins (Appendix B), suggesting that 
in addition to its role in restricting flavivirus, it could promote a broad protection to several groups 
of virus. Therefore, studying this SNP in OAS1 could prove useful as a biomarker for both viral 
and bacterial susceptibility. Although less common, the OAS1 rs10774671 SNP has also been 
linked to several autoimmune disease, including: Multiple Sclerosis (MS), Sjögren’s Syndrome 
and Type I Diabetes (259, 444–446). This autoimmune response results from homozygous 
expression of the G allele, which may overexert the immune response leading to cellular and tissue 
damage. Given that both cGAS and IRF1 have been associated with the development of 
autoimmune responses (447, 448), it is possible that autoimmunity related to homozygous 
expression of OAS1 P46 or Oas1b is mediated by these proteins. We have conducted preliminary 
studies of autoimmune development by applying a model of experimental autoimmune 
encephalomyelitis (EAE) in our Oas1b-KI mice (used to model human MS). In this model, EAE 
is induced by activating self-reactive CD4+ T cells against myelin antigen, which migrate to the 
CNS and initiate inflammatory responses resulting in paralysis and death (449–451). Our 
preliminary experiments revealed higher EAE scores in Oas1b-KI mice as compared to WT mice 
(Fig. 41), suggesting that Oas1b-KI mice are more susceptible to autoimmune disease. Therefore, 
it is possible that P46 and Oas1b, in addition to providing host protection to infection, may 
predispose the host to autoimmunity. This may explain why the majority of Eastern populations 
are heterozygous for the G allele of OAS1 rs10774671, originating from evolution and selective 
pressure. Together these results prove that non-canonical mechanisms exist for OAS family 
proteins that are required for controlling viral and bacterial infections.  
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Figure 41. Heterozygous expression of Oas1b predisposes mice to autoimmunity 
Autoimmunity of WT and Oas1b-KI mice was assessed by an EAE model adapted from McGeachy et al. 2009 (451). 
Mice were immunized subcutaneously in the flanks with myelin antigen in emulsified complete Freund’s adjuvant 
(CFA). Additionally, pertussis toxin was administered intraperitoneally on the day of immunization and 2 days post 
immunization. We observed clinical signs of paralysis in two independent experiments (14 and 21 days each). The 
EAE scored were reported for each day and represent the following: 1 = limp tail, 2 = impaired motor function, 3 = 
partial paralysis of hind limbs, 4 = complete paralysis of hind limbs, 5 = fore limb weakness with hind limb paralysis, 
6 = dead or moribund.  
 
In conclusion, our studies propose a novel mechanism of OAS1 antiviral activity to WNV 
and antibacterial activity to Lm and Fn, which is independent on NTase activity and RNase L 
activation (Fig. 42).  During viral and bacterial infections type I and II IFNs are induced, leading 
to the expression of several ISGs. Among these ISGs, OAS1 confers host protection by enhancing 
the synthesis of several proteins. OAS1 localizes to the ER and directly binds to mRNAs to 
enhance their translation, promoting the synthesis of several basal and IFN-inducible proteins 
including cGAS and IRF1. cGAS is known to be activated by endogenous DNA originating from 
mitochondria under cellular stress, which is triggered by virus infection (382). Once active, cGAS 
induces type I IFN signaling required to clear infection in an autocrine and paracrine manner. 
During infection, OAS1 enhances the synthesis of several transcription factors, including IRF1. 
We believe that these transcription factors mediate the transcriptional regulation of several innate 
immune genes upregulated by OAS1. Among these genes are several GBPs, which are known to 
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confer antibacterial protection by disrupting bacteria containing vacuoles or directly affecting the 
integrity of bacterial membranes. This leads to the activation of inflammasome pathways needed 
to secrete inflammatory cytokines responsible for clearing infection. However, the direct impact 
of GBPs and inflammasome signaling in OAS1 mediated antibacterial immunity has yet to be 
determined and is being explored in ongoing research projects in our lab. Additionally, several 
antiviral proteins are transcriptionally regulated by OAS1, including RLRs, IFIT proteins and 
ISG15 (Appendix B). This suggests that OAS1 may potentiate immune signaling to several 
intracellular pathogens providing a broad spectrum of host immunity. Overall, our studies 
highlight the importance in understanding the mechanisms by which OAS family proteins restrict 
intracellular pathogens, providing a basis for the development of targeted therapies to improve 
host immunity. 
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Figure 42. Model of non-canonical antiviral and antibacterial activity of OAS1 
During intracellular infection IFN are induced, which act in an autocrine and paracrine manner to induce immune 
protection. Type I IFN leads to the expression of OAS1 that then localizes to the ER. OAS1 binds basal and IFN-
inducible mRNAs, facilitates association with polyribosomes found on the ER surface and enhances translation of 
these mRNAs. cGAS and IRF1 levels are enhanced through this mechanism, which are required for antiviral and 
antibacterial activity respectively.  
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Appendix A  
OAS1 sequence alignment 
A.1 Background and Alignment 
As previously described in Fig. 5, there are several OAS1 isoforms expressed by the OAS1 
gene and different murine Oas1 protein expressed from different genes in the same locus. The 
expression of OAS1 isoforms has been linked to the SNP rs10774671 at the acceptor site of exon 
6 of OAS1 (Fig. 9) (255, 260). Additionally, the presence of the G allele leads to the expression of 
P46 isoform and confers protection to WNV and M. tuberculosis (243, 246). Genotyping of 
susceptible individuals found a correlation between the A allele and P42 expression (referred to as 
p41/4 in the alignment, Fig. 43), suggesting that P46 is the protective factor against these 
pathogens. In this dissertation we confirmed that expression of P46 enhanced the translation of 
several target mRNAs, including cGAS and IRF1. cGAS was shown to be necessary for antiviral 
activity against WNV and IRF1 was shown to be required for antibacterial activity against L. 
monocytogenes (Lm) and F. novicida (Fn). Alignment between different OAS1 isoforms revealed 
that P42 and P46 differ only in the C-terminal (Fig. 43), therefore the protective factor is outside 
of the catalytic domain of these proteins and must be related to the C-terminal of P46. The sequence 
of P46 reveals a CAAX motif, not found in P42, required for prenylation, which confers a high 
affinity for the ER (441). Additionally, truncation of Oas1b at the C-terminal has been associated 
with susceptibility to WNV, as compared to mice expressing full length Oas1b, which promotes 
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RNase L independent antiviral activity to WNV (228, 251, 253). Amino acids 354-371 found at 
the C-terminus of Oas1b are within a transmembrane domain shown to anchor Oas1b to the ER 
(Fig. 43) (384). Our experiments have shown that OAS1 and Oas1b both localize to the ER, 
suggesting that these sequences found at their C-terminal domains are necessary for localization 
and function.  
Previous studies had identified critical residues within a catalytic triad for OAS proteins 
needed for synthesis of 2’-5’ oligoadenylates (235, 236). A catalytic mutant made in porcine OAS1 
(DADA) abolishes catalytic function, and through sequence alignment we identified these 
residues, D75A and D77A, in human OAS1 highlighted with black arrows (Fig. 42). We 
performed NEB mutagenesis to create this mutant in order to determine the necessity for catalytic 
activity for OAS1 antiviral and antibacterial immunity. We showed that P46 DADA was capable 
of inhibiting both WNV-KUN and Lm, confirming that the NTase activity of OAS1 is not needed 
for these phenotypes. Similarly, several amino acid residues of OAS proteins are essential for 
binding dsRNA and NTase activity (237, 385). We showed that a critical residue of OAS1 (K60), 
which is conserved in mouse Oas1b (Fig. 43), was required for binding mRNA and promoting 
their translation and antiviral activity against WNV. We first created several RNA binding mutants 
in Oas1b using NEB mutagenesis and the residues targeted for mutagenesis are highlighted with 
black arrows (K42E, K57E, K60E and K191E) in Fig. 43. Mutagenesis of K60 was sufficient to 
abolish RNA binding and promote susceptibility to WNV. Since the K60 residue is conserved 
between human OAS1 and mouse Oas1b, we created the K60E mutant in human OAS1 and 
showed that RNA binding was not apparent and resulted in higher viral titers. This data confirmed 
that translational enhancement of mRNAs by OAS1 is dependent on direct RNA binding, and 
consequently antiviral and antibacterial activity.  
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Figure 43. OAS1 sequence alignment 
The amino acids sequences of human OAS1 isoforms,  mouse Oas1 genes and porcine OAS1 were aligned using 
Clustal Omega (452). Consensus sequence represents the most frequent amino acids with a consensus threshold of 
50%. Sequence conservation for each column is represented by colored bars above the consensus sequence. Low 
sequence conservation is indicated by smaller blue bars as compared to higher conserved residues represented by 
larger yellow and red colored bars. Amino acids in each column were marked based on properties and conservation 
(Blue = hydrophobic, Cyan = aromatic, Purple = negative, Green = polar, Red = positive, Orange = glycine, Yellow 
= proline). CTIL CaaX motif of OAS1 P46 is highlighted in light yellow.  
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Appendix B  
OAS1 regulates the protein levels of several basal and IFN-inducible proteins  
B.1 Introduction  
The role of OAS proteins was first attributed to antiviral defense through the synthesis of 
2’-5’ oligoadenylates and RNase L activation. However, this does not explain the antiviral 
phenotype observed in murine Oas1b to WNV, which is independent of enzyme activity (253). 
Furthermore, OASL exhibits enzyme independent antiviral activity through enhancing RIG-I 
signaling pathways (13, 239), and OAS3 has been shown to be required and sufficient for RNase 
L activation (17). Together these studies suggest that non-canonical roles may exists for other OAS 
family members. In this dissertation we demonstrate that OAS1 can provide antiviral and 
antibacterial activity through isoform P46. To determine the mechanisms by which P46 conferred 
protection, we evaluated the proteomic and transcriptome of OAS1-deficient THP1 cells compared 
to WT cells. These analyses identified several proteins that were post transcriptionally regulated 
by OAS1. cGAS and IRF1 protein levels were enhanced and through polysome profiling, 
radiolabeling of nascent protein synthesis and RIP analysis, we revealed that OAS1 directly bound 
cGAS and IRF1 mRNA in order to promote translation of these two mRNA. Overall P46 enhanced 
the protein synthesis of several basal and IFN-inducible proteins, including cGAS and IRF1, 
which were shown to mediate antiviral and antibacterial activity respectively. In chapter 3 we 
highlighted the top 30 most post transcriptionally down-regulated proteins in OAS1-deficient cells 
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and in this section, we list all 87 proteins down-regulated and all 18 proteins up-regulated in the 
absence of OAS1. Additionally, we identified 145 genes that were transcriptionally regulated by 
OAS1, many with potential antiviral and antimicrobial activity.  
B.2 Results and Discussion  
SILAC and RNAseq analysis was carried out as described in Methods 2.2.21-22. To 
determine the antiviral and antibacterial mechanisms of OAS1, we screened our proteomic and 
RNAseq analyses to identify proteins or pathways that may be required for these activities. Our 
data set was divided in two groups: proteins post transcriptionally regulated by OAS1 (Table 12-
13), and proteins transcriptionally regulated by OAS1 (Table 14).  In this dissertation we found 
that OAS1 directly enhanced translation of target mRNAs, which explains why several proteins 
levels were downregulated in OAS1-deficient cells without significant changes in mRNA 
expression as compared to WT cells (Table 12). The levels of a few proteins were significantly 
decreased in OAS1-KO cells as compared to WT cells (Table 13), however there have not been 
any major antiviral functions associated to these proteins.  
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Table 12. Proteins post transcriptionally upregulated by OAS1 
WT/OAS1-KO Log2 (Peptide Intensity 
Ratio) after IFN treatment 
RPKM Ratio after IFN treatment 
Gene 0 h 4 h 8 h 0 h 1 h  2 h 4 h  8 h  
cGAS 3.58 -0.68 -0.13 0.60 0.66 0.59 0.56 0.90 
MED17 3.16 0.51 0.00 0.90 1.05 0.88 0.82 1.36 
MP68 3.04 0.48 0.44 0.71 0.62 0.74 0.75 0.64 
GEMIN2 2.86 0.44 -0.45 0.69 0.74 0.48 0.56 0.89 
TTC19 2.60 0.00 0.22 0.84 0.81 0.68 0.60 1.04 
SMAP2 2.48 2.67 2.54 0.93 0.87 0.82 0.68 0.94 
TMEM199 2.48 -0.05 -0.48 0.98 0.95 0.95 0.95 1.10 
TOMM40L 2.42 2.42 0.35 0.99 0.88 0.75 0.59 0.99 
RNMT 1.70 -0.18 0.05 0.95 0.92 0.79 0.83 1.16 
NMD3 1.68 1.25 0.00 0.98 1.09 0.89 0.78 1.60 
WDR4 1.62 0.52 0.00 0.95 0.84 0.75 1.06 0.89 
RSRC2 1.54 -0.58 0.22 0.68 0.89 1.03 0.57 0.84 
TRAM1 1.54 -0.46 0.00 0.74 0.77 0.64 0.71 1.40 
FUCA1 1.53 0.00 0.00 0.74 0.78 0.72 0.54 0.82 
JMJD1C 0.43 6.54 0.06 0.69 0.80 0.95 0.80 1.37 
KMT2B -0.22 3.63 0.00 0.80 0.85 1.12 0.95 0.70 
KIF22 0.01 2.90 1.88 0.99 0.93 0.92 0.73 0.72 
SMAP2 2.48 2.67 2.54 0.93 0.87 0.82 0.68 0.94 
INPP5F -0.26 2.62 5.97 0.90 0.81 0.97 0.70 0.88 
DNAJB1 2.17 2.60 2.69 0.81 0.96 0.92 0.72 0.86 
TOMM40L 2.42 2.42 0.35 0.99 0.88 0.75 0.59 0.99 
LSM5 0.06 2.26 0.36 1.07 1.18 0.92 0.57 1.07 
SMG6 0.82 2.12 0.00 0.79 0.85 0.78 0.82 0.79 
SPAG5 0.01 2.08 0.90 0.88 0.85 0.87 0.64 0.86 
MECR 0.17 2.05 0.00 0.98 0.89 0.93 0.76 0.94 
DDX31 1.14 2.03 1.22 0.93 0.85 0.73 0.84 1.12 
ETFDH 0.17 1.96 0.76 0.98 0.96 0.91 0.80 1.18 
CENPE 0.54 1.84 0.93 0.72 0.83 0.94 0.61 1.07 
SLC37A4 0.19 1.79 -0.11 0.59 0.58 0.64 0.52 0.52 
ARHGAP9 -0.38 1.78 -0.65 1.01 0.82 0.74 0.63 0.62 
MARS 1.14 1.74 1.27 1.04 1.05 1.12 0.88 0.94 
DPP9 0.21 1.74 1.40 1.13 1.11 1.15 1.32 1.16 
NBAS -0.16 1.69 0.28 1.04 0.86 0.74 0.79 1.17 
AGPAT3 -0.23 1.65 0.43 0.83 0.75 0.83 0.82 0.91 
DDX27 1.20 1.63 1.39 0.92 0.84 0.86 0.71 0.92 
DHRS9 0.91 1.63 0.00 0.91 0.97 0.92 0.74 0.96 
CEP250 0.00 1.62 -7.55 0.74 0.67 0.90 0.71 0.88 
FASTKD2 1.40 1.61 0.99 0.82 0.91 0.86 0.74 1.42 
PCCA 0.00 1.60 -0.22 0.86 0.84 0.79 0.67 1.00 
TMEM230 0.00 1.58 0.76 0.96 1.00 0.91 0.68 1.11 
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Table 12 continued  
GCHFR 0.00 1.56 1.36 1.44 1.26 1.20 1.54 1.21 
UBR5 -0.52 1.55 -0.34 0.72 0.77 0.85 0.65 1.04 
CCZ1;CCZ1B 0.09 1.51 0.55 0.88 0.98 0.98 0.57 0.86 
STAT5A 0.01 1.22 0.44 0.88 0.83 0.62 0.57 0.66 
STAT5B 0.01 1.22 0.44 0.83 0.79 0.70 0.64 0.75 
INPP5F -0.26 2.62 5.97 0.90 0.81 0.97 0.70 0.88 
MAFG -0.73 -0.26 3.61 0.85 0.74 0.94 1.09 1.01 
UAP1 0.09 1.05 2.97 0.91 1.05 0.88 0.71 1.07 
DNAJB1 2.17 2.60 2.69 0.81 0.96 0.92 0.72 0.86 
LRCH3 0.14 0.36 2.60 0.98 0.97 1.07 0.86 1.11 
SMAP2 2.48 2.67 2.54 0.93 0.87 0.82 0.68 0.94 
WDR74 0.46 0.25 2.37 1.04 0.93 0.90 0.79 0.84 
TAP2 0.71 -0.14 2.26 0.86 0.80 1.17 1.04 1.20 
TAP1 0.95 -0.54 2.23 1.25 1.13 1.25 1.29 1.32 
RNF213 0.24 -0.48 2.23 0.75 0.76 1.44 1.47 1.51 
ASF1B -0.23 0.00 1.93 0.70 0.70 0.70 0.66 0.72 
WARS 0.53 -0.91 1.91 1.08 1.38 1.65 1.19 1.40 
KIF22 0.01 2.90 1.88 0.99 0.93 0.92 0.73 0.72 
DTX3L 0.00 -0.23 1.87 0.81 0.78 0.88 0.82 1.39 
EXOSC5 1.08 -0.36 1.86 1.03 0.92 0.83 0.96 0.90 
TRAFD1 0.00 0.01 1.84 0.88 0.86 1.10 1.21 1.28 
PARP14 0.14 -0.71 1.81 0.71 0.73 1.14 0.95 1.48 
MED14 0.54 0.70 1.80 0.74 0.82 0.83 0.68 1.10 
IFI30 1.32 -0.28 1.76 1.71 1.38 1.62 1.02 1.10 
MAD2L2 0.44 0.00 1.75 1.70 1.54 1.50 1.35 1.24 
PLEKHO2 -0.08 -0.17 1.74 0.98 0.91 0.90 0.96 1.37 
DIEXF 0.18 1.11 1.73 1.03 1.14 1.03 0.90 1.37 
XRN1 0.63 0.00 1.72 0.67 0.88 1.07 0.83 1.66 
WDR70 1.07 0.09 1.71 1.18 1.11 1.09 1.00 1.51 
PCBD2 1.07 1.27 1.69 1.63 1.50 1.52 1.23 1.68 
PCTP 0.21 0.37 1.68 0.76 0.81 0.59 0.67 0.99 
LGALS3BP 0.00 -1.77 1.67 1.30 0.86 1.22 0.82 0.88 
SP110 0.00 -1.52 1.67 1.15 1.17 0.97 0.78 1.39 
ANKRD17 0.74 0.26 1.65 0.64 0.73 0.85 0.67 0.94 
SLC27A2 1.01 1.05 1.65 1.32 1.38 1.21 0.82 1.22 
FARS2 1.26 0.90 1.58 1.67 1.59 1.28 1.34 1.65 
STAT1 0.29 -0.85 1.57 0.67 0.77 0.79 0.76 1.40 
NUB1 -0.02 -0.06 1.56 0.81 0.76 0.91 0.90 1.20 
ZNFX1 0.00 0.25 1.54 0.71 0.83 1.19 0.85 1.12 
DIMT1 1.04 1.20 1.54 1.59 1.54 1.14 0.72 1.23 
LRRC8C 0.52 0.91 1.52 1.17 1.21 1.16 0.91 1.69 
MRPS36 1.08 1.27 1.52 0.93 0.88 0.94 0.79 0.98 
ISCU 1.20 0.84 1.51 1.03 1.08 0.94 0.81 1.19 
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FTL 0.82 1.09 1.51 1.47 1.30 1.49 1.14 1.39 
IRF1 0.00 0.46 0.00 1.20 1.41 1.36 1.22 1.34 
STAT2 -0.03 -0.64 1.41 1.06 0.92 1.02 0.93 1.35 
STAT3 0.16 -0.02 0.91 0.73 0.79 0.99 0.87 1.10 
 
Table 13. Proteins post transcriptionally downregulated by OAS1 
WT/OAS1-KO Log2 (Peptide Intensity 
Ratio) after IFN treatment 
RPKM Ratio after IFN treatment 
Gene 0 h 4 h 8 h  0 h 1 h 2 h 4 h 8 h 
CTSG -1.73 -1.67 -2.24 0.64 0.63 0.69 0.58 0.58 
ICAM3 -1.80 -2.10 -1.92 0.77 0.69 0.67 0.65 0.58 
NO66 -1.89 0.14 0.24 0.94 0.98 0.81 0.78 0.90 
CKAP4 -1.94 -1.37 -1.73 0.70 0.60 0.45 0.49 0.73 
KIF20A -2.08 1.23 0.95 0.93 1.00 1.06 0.82 1.20 
GOLGA4 -2.57 -0.14 0.00 0.69 0.76 0.78 0.65 1.09 
JUP -4.78 -5.07 -4.41 1.38 1.19 1.33 1.37 1.40 
SP110 0.00 -1.52 1.67 1.15 1.17 0.97 0.78 1.39 
EXO5 -0.23 -1.71 0.00 0.79 0.80 0.85 0.75 0.91 
LGALS3BP 0.00 -1.77 1.67 1.30 0.86 1.22 0.82 0.88 
UBE2L6 0.00 -2.01 0.16 0.87 0.70 0.69 0.60 0.79 
FAR2 -0.16 -2.27 -0.40 0.80 0.83 0.75 0.60 0.99 
NFIX -1.13 -8.18 -8.00 0.92 0.83 0.80 0.82 0.79 
AZU1 -1.44 -1.20 -2.07 1.15 0.94 1.02 1.05 0.68 
NME4 -0.88 -0.10 -2.65 1.05 0.96 1.14 0.77 0.63 
AKAP2 -0.05 -0.19 -2.10 1.02 1.04 0.93 0.95 1.44 
PPP6R2 0.00 0.23 -4.48 0.99 0.86 0.97 0.98 0.91 
RNASE2 -1.32 -1.43 -1.49 0.93 0.91 1.10 0.58 0.76 
 
Among these proteins, we identified cGAS as a critical component of OAS1 and Oas1b 
mediated antiviral activity to WNV (Chapter 3). Additionally, the antiviral activity of OAS1 was 
abolished in IFNAR1-deficient cells and IFN signaling was enhanced in Oas1b-KI BMDMs, 
suggesting that cGAS mediated antiviral activity required downstream type I IFN signaling. 
Similarly, IRF1 protein levels were enhanced by OAS1 and IRF1 was essential for mediating 
OAS1 antibacterial activity against L. monocytogenes and F. novicida (Chapter 4). Beyond these 
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immune phenotypes described, other proteins affected by the loss of OAS1 may modulate other 
cellular processes. Functional annotation analysis was performed on gene lists generated from our 
datasets (Fig. 44), using DAVID bioinformatics tools (Methods 2.22.2) (372, 373). Among these 
proteins post transcriptionally regulated by OAS1, we identified several DNA and RNA binding 
proteins in addition to several proteins known to regulate gene transcription. Many of these are 
involved in regulating innate immune signaling leading to a global suppression of virus and 
bacterial replication, including cGAS, IRF1, and STAT proteins. Others are important in 
transcription, maturation of mRNA and translation, for example the transcription factor MAFG 
(453), RNA guanine-7 methyltransferase (RNMT) (454) and mediators of RNA polymerase II 
transcription complex subunit 14 and 17 (MED14 and MED17) (455, 456).  
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Figure 44. Potential roles for proteins post transcriptionally regulated by OAS1 
The list of genes from Table 12 were uploaded and submitted to the online DAVID bioinformatics tool. Function 
annotation analysis was performed to predict major biological functions associated to genes post transcriptionally 
regulated by OAS1. The data is represented as heatmaps using Z-scored scaled log2 fold change of WT to OAS1-KO 
peptide intensity ratio and unscaled RPKM WT to OAS1-KO ratio.  
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OAS1 also enhanced the levels of several proteins that were related to increased mRNA 
transcription. However, OAS1 has not been described to bind DNA, therefore it is unlikely that 
OAS1 directly affected the transcription of these genes. It is more probable that several 
transcription factors post transcriptionally by OAS1, identified in Fig. 44, are responsible for 
regulating the transcription of these target genes. For example, IRF1 is known to regulate the 
expression of several IFN-inducible genes, and in Chapter 4 we described that the antibacterial 
activity of OAS1 is mediated through this transcription factor. Therefore, it is likely that OAS1 
provides antibacterial protection through the expression of these IFN−inducible genes. To 
identify genes transcriptionally up/downregulated in the absence of OAS1, we filtered our dataset 
for proteins induced at 4 and 8 h of IFN treatment with significant changes in their RPKM values 
(Methods 2.2.22). We identified a total of 145 genes transcriptionally regulated by OAS1 and these 
are listed in Table 14.  
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Table 14. Proteins transcriptionally regulated by OAS1 
WT/OAS1-KO Log2 (Peptide Intensity 
Ratio) after IFN treatment 
RPKM Ratio after IFN treatment 
Gene 0 h 4 h 8 h 0 h 1 h 2 h 4 h 8 h 
IFIT1 0.0 0.0 3.6 1.02 0.30 0.71 0.97 2.18 
GCH1 0.0 0.0 3.4 -0.39 -0.26 0.57 0.63 1.14 
AKR1C2 4.2 4.0 3.3 6.40 6.09 6.62 5.84 7.36 
AKR1C1 4.2 4.0 3.3 2.07 2.72 2.70 2.94 2.20 
GBP7 0.0 -1.3 3.2 0.00 -2.79 0.00 -0.23 0.31 
IFIT2 0.0 0.0 3.1 -0.18 0.13 1.30 0.39 1.12 
GBP1 0.0 -1.5 3.0 0.00 1.22 1.86 0.53 0.92 
OAS2 0.0 0.0 2.9 0.09 0.09 0.06 0.30 1.60 
CXCL10 0.0 1.3 2.9 -1.66 1.39 1.63 1.65 1.76 
GBP5 0.0 -0.6 2.8 1.94 1.34 1.96 0.91 1.25 
GBP4 0.0 -1.4 2.7 -0.39 0.39 1.02 0.02 0.49 
ISG15 1.0 0.6 2.6 0.77 0.44 0.42 1.26 1.72 
APOL2 0.0 -0.7 2.6 0.28 0.19 1.29 0.54 0.30 
GBP2 0.0 -1.0 2.6 1.27 1.19 1.59 0.14 0.49 
HMOX1 0.0 0.6 2.6 0.55 1.82 3.19 2.55 1.83 
PPP1R27 3.9 2.6 2.6 4.51 4.25 4.56 4.49 3.96 
NCF1 1.6 0.2 2.5 1.79 1.50 1.69 1.79 1.47 
NCF1C 1.6 0.2 2.5 1.67 1.19 1.27 1.54 1.22 
NCF1B 1.6 0.2 2.5 1.05 0.98 1.41 1.24 1.10 
IFIH1 0.0 -0.5 2.5 -0.84 -0.61 -0.35 -0.05 1.04 
IFIT3 0.0 -1.8 2.2 0.13 -0.04 0.90 0.27 1.31 
NLN 1.2 2.2 2.2 0.69 0.86 0.78 0.56 1.34 
FTH1 -0.5 0.9 2.1 1.15 0.99 1.04 0.89 1.40 
PPWD1 1.0 2.2 2.0 0.81 0.93 1.18 0.36 0.96 
NQO1 1.7 1.9 1.9 0.76 0.65 0.67 0.53 1.22 
CD36 1.2 1.6 1.9 1.61 1.74 1.56 1.51 2.72 
NDUFAF2 1.5 0.0 1.8 1.16 1.41 1.33 0.41 1.23 
APOC2 1.5 1.7 1.8 1.56 1.51 1.81 0.85 0.82 
TAF13 0.7 0.0 1.8 0.24 0.17 -0.10 0.11 1.13 
S100A10 1.2 1.4 1.7 1.19 1.04 1.21 0.36 0.62 
PCK2 1.7 1.0 1.7 1.06 0.93 0.78 0.65 0.45 
ACOT13 1.7 1.7 1.7 0.88 0.94 1.16 0.22 0.65 
NXN 2.4 2.1 1.7 2.26 2.08 2.01 1.82 2.47 
GTF2H2 1.0 1.4 1.6 1.42 1.17 1.15 0.68 1.75 
NCAM1 1.7 2.0 1.6 1.50 1.53 1.69 1.25 1.65 
ASS1 1.3 1.5 1.6 1.83 1.76 1.69 1.49 1.36 
DDX58 0.0 0.0 1.6 0.09 0.32 0.53 0.64 2.17 
THBD 0.0 0.9 1.6 1.29 1.01 -0.10 0.32 1.50 
SAMD9 0.2 0.0 1.6 -0.78 -0.50 0.03 -0.26 1.08 
SNX18 1.4 1.6 1.6 0.48 0.90 1.07 0.42 1.69 
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NUP153 1.3 1.6 1.6 0.27 0.32 0.54 0.45 1.20 
VIM 1.8 1.8 1.6 0.99 1.12 1.16 0.79 1.18 
EEF1E1 1.4 1.6 1.5 1.01 1.17 0.85 0.54 1.20 
LGALS3 1.4 0.5 1.5 1.29 1.24 1.15 0.67 1.10 
C3 0.0 0.0 1.5 -1.69 -1.16 0.54 -0.38 -0.35 
SKIV2L2 1.0 1.4 1.4 0.79 0.86 0.64 0.43 1.29 
DHX29 1.5 1.3 1.4 0.11 0.29 0.27 0.32 1.19 
PHGDH 1.4 1.4 1.4 1.23 1.13 0.80 0.72 0.59 
IPO11 1.2 1.2 1.4 0.76 0.63 0.43 0.37 1.30 
EMB 0.0 0.0 1.3 0.49 0.68 0.80 0.32 1.29 
DPYSL2 1.2 1.4 1.3 1.32 1.20 0.75 0.51 0.39 
MCCC2 1.2 1.2 1.3 0.61 0.68 0.69 0.38 1.07 
RIPK1 0.0 0.9 1.3 0.66 0.58 0.78 0.74 1.24 
CLCC1 0.7 1.2 1.3 1.20 1.01 1.37 0.44 1.03 
MAPK10 0.8 0.6 1.3 -1.11 0.00 -1.00 -3.36 -1.43 
PLD3 1.2 1.1 1.3 1.07 0.90 1.05 1.21 0.98 
TNFAIP8 1.2 0.6 1.2 1.10 1.41 1.17 1.24 1.52 
SLC16A1 1.0 0.9 1.2 0.46 0.62 0.37 0.35 1.07 
AK6 1.4 1.3 1.2 0.77 0.99 0.76 0.19 1.12 
ENO3 0.9 0.7 1.2 -0.43 -0.38 -0.18 -0.57 -1.20 
GNL3L 0.1 0.5 1.1 -0.84 -1.24 -0.16 0.37 -0.20 
DDAH2 0.8 0.9 1.1 1.29 1.06 1.11 0.86 0.35 
SRFBP1 0.9 0.4 1.1 -0.42 -0.29 -0.11 0.09 1.13 
HSD11B1 0.0 0.0 1.1 -0.96 -1.00 -0.96 -0.39 0.37 
LARP4 0.0 0.0 1.1 -0.83 -0.79 -1.01 -0.84 0.33 
CBS 1.2 1.2 1.1 0.84 0.91 0.74 0.46 1.21 
CRELD2 -1.0 -0.6 1.1 -0.93 -1.16 -1.21 -1.00 -0.97 
PGD 1.2 1.0 1.1 0.97 0.90 0.91 0.95 1.13 
RASA1 0.8 0.8 1.1 0.47 0.48 0.33 0.30 1.32 
PHIP 0.3 0.3 1.0 -1.00 -0.63 -0.38 -0.83 0.05 
PIK3R1 0.8 1.1 0.9 0.34 0.48 0.38 0.55 1.29 
CHI3L1 1.0 1.1 0.8 1.86 1.64 1.83 1.71 1.83 
GLRX 0.9 1.0 0.7 0.81 0.66 0.59 0.09 1.11 
CWC27 0.8 1.4 0.6 0.92 0.95 0.69 0.37 1.10 
MSRA 1.2 0.4 0.6 -0.50 -0.12 0.43 -1.21 -1.17 
MYO5C 0.6 1.1 0.5 -0.74 -1.74 -2.17 -3.00 -1.00 
ABCB10 0.2 0.8 0.5 -0.82 -0.75 -1.09 -0.74 0.19 
CTNNA2 0.5 2.5 0.5 0.00 0.45 -0.81 -0.58 -1.12 
MT-ND2 1.2 0.8 0.4 -0.50 -0.12 0.43 -1.21 -1.17 
MRPS30 0.4 1.2 0.4 1.37 1.33 1.35 0.67 1.61 
GK 0.7 1.1 0.3 0.33 0.39 0.57 0.30 1.02 
MTO1 -1.1 0.5 0.3 -0.90 -0.75 -0.52 -1.06 -0.30 
PIK3C2A 0.8 0.7 0.3 -1.02 -0.72 -0.43 -0.66 0.38 
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DNAJA4 -0.9 -1.3 0.2 -1.25 -0.97 -0.93 -1.40 -1.14 
STAM -1.1 0.1 0.0 -0.88 -0.75 -0.84 -1.05 -0.39 
ATP2A3 -1.2 0.0 0.0 -0.67 -0.87 -0.85 -1.01 -1.52 
STXBP5L -1.5 0.0 0.0 -1.39 -1.44 -1.22 -1.47 -0.79 
PRAM1 -2.0 0.0 0.0 -1.43 -1.74 -1.67 -1.94 -1.91 
RAP1GAP2 -2.8 -1.2 0.0 -1.93 -2.20 -2.00 -2.40 -1.86 
CLGN -0.3 -1.3 0.0 -1.69 -1.56 -1.40 -1.92 -1.33 
PM20D2 -1.6 -1.5 0.0 -1.64 -1.47 -1.47 -1.72 -0.70 
DYNC2H1 -0.5 -3.6 0.0 -1.14 -1.25 -1.17 -1.30 -0.40 
IGHA1 -3.5 -4.6 0.0 0.00 2.50 1.58 0.32 0.00 
ARL6IP5 -1.1 0.0 -0.4 -0.51 -0.33 -0.58 -1.01 -0.03 
UNC13D -1.1 0.0 -0.4 -1.10 -1.30 -1.48 -1.36 -1.42 
GEMIN2 2.9 0.4 -0.4 -0.53 -0.44 -1.06 -0.85 -0.16 
LMO7 -0.7 -1.2 -0.5 -0.95 -0.64 -0.65 -1.36 -0.89 
BMI1 -0.4 -1.6 -0.5 -1.55 -1.31 -1.30 -1.47 -0.21 
NCF2 -0.8 -1.1 -0.7 -1.00 -0.91 -0.93 -1.24 -0.63 
APP -0.8 -1.4 -0.7 -1.07 -0.98 -1.14 -0.93 -0.27 
EI24 -0.9 -1.0 -0.7 -0.80 -0.81 -0.93 -1.24 -0.73 
CDK2AP1 -1.4 -1.2 -0.8 -0.58 -0.34 -0.60 -1.06 -0.39 
SH2B2 -1.7 -1.3 -0.8 -0.76 -1.03 -0.87 -1.00 -0.77 
SPATS2L -1.2 -1.8 -0.9 -1.43 -1.50 -1.46 -1.50 -0.55 
DCPS -1.1 -1.1 -0.9 -1.10 -1.27 -1.26 -1.36 -1.11 
SLC22A18 -1.0 0.0 -1.0 -0.21 -0.57 -0.50 -0.73 -1.04 
NUDT19 0.0 -1.7 -1.0 -0.37 -0.45 -0.78 -1.18 -0.46 
H1F0 -1.1 -1.2 -1.0 -0.66 -0.97 -1.19 -1.34 -0.96 
PGM1 -0.9 -1.0 -1.0 -0.40 -0.63 -1.16 -0.92 -0.74 
CTSZ -1.3 -1.1 -1.0 -1.05 -1.05 -0.77 -0.80 -0.79 
LY75 -1.3 -0.9 -1.1 -1.01 -0.99 -1.12 -0.79 -0.05 
HK1 -1.1 -1.2 -1.1 -0.65 -0.77 -0.97 -1.24 -0.97 
AIF1 -0.8 -1.2 -1.1 -0.41 -0.55 -0.74 -1.40 -0.66 
CDK19 -0.9 0.0 -1.1 -0.66 -0.58 -0.96 -1.11 -0.53 
ECHDC1 -1.0 -0.9 -1.1 -0.63 -0.59 -0.81 -1.00 -0.11 
NLRX1 -1.2 -1.3 -1.1 -0.98 -1.17 -1.38 -1.26 -1.21 
PDLIM1 -0.9 -1.0 -1.1 -0.35 -0.43 -0.43 -1.05 -0.65 
HSP90AB4P 0.0 -0.2 -1.2 -0.32 0.81 2.58 -1.32 0.58 
MYEF2 -1.4 -0.7 -1.2 -1.01 -0.82 -0.93 -1.41 -0.76 
PITRM1 -1.2 -1.0 -1.2 -0.88 -0.91 -0.93 -1.12 -0.70 
SYNJ2BP -1.3 -0.8 -1.2 -1.07 -1.08 -0.98 -1.35 -0.29 
MYO18A -1.1 -1.0 -1.2 -0.80 -0.98 -0.81 -1.10 -1.54 
RAB32 -1.3 -1.3 -1.2 -0.82 -0.97 -1.85 -1.49 -0.95 
FLI1 -1.5 -1.0 -1.2 -0.75 -0.71 -1.03 -1.49 -0.67 
TCEAL3 -1.4 -1.1 -1.3 -0.42 -0.61 -0.69 -1.11 -0.75 
GCA -1.5 -1.3 -1.3 -1.40 -1.13 -1.77 -1.68 -0.61 
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HIST2H2AA3 -0.4 -0.3 -1.3 0.83 0.57 0.84 1.91 0.83 
PLD4 -1.1 -1.2 -1.4 -1.18 -1.48 -1.24 -1.06 -1.17 
MARCKS -1.7 -1.4 -1.5 -1.93 -1.67 -1.85 -0.91 0.26 
IFT27 -0.9 -0.7 -1.7 -0.66 -0.68 -0.72 -1.23 -0.97 
HINT3 -1.4 0.0 -1.7 -0.92 -0.70 -1.12 -0.94 -0.07 
CKAP4 -1.9 -1.4 -1.7 -0.52 -0.73 -1.16 -1.02 -0.46 
NRGN -1.6 -1.3 -1.7 -0.68 -1.11 -0.80 -1.32 -1.62 
ST14 -1.6 -0.9 -1.8 -1.57 -1.79 -1.77 -1.55 -1.79 
LARP4B -0.8 -1.1 -1.9 -0.90 -0.83 -0.79 -1.01 -0.61 
CLEC11A -1.3 -0.9 -2.0 -0.68 -1.23 -1.20 -0.81 -1.31 
S100A8 -2.2 -2.4 -2.1 -1.02 -1.05 -1.20 -2.06 -1.27 
S100A9 -2.4 -2.6 -2.3 -1.57 -1.80 -2.01 -1.95 -1.44 
C7orf55 -0.1 -0.1 -2.4 -0.02 -0.32 -0.62 -0.74 -1.09 
BIK -2.1 -1.6 -2.8 -0.97 -1.30 -1.41 -1.75 -1.53 
NR2E3 -3.6 -3.6 -3.7 -0.58 0.00 2.34 0.00 0.00 
TGM3 -1.7 -4.0 -4.4 -2.25 0.00 0.58 -1.22 -2.64 
GSDMA -3.4 -2.2 -6.1 -1.93 -2.58 -2.58 -2.00 -0.87 
NFIA -1.1 -8.2 -8.0 -0.74 -1.58 -1.42 -1.58 -0.81 
NFIB -1.1 -8.2 -8.0 0.00 -1.59 -2.25 0.00 0.02 
 
To investigate the biological functions of genes up-regulated by OAS1, functional 
annotation analysis was performed using DAVID bioinformatics tools (Methods 2.22.2) (Fig. 45). 
As expected, we found several genes that were involved in innate immune signaling pathways. For 
example, RLRs, C3 complement protein and IFIT 1-3. The role of IFIT proteins in antiviral 
immunity has been well established (166, 167, 300, 457), suggesting that OAS1 may provide broad 
antiviral protection through the activation of transcription factors and expression of several ISGs. 
Additionally, several GBP proteins were up-regulated, which are regulated by IRF1 and confer 
antibacterial activity through inflammasome activation (Chapter 4, Fig. 39) (124, 205, 430).  
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Figure 45. Potential roles for proteins transcriptionally regulated by OAS1 
The list of genes from Table 14 were uploaded and submitted to the online DAVID bioinformatics tool. Function 
annotation analysis was performed to predict major biological functions associated to genes transcriptionally regulated 
by OAS1. The data is represented as heatmaps using Z-scored scaled RPKM and peptide intensity values of WT and 
OAS1-KO cells.   
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All together our proteomic and transcriptome analysis revealed that OAS1 enhanced the 
levels of several basal and IFN-inducible proteins by directly enhancing mRNA translation or 
regulating gene transcription through transcription factors. These proteins have broad functions, 
including regulating transcription, inflammation, antiviral defense and antimicrobial immunity. As 
we have done with cGAS and IRF1, this dataset serves a starting point to study the relationship 
between OAS1 and several other proteins described here, which are beyond the scope of my 
dissertation.  
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